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Abstract
The intestinal crypt is a highly dynamic system, as the entire epithelium is
constantly turned over and renewed by the proliferative stem cells located at the bottom of
the crypt. While this system is crucial for nutrient absorption, any derangements in the
proliferative cells can quickly lead to cancer. In this thesis, we sought to better understand
the behavioral and genetic characteristics of the different cell types along the intestinal
crypt, in a mouse model. We first attempted to quantify the migration velocities and
proliferative rates at a single-cell level using 5-ethynol-2'-deoxyuridine (EdU) pulse-chase
labeling. While we observed marked differences in the proliferation rates between the
absorptive and secretory lineages (the former is faster), our experimental setup was
unable to resolve any possible differences in migratory behaviors. We then turned our
attention to quantifying the spatial expression patterns of selected transcripts in the
intestinal crypt, both in wildtype and in an inducible APC-loss cancer model. We were able
to show that the transcript expression profiles of key differentiation and proliferation
markers (Creb313, Gob5, Ki-67, cMyc), as well as the ephrin signaling (EphB2 and
EphrinBl) were significantly altered in the early stages (7 days) of adenoma formation. A
more detailed analysis also separated this derangement in terms of extrinsic factors (e.g.
altered cell composition along the crypt) and intrinsic factors (e.g. inherent change of
cellular expression profile after APC loss). What is particularly interesting is that even
differentiated cells in adenomas can exhibit such derangements. Our hypothesis to explain
this observation is that these differentiated cells actually come from transformed stem cells.
To test this hypothesis, we needed to verify that these cells indeed have excision at the
Apc locus. After several approaches involving both single-molecule fluorescent in situ
hybridization and quantitative polymerase chain reaction (PCR), the results were ultimately
inconclusive. However, we propose several additional approaches that this hypothesis can
be verified, and if verified, some biologically significant questions that can be addressed
regarding the early dynamics of stem cells in intestinal cancer development.
Thesis supervisor: Alexander van Oudenaarden
Title: Professor of Biology and Physics, MIT
Thesis co-supervisor: Scott Manalis
Title: Professor of Biological and Mechanical Engineering, MIT
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Chapter 1. The intestinal crypt in health and disease
The intestine plays a vital role in nutrient absorption, and as such, a large effective
surface area is needed. In order to accord the surface area of about 250 square meters in
an organ that can fit into the human body (Wilson, 1967), the macroscopic interior of the
intestine surface consists of many microscopic folds known as the villi (the hills) and the
crypts (the valleys). These structures are illustrated below (taken from Kimball, 2012 and
Burrell, 2012). Furthermore, as the intestinal environment is highly abrasive, there is a high
turnover rate of the intestinal epithelium (Creamer et al., 1961)---in fact, on average every
2-3 days in mice (Okamoto and Watanabe, 2004) and 5-6 days in humans (Ross et al.,
2003). This implies that the intestinal epithelium must constantly renew itself, and contains
progenitor cells, which are necessary for self-renewal, self-maintenance, and multi-lineage
differentiation (Cheng and Leblond, 1974). Indeed, studies have identified the intestinal
crypt to be a highly diversified niche, consisting of self-renewing stem cells that can also
give rise to the various lineages. We briefly describe these lineages and their functions
below.
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Figure 1.1. The left diagram shows a schematic illustration of the crypt with the villus at the
intestinal epithelium (taken from Burrell, 2012). The right diagram shows a hematoxylin
and eosin cross-section of the intestinal tube, showing not only the crypts and the villi, but
also the structures below (taken from Kimball, 2012).
1.1 Differentiated lineages
In this section, we discuss the functions of the various differentiated lineages, which
are shown in the picture below for reference (taken from Crosnier et al., 2006). In the
following section, we will discuss the stem cell in depth.
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differentiated intestinal cell types, as well as the illusive intestinal stem cell. Picture taken
from Crosnier et al. (2006).
1. 1.1 Paneth cells
At the base of the crypt, there resides a differentiated population of long-living cells
known as Paneth cells. Under a microscope, these cells are marked by large eosinophilic
granules, which contain anti-microbial compounds, such as lysozyme and cryptdins---
which are also known as defensins (Ouellette and Selsted, 1996). When these compounds
are secreted apically into the lumen of the crypt, they control the growth and behavior of
the intestinal microbes. Thus, it can be said that the Paneth cells are important for
maintaining the gastrointestinal barrier. Unlike the long turnover of the other differentiated
cell types, Paneth cells are long-living: its lifespan is estimated to be about 60 days
(Ireland et al., 2005). Like the goblet and enteroendocrine cells, the Paneth cells belong to
the secretory lineage. The picture below (taken from Ganz, 2000) shows the approximate
position (niche) in the crypt where the Paneth cells are located.
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Figure 1.3. A schematic of the crypt and villus structure in the intestine showing the
locations of the Paneth cells at the base of the crypt. As shown in the inset schematic,
these Paneth cells secrete antimicrobial compounds as well as other chemicals that
uniquely define the intestinal stem cell niche. Figure taken from Ganz (2000).
1.1.2 Enterocytes
The predominent cells in the intestine are enterocytes, which belong to the
absorptive lineage. These cells are marked by apical microvilli, and facilitate the uptake
and transportation of nutrients (water, sugar, amino acids, ions, etc.) across the intestinal
epithelium (Ross and Pawlina, 2003).
1.1.3 Goblet cells
Goblet cells belong to the secretory lineage, and they are characterized by the
presence of large vacuoles in the cytoplasm, which contains mucin (Kim and Ho, 2010).
The mucin is secreted into the lumen and protects the lining of the intestine. Goblet cells
belong to the secretory lineage. The picture below shows some intestinal villi under a
hematoxylin and eosin (H&E) stain, as well as the distinguishing features between
enterocytes and goblet cells (taken from Ownby, 2002).
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Figure 1.4. This hematoxylin and eosin stain cross-section shows a crypt with the base
towards the right and the villus top towards the left. Different types of epithelial cells can be
seen to line the villus, including enterocytes and goblet cells. Note the difference in the cell
morphology. Picture taken from Ownby (2002).
1.1.4 Enteroendocrine cells
Very little is known about this minor subpopulation belonging to the secretory
lineage. It is believed that the enteroendocrine cells have chemoreceptors that sense the
gut environment, and in response, produce endocrine signals such as seratonin and other
peptides (Park and Kwon, 2011).
1.1.5 Tuft cells
These cells are also very little known, except for their long microvilli---which gain
them the alternative name brush cells (Sato, 2007). Even their functions are poorly known,
except that they are believed to release opioids and prostaglandin-synthesizing enzymes
(Gerbe et al., 2011). In another study, DCAMKL-1 expression is named as an identifier of
Tuft cells (Gerbe et al., 2009).
1.1.6 Microfold cells (M cells)
This rare population of cells is found near the Peyer's patches, which are lymphoid
nodules located beneath the intestinal epithelium (Jung, 2010). These cells are involved in
immunity because they are capable of phagocytosing or endocytosing antigens or other
organisms and delivering these into lymphocytes or antigen-presenting cells known as
dendritic cells (Kraehenbuhl, 2000). There is some debate regarding the origin and
differentiation of the M cells. However, experiments by Lelouard et al. (2001) in the rabbit
gut seem to suggest that the M cells come from the intestinal stem cells as a distinct
lineage. In addition to absorptive and secretory functions, M cells illustrate the immune
aspect of the intestine, and the picture below illustrates the intestine (as well as the role of
M cells) from this immune perspective (taken from Abraham and Cho, 2009).
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Figure 1.5. This figure illustrates the intestinal epithelium from an immune perspective,
noting the specific immune roles M cells as well as the other key players. Picture taken
from Abraham and Cho (2009).
1.2 Undifferentiated cells
As mentioned above, the high rate of epithelial turnover in the intestinal crypt
implies the existence of regenerative cells (Marshman et aL, 2002), and there has been a
long search for these cells as well as their relevant markers, and this process is
complicated with two different views of the stem cell niche, the "+4" cells and the crypt
base columnar cells (CBCs), which we will describe below.
One of the earliest searches was performed by Cairnie et aL (1965). By determining
the kinetic parameters within the intestinal crypt, these researchers were able to predict
the regenerative cell to positions of 4-5 cells from the crypt base, just above the Paneth
cells which occupy positions lower than that-therefore we will call these putative stem
cells "+4" cells. This was later confirmed by the observation that these cells can retain
DNA labels for long periods (Potten et aL, 1974). This is an indirect suggestion that the
cells might be stem cells, as it has been argued via the "immortal strand hypothesis" (Cairn,
1975) that one characteristic of stem cells is that they retain their mother DNA strand upon
replication, giving the daughter strand to the progeny cells primed for differentiation,
because this selective retention of DNA template can prevent replication errors from
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accumulating in the stem cells. This argument is at best tenuous, as the immortal strand
hypothesis is still widely disputed (for example, Rando, 2007), replete with
counterexamples in systems such as the hematopoietic stem cells (Kiel et a., 2007).
Another line of argument that these "+4" cells may be stem cells is that these cells were
observed to be highly sensitive to X-ray and gamma radiation (Potten, 1977). The
argument, so it goes, is that this sensitivity defines a characteristic of stem cell because it
prevents these cycling cells from accumulating genetic damages. However, once again,
we see that this argument is at best indirect. However, more recent and direct evidence
put this hypothesis in a more positive light. For example, Sangiorgi and Capecchi (2008)
used a lineage tracing approach specifically for Bmil, which is previously known to play a
role in hematopoietic and neural stem cells. These researchers used a LacZ mouse strain
activable with a tamoxifen-inducible element under the Bmil locus, and demonstrated that
the Bmil+ cells are able to give rise to all the different intestinal lineages. Furthermore, the
ablation of Bmil led to an attrition in crypts. In similar experiments, other markers such as
Tert (Montgomery et al., 2011), Lrig1 (Powell et al., 2012), and Hopx (Takeda et al., 2012)
were also proposed to be putative "+4" cell markers. For example, Hopx is also observed
in neural (De Toni et al., 2008) and heart stem cells (Chen et al., 2002), and isolated
Hopx+ "+4" intestinal cells have the ability to form organoid structures (Takeda et al.,
2012).
On the other hand, there is a slightly different picture given by Cheng and Leblond
(1974). In particular, using 3H-thymidine labeling, they demonstrated that the radioactive
elements ingested by some cells at the base of the intestinal crypt were later seen in the
upper differentiated parts of the crypt. These cells were often located as thin slivers in-
between the large secretory Paneth cells at the crypt base below cell position 4, and,
owing to their thin geometry, were known as the crypt base columnar (CBC) cells. This is
illustrated in the picture below showing a crypt base, with red arrows indicating the Paneth
cells, and black arrows labeling the so-called CBCs (Barker et al., 2012).
Figure 1.6. This high-resolution picture shows the bottom of the crypt. Note, as the red
arrows indicate, the Paneth cells with the characteristic lysozyme-containing vesicles. Also
note, in particular, as the black arrows indicate, the columnar-shaped cells wedged
between the Paneth cells that exhibit quite a different cell morphology. These columnar
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cells are called crypt base columnar (CBC) cells, and are believed to be the intestinal stem
cells. Picture taken from Barker et al. (2012).
In Bjerknes and Cheng's (1981) "stem cell zone" hypothesis, the CBC cells give rise
to differentiated cells, which either migrate upwards towards the crypt rim, or in the case of
the Paneth cells, migrate downwards towards the crypt base. The argument was later
strengthened by the identification of molecular features using RT-PCR, showing not only a
difference in expression of CBCs compared to their neighboring Paneth cells, but also a
similarity to the expression signatures of the hematopoietic and neural stem cells
(Stappenbeck et al., 2003). This was verified by more elaborate transcriptional profiling
and quantitative mass spectrometry later (Muhoz et aL., 2012). More specifically, Barker et
aL. (2007) demonstrated that these CBCs express Lgr5, a putative stem cell marker in
other systems such as hair follicles (da Silva-Diz et al., 2012) and nephrons (Barker et al.,
2012). Further lineage tracing experiments done on these Lgr5+ cells demonstrate that the
CBCs are able to regenerate the full gamut of differentiated intestinal lineages (Barker et
al., 2007), and when isolated, these Lgr5+ CBCs are able to generate colon organoids that
can also be funtioning over the long term when grafted in vivo (Yui et al., 2012). Zhu et al.
(2009) performed a similar lineage tracing study of the CBCs using other markers such as
Prom 1 and Cd133, and demonstrated similar results in the identification of putative stem
cell markers.
While opinions may still differ, there is increasing consensus that the "+4" cells and
the Lgr5+ CBCs are in fact two subpopulations of intestinal stem cells, with complementary
activities. For example, after the ablation of CBCs via a knock-in human diphtheria toxin
receptor (DTR) at the Lgr5 locus, Tian et aL. (2011) showed experimentally that the Bmil+
"+4" cells can increase their progeny production and replace the ablated CBCs.
Furthermore, Takeda et aL. (2011) showed a more complex interconversion dynamics both
from "+4" cells to CBCs, as well as from CBCs to "+4" cells. While this observation is
interesting, it is hardly surprising, as the same interconversion mechanism has also been
proposed within the stem cell populations of other tissues and systems (as reviewed in Li
and Clevers, 2010). The diagram below illustrates the complex interactions between the
stem cell populations, as postulated by a recent review (Rizk and Barker, 2012).
Figure 1.7. A diagram that illustrates the postulated interconversions between the different
cell subpopulations at the base of the crypt. Dark blue cells denote "+4" cells, green cells
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denote CBCs, grey cells denote Paneth cells, and light blue cells denote transit amplifying
cells. Figure taken from Rizk and Barker (2012).
1.3 Cell mobility
Now we have discussed both the differentiated intestinal lineages as well as the
stem cells, we use this section to consider the dynamics between the two parts. Namely,
as the stem cells constantly cycle and produce more cells, how do the differentiated
lineages behave? As the stem cells produce progenies at a given rate, and as a mature
intestine does not expand in size, we expect that the mature cells are also being shed off
at the same rate. Within this steady state of influx and outflux, what exactly happens to the
cells? How do they migrate spatially, for example?
We give an overview of three possible hypotheses-known as basement membrane
flow, mitotic pressure, and active migration-and briefly discuss the merits and pitfalls of
these models.
In the basement membrane flow hypothesis, as propsed by Partridge and Simpson
(1980), the basal lamina-upon which the intestinal epithelium sits-is constantly moving
in the direction from the crypt base to the crypt rim, thereby propelling the motion of cells
upward the crypt. There is general consensus that the basement membrane flow
hypothesis has been discredited by two observations. The first observation is simply that
the basal lamina, with a thickness of 50-100 nm, cannot possibly support physically the
active transportation of the much larger cells, which are on the order of 10 microns in size
(Heath, 1996). The second observation was made by Trier et al. (1990), who stained the
basal lamina with anti-laminin, and remarked that the label was retained for about 4 weeks.
This time frame is clearly incompatible with the rate at which the epithelium is turned over
(several days in both humans and mice). However, researchers such as Turck et al. (2005)
believe that the basement membrane still plays a non-trivial role in the epithelial cell
migratory behaviors through chemical signaling. The second hypothesis, known as the
mitotic pressure hypothesis, posits that as the stem cells at the crypt base divide, the
creation of new cells put a pressure on the column of cells above, thereby pushing the
column upwards (Loeffler et al., 1986). This has in fact been the paradigm used in some
early modeling attempts on cell migration, such as Finney et al. (1989) and Paulus et aL
(1993), where a rigid lattice model was utilized, and cell migration was signified by the
displacement of the entire lattice column upwards by one cell position. A typical model
setup representing this paradigm is illustrated in the diagram below (taken from Kaur and
Potten, 1986).
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Figure 1.8a. A typical early-stage model of intestinal epithelial cell migration, using the rigid
lattice model approach (figure taken from Kaur and Potten, 1986). In this approach, the
stem cells (denoted by A) can differentiate into Paneth cells (denoted by P), or other cell
lineages, which undergo various degrees of maturation and subsequent division (denoted
by 1, 2, 3, and 4) before becoming terminally differentiated (denoted by M). Each time a
cell divides, it pushes the entire column upwards.
However, the main complaint about the mitotic pressure hypothesis is about the
elasticity of intestinal cells, and whether or not such elasticity can provide sufficient
pressure on an entire column of cells to fully explain the migration pattern (Wong et al.,
2010). Furthermore, this hypothesis as the sole explanation of cell migration was further
brought into question by the observation that disrupted mitotic activity did nothing to affect
the migration speed (Kaur and Potten, 1986). Finally, the third hypothesis is known as
active migration, where the epithelial cells have the ability to migrate due to chemical cues.
While no conclusive demonstration of active migration has been shown, this hypothesis is
at least indirectly supported by the existence of signaling gradients such as EPHB and
EFNB (a.k.a. EPHRIN-B) along the longitudinal axis of the crypt (Pasquale, 2008), since
both EPHB and EFNB can cause the cytoskeleton to reorganize, and thereby alter the
migration behaviors and patterns in a predictable manner as a function of cell position from
the crypt base (Bochenek et al, 2010). This debate still continues today, and more likely
than not, the real answer probably does not exclusively lie with one hypothesis, but rather
a combination of various factors such as chemical cues and physical pressure.
Unfortunately, we do not have the experimental tools within our access to conclusively
settle this debate.
While we do not have the tools to settle the mechanistic debate on how cells move,
we are nonetheless interested at the phenomological level, and there does indeed exist a
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phenomological model (called the conveyor belt model) that we can test and question.
Generally, it has been the consensus that the cells are generated at the crypt base, and
shed off at the top of the villi, at a distance far away from the crypt base. This gives us
some boundary conditions: a typical cell should migrate from the crypt base upwards
towards the crypt rim. In what Barker et al. (2008) called the "conveyor belt model", after a
stem cell gives rise to a progeny fated for differentiation, this progeny cell starts moving
upwards. First it becomes rapidly dividing transit amplifying cells at around cell position 5-
10. After that, the cell becomes terminally differentiated and continues its upward
migrations, until it is shed off. The crux of the conveyor belt model is that the cells migrate
upwards in an orderly and continuous fashion: if a constant migration speed is assumed
for all cells, then the cells should rarely "overtake" each other. A cell that is generated from
a stem cell later in time will end up in a lower position compared to a cell that is generated
earlier, and will be shed off later as well. A corollary of this view is that two neighboring
cells should remain close to each other as they migrate upwards the crypt, with minimal
random "diffusion". However, this view has been challenged by some experimental
evidence, such as observations by Bjerknes and Cheng (1999) in a study where they
randomly mutated the cells somatically by chemical means at the Dlb-1 locus. Normally,
the presence of functioning Dlb-1 can be stained for Dolichos biflorus agglutinin (which
binds to the locus). By crossing wildtype with Dlb-1 -/- mice and selecting for the
heterozygote (Dlb-1 +/-), the researchers treated the mice with N-n itroso-N-ethylurea
(NEU). For somatic mutations that happend to hit the remaining functioning Dlb-1 allele,
the loss of both copies of Dlb-1 can be visualized by this stain (Cosentino and Heddle,
1995). These researchers noted, in particular, that after mutagenesis, the mutant cells
were sometimes apart at great distances from each other in the same crypt, as illustrated
below. Since somatic mutagenesis is a rare event, it can be assumed that these different
mutant cells came from the same mother cell which had been hit earlier in the Dlb-1 locus.
If we believe in the conveyor belt model, then this observation becomes somewhat
surprising, because the conveyor belt model would predict that, since a mother cell gives
rise to two neighboring cells, these cells should migrate upwards together and remain
relatively close to each other. Therefore, the observation of "clonal dispersion" calls some
aspects of the conveyor belt model into question.
A
Figure 1.8b. These two figures show lineage tracing of cells from a single progeny, using
the technique explained in the text above and in Bjerknes and Cheng (1999). Note that
even though most of these cells probably come from the same progeny, they are quite far
apart from each other, demonstrating the phenomenon of "clonal dispersion". Picture taken
from Bjerknes and Cheng (1999).
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Even so, this issue has at best only received passing treatment in the past, whereas
we think that its resolution will have great implications in our understanding of the
migratory behaviors of intestinal cells as a whole. For example, do the different lineages
migrate at different speeds? From the point of view of the conveyor belt model, it is
tempting to answer affirmatively. However, we already know that one of such differentiated
lineage, namely the Paneth cells, definitely have very different migratory and proliferative
behaviors compared to the other lineages, in that while the other lineages tend to migrate
upwards, Paneth cells migrate downwards towards the crypt base. If this is the case, what
is our reason to believe that even enterocytes and goblet cells, for example, behave the
same in terms of migration velocity and other behaviors? It is of our great interest to
explore this issue further, in particular because we have access to labeling tools that can
potentially help us elucidate this topic more conclusively.
1.4 Aberrations in intestinal cancer
While the wildtype behaviors in the intestinal crypt and the search for stem cells are
highly interesting, these topics are also highly relevant in the context of the intestinal
cancer, which in the United States ranks amongst the top five most common cancers (NCI,
2011). While some instances of human colorectal cancers arise from spontaneous
mutagenesis, there is a class of intestinal cancers which are tightly linked to a locus in the
Apc gene. In particular, people with what is known as the familial adenomatous polyposis
(FAP) suffer from the presence of numerous benign polyps in the colon, and often develop
colorectal cancer before the age of 40 (Bisgaard et al., 1994). Kartheuser et al. (1995)
carried out a comprehensive linkage analysis, and demonstrated some specific common
loci in the Apc gene where mutations could lead to nonsense or missense mutations to the
APC protein. Incidentally, Medema and Vermeulen (2011) also showed that up to 85% of
spontaneous non-hereditary intestinal cancers can also be attributed to Apc mutations.
In fact, it is hardly surprising that the Apc locus is linked to intestinal cancer in this
case. APC is a key negative regulator in a signaling pathway known as WNT (Goss and
Groden, 2000). WNT signaling is an ancient pathway that is conserved over many species,
such as Drosophila melanogaster (Klaus and Birchmeier, 2008) and Caenorhabditis
elegans (Thorpe et al., 1997), xenopus (McMahon and Moon, 1989), rats (Katoh and
Katoh, 2005), and humans (Luo et al., 2007). In humans, for example, WNT signaling is
also known for controlling the genesis and development of various systems from the skin
(Widelitz, 2008), bone (Krishnan et al., 2006), blood (Luis et al., 2011), to the intestine
(Gregorieff and Clevers, 2005). In fact, the WNT pathway is so ubiquitous because of its
vital role in controlling the self-renewal of stem cells (for example, Logan and Nusse, 2004)
Molecularly, the consensus is that the APC protein, when expressed and
functioning (i.e. when WNT signaling is "off"), physically interacts with the P-catenin (and
other proteins such as Axin, CKI, and GSK-3) by forming a complex (Hart et al., 1998;
Kieda et al., 1998). This leads to the phosphorylation of p-catenin by casein kinase la
(CKla) and GSK-33 (Liu et al., 2002; Amit et al., 2002), which leads to APC's
phosphorylation as well and significantly increases APC's binding affinity (Liu et al., 2006;
Yang et al., 2006). This phosphorylation step leads to -Trcp ubiquitination, which leads
quickly to proteasome degradation (Hart et al., 1999; Jiang and Struhl, 1998). There is
quite a clear understanding as well evidence of this multi-step process because
researchers such as Xing et al. (2008) have solved the structure of this degradation
complex. Therefore, the process described above keeps in check the level of cytoplasmic
P-catenin by reducing its stability. On the other hand, when APC protein loses its function
or when the WNT signaling is "off", then APC does not form the degradation complex with
p-catenin, Axin, or GSK-3. Both Axin and GSK-3 relocate to the cell membrane and bind to
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LRP 5/6 via Dvi (Zeng et al., 2008; Bilic et al., 2007). This results in the accumulation of
non-degraded P-catenin in the cytoplasm. This excess P-catenin then translocates through
the nuclear membrane (Fagotto et al., 1998; Wu et al., 2008), and there in the nucleus,
interacts with transcription factors in the TCF family, such as TCF-4 and LEF-1 (van de
Wetering et al., 1997; Brunner et al., 1997). This interaction with P-catenin displaces the
repressors Groucho/TLE1 from the transcription factors (Daniels and Weis, 2005). This
frees the transcription factors and leads to the active transcription of a host of genes such
as Myc (Hu and Rosenblum, 2005; He et al., 1998). Beyond this, Soliman and Riabowol's
(2007) investigation has suggested that P-catenin can also act through Pygopus to initiate
epigenetic changes. For simplicity's sake, the two diagrams below concisely summarizes
the molecular description above, with the left diagram illustrating the case when the WNT
signaling is "off" (APC is active), and the right diagram, when the WNT signaling is "$on"1
(taken from Chen et al., 2008).
I LRP
A B
Figures 1.9. A schematic of the WNT signaling pathway in the intestine. When the WNT
signaling is "off", as shown on the left, APC forms a complex with -catenin, fating it for
degradation. When the WNT signaling is "on", as shown on the right, P-catenin builds up in
the cytoplasm and translocates into the nucleus, where it activates a different genetic
program. Picture taken from Chen et al. (2008).
Aberrations in WNT signaling has already been implicated in various cancers. In
skin cancer, for example, it has been suggested that CD34*/K14* cells are likely the
cancer stem cells which can give rise to secondary and more invasive tumors (Lapouge et
al., 2012). Not only is nuclear P-catenin heightened (Chan et al., 1999), but it has also
been demonstrated that tumor regression can be correlated with an ablation of P-catenin
(Malanchi et al., 2008). Similar observations have been made regarding the role of P-
catenin in liver cancer (Buendia, 2000; Thorgeirsson and Grisham, 2002), prostate cancer
(Gerstein et al., 2002; Voeller et al, 1998), and ovarian cancer (Lee et al, 2003), though in
these cancers, unlike the colorectal cancer, often other non-Apc loci involved in the WNT
signaling are mutated (Watanabe et al., 1996). In fact, it has become common to stain for
the nuclear localization of -catenin as a measure of the strength of WNT signaling in the
study of cancers (e.g. Barker et al, 2009).
While, as described above, there is a link between WNT signaling and intestinal
cancer, it behooves for us to understand first how WNT signaling operates in the specific
context of the intestinal crypt. According to the current consensus, WNT exists as a high-
to-low gradient from the crypt base to the crypt rim, along the crypt's longitudinal axis.
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Through the regulation of the regenerative capacities of the intestinal stem cells, WNT
plays a large role in intestinal homeostasis. As an illustration, an overexpression of WNT
signaling by R-spondin-1 results in hyperplastic growth, marked by the enlargement of the
stem cell niche beyond the crypt base (Kim et al., 2005). Similarly, Pinto et al. (2003)
demonstrated that upon WNT inhibition by DKK1, the intestinal crypt shows atrophy. From
a more molecular resolution, Gregorieff et al. (2005) showed that the stem cell niche at the
crypt base has a particular microenvironment-supplied either by the surrounding
mesenchyme or by the Paneth cells-that is rich in WNT signaling molecules such as
WNT3A, and this is believed to maintain and spatially confine the intestinal stem cell niche
(Sato et al., 2010).
From the paragraphs above, we understand that WNT signaling is responsible for
maintaining the intestinal stem cell niche, and that aberrations in WNT signaling can lead
to intestinal cancer. In order to understand in depth what happens to the intestinal crypt
during APC-dependent cancer initiation, a seminal work was carried out by Barker et al.
(2009) that made use of a mouse model with a tamoxifen-inducible Cre under a Lgr5
promoter. When tamofixen is injected, the Lgr5+ stem cells (which, as we recall earlier, is
a putative marker for CBCs in the crypt) expresses Cre, which excises a fragment of the
Apc gene, rendering the APC product non-functional. The researchers, using lineage
tracing, were able to demonstrate that these transformed stem cells resulted in an
expansion of Lgr5+ cells high nuclear P-catenin localization beyond the normal confines of
the stem cell niche within the crypt, and microadenoma formation followed. Based on
these observations, the researchers claimed that the intestinal stem cells are the cells-of-
origin of intestinal cancer. Further studies have also confirmed the upregulation of
downstream WNT targets such as MYC (for example, Sansom et al., 2004), further
confirming the role of WNT in intestinal cancer development.
While there has been much work done to study the initial tumorigenesis stage of the
intestinal cancer and the roles that WNT signaling and the intestinal stem cells may play,
there are still many unexplored questions. For example, if we map the spatial signatures of
the expression patterns of key markers within the intestinal crypt, how do these signatures
change in light of Apc loss? Does intestinal tumor develop from the deterministic clonal
expansion of the transformed stem cells, or is there also room for stochastic variations that
can reveal more about the complex dynamics of cancer development? The latter part of
this thesis is specifically inspired by questions as such.
1.5 Research questions
In the overview given above, we have identified some unresolved areas to explore,
and in this section, we conslidate these areas into research questions that we will attempt
to tackle in this thesis.
1.5.1 Lineage dependence of cell migration
As we explained above, one missing piece of the intestinal crypt puzzle is a clear
understanding of how cells migrate in the epithelial sheet. On the phenomenological level,
we have propositions such as the clonal conveyer belt model (by Barker et al., 2009), but
there is also evidence (such as clonal dispersion) that challenges this model. We want to
better quantify this migratory behavior.
In particular, we will first focus on the following question: Do cells of different
lineages migrate differently? In particular, we already observe a significantly different
migration pattern for the downward-migrating Paneth cells. If we extend this reasoning
further, are there any differences between the upward-migrating goblet cells versus
enterocytes?
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As described later, we aim to quantify this by performing EdU pulse-chase
experiments, in conjunction with single-molecule fluorescent in situ hybridization (FISH).
This series of experiments will allow us to quantify in depth the migration speed and
distribution as a function of the cell lineage.
The hope is that with a thorough understanding of the wildtype behavior, we can
then proceed to study how the migration behavior may be deranged in the case of
intestinal cancer, as we also have access to a mouse model for intestinal cancer.
Unfortunately, we were unable to carry the study this far, but in Chapter 3 below, we will
present the information we managed to extract from the EdU pulse-chase experiments.
1.5.2 Expression pattern changes in cancer
As elaborated above, in recent years, there has been increasing interest in studying
the very early stages of intestinal cancer, and relating these observations with the
intestinal stem cells and WNT signaling. This is a nascent field filled with many
unanswered questions. While prior studies have given us a rough sketch of the
carcinogenesis process in the intestinal crypt, we nonetheless lack a detailed and
quantitative understanding of the full gamut of different intestinal markers that may have
become deranged as cancer develops.
Having access to an inducible mouse model for cancer (which we will describe in
Chapter 2), we aim to quantify the detailed spatial expression profiles of the different
intestinal markers (such as for differentiation and proliferation) in much better resolution. In
Chapter 4, we introduce a spatial approach to quantify the expression profiles in a method
called the cryptogram, and then examine a much closer look between intrinsic and
extrinsic factors that may have altered the expression pattern.
As we will show later, our studies will lead us to a crucial question: How do the
transformed intestinal stem cells behave? Can we establish an easy proxy for such
transformed cells and then use the proxy to study the stem cells' subsequent behaviors?
These are questions that we attempt to tackle in Chapter 5.
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Chapter 2. Experimental Methods
2.1 Mouse genotype
We selected the mouse model for our study, because the mouse system in this
case closely emulates the human system in the intestinal regeneration and cancer
development, but at the same time, mice are much easier to work with than humans or
other mammals, allowing for more elaborate explorations that would otherwise be very
difficult or even impossible in other circumstances. In this section, we briefly describe the
genotypes of the various mouse strains that we used.
2.1.1 Wildtype strain
The mouse that will be referred to as "wildtype" is on a C57B1/6 background (Jackson
Laboratory, Bar Harbor, ME). This mouse strain is used primarily in the cell mobility
experiments (Chapter 3), as well as the control in the ensuing chapters. All the genetically
modified mouse strains below are based on the same background.
2.1.2 Lgr5:Cre;Apc strain
This mouse has one copy of the Lgr5 gene knocked out and replaced by the knock-in
cassette EGFP-IRES-CreERT 2 at the ATG sequence of the Lgr5 locus. Therefore, in cells
which normally express LGR5, Cre will be expressed instead, and we will see such cells
fluoresce in GFP. Note that only one copy of the Apc gene is knocked in, because the
homozygous Apc null genotype is embryonically lethal (Blat, 2012). At the same time, a
pair of loxP sites has been introduced so that they flank exon 14 of the Apc gene, as
described in Colnot et al. (2004). As shown in the schematic below (taken from Colnot et
al., 2004), the first schematic shows the Apc gene in a wildtype mouse, with their exon
numbers labeled. The second schematic is the targeting fragment that is used to
genetically modify the mouse, using targeted mutagenesis. The third schematic shows the
Apc locus of the mouse after targeted mutagenesis, which is the mouse that we use. Now,
if we inject tamoxifen into the mouse, then those cells which express LGR5 will have
activated Cre that can act upon the flanking loxP sites around exon 14 of the Apc locus,
thereby excising exon 14, as shown in the fourth schematic below. We note that in our
mouse model, only a small portion of the Apc gene is excised upon tamoxifen injection.
However, what this does is to create a nonsense mutation that results in a premature stop.
This creates a truncated protein that is non-functional. We are also aware of other
alternative models for APC loss. For example, Cheung et al. (2010) describes another
mouse model of APC loss in which the entire Apc gene is excised, and the study reports
that this particular phenotype results in a more severe polyposis in mice. We acknowledge
that different mouse models of APC loss may give rise to different phenotypes, and we
chose to use our particular model, in particular because it more truthfully mirrors the actual
case in polyposis patients: instead of the outright deletion of an entire gene, a small
mutation leads to a nonsense mutation and a non-functional protein.
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Figure 2.1. A schematic of the genotype of the genetically modified mouse at the Apc locus.
The first line shows the wildtype Apc locus. The second line shows the targeting fragment
that was used by Colnot et al (2004) to initiate targeted mutagenesis in wildtype mice. The
third line shows the resultant genotype at the Apc locus of the mutagenized mice. Note the
loxP sites flanking exon 14 of Apc. The fourth line shows the result after tamoxifen-induced
Ore excision of the Apc locus. Note that this has caused a loss of exon 14 of Apc, resulting
in a truncated, non-functional APo protein. Picture taken from Colnot et al. (2004).
2.1.3 Rosa26:TOM strain
At the same time, we have access to a different mouse strain which we will simply
call Rosa26:TOM (TOM stands for the tdTomato protein). This particular strain was not
used extensively in our studies, but its cross with Lgr5-re was.
In the Rosa26:TOM strain, the following construct is used. As described above for
the Lgr5:Cre;Apc strain, the Lgr5:Ore element remains the same, in which Ore and GFP
are co-expressed under a Lgr5 promoter. Instead of floxed Apc, another element is
introduced at the constitutively active Rosa-26 locus: a lox P-stop-loxP-tdTom ato cassette,
as shown in the schematic below (adapted from Marro et al, 2011). When Ore is not
active, the stop element preceding the tdTomato cassette prevents the cell from
expressing tdTomato (also denoted as TOM). However, upon tamoxifen injection, those
cells which express LGR5 (and hence Ore) will have the stop element excised, thereby
causing TOM to be expressed (as illustrated in the schematic below). This strain was
made in a manner similar to that described in Barker et al. (2008).
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Figure 2.2. A schematic showing the Rosa-26 locus and the Lgr5 locus of the Rosa26-
TOM mouse strain. At the Rosa-26 locus, the loxP-stop-loxP sequence before tdTomato
prevents the gene from being expressed. At the Lgr5 locus, the mouse has a knock-in
GFP-IRES-Cre element that is expressed only in Lgr5+ cells. However, after tamoxifen-
induced Cre excision, the stop sequence at the Rosa-26 locus is excised, and tdTomato (a
fluorescent protein) is caused to be expressed in the affected cells. Figure adapted from
Marro et al. (2011).
2.1.4 Lgr5-Cre;Apc;Rosa26-TOM cross
Finally, we also made use of a cross between the Lgr5:Cre;Apc strain and the
Rosa-26:TOM strain. This strain has the phenotypes of both strains described above.
Namely, when tamoxifen is injected, in the Lgr5-expressing cells, GFP is expressed, ann
exon of Apc is excised, and in addition to that, TOM is also expressed.
2.2 Sample preparation
2.2.1 Mouse work
The mice were bred in according to a protocol approved by MIT's Committee on
Animal Care (protocol number: 1111-138-14). All the procedures related to mouse work
are described therein, and we include a copy of the protocol in the appendix. Only mice
above the age of 6 weeks were considered for our experiments. If our experiment called
for tamoxifen injection (for Apc induction, etc.), then this injection was given a specified
number of days before sacrifice. If our experiment called for EdU injection-350 pL of 3
mM of EdU (Invitrogen, Grand Island, NY) in 1x PBS-then this injection took place 2
hours before sacrifice. Once a mouse was asphyxiated by carbon dioxide, the intestine
was removed for subsequent processing.
2.2.2 Mouse genotyping
In order to confirm the correct genotype of the Apc mouse, the following genotyping
protocol was used, courtesy to the Jack Lab (Cambridge, MA).
A segment of the mouse tail was cut off and put into a clean Eppendorf tube. A lysis
buffer containing the following elements was added: 5 pL of 1 M Tris (pH = 8.0), 10 pL of
5M NaCl, 10 pL of 0.5M EDTA (pH = 8.0), 25 pL of 10% SDS, and 450 pL of nuclease-free
water. The mixture was incubated at 550C overnight. Then, 250 pL of 6M NaCl was added,
and the tube was shaken vigorously before being put on ice for 10 minutes. Then the
Eppendorf tube was spun at 40C at low speed (#6 on Hemle centrifuge) for 10 minutes.
The supernant was put into a clean Eppendorf tube, and 650 pLof isopropanol was added
and mixed. The mixture was incubated for 15 minutes, and then centrifuged at maximum
speed fo 10 minutes, both at room temperature. Then the tube was inverted for 5 minutes
in order to dry. The DNA pellet was resuspended in 200 pL nuclease-free water, incubated
at 550C for 10 minutes, and then stored at -200C until it is needed for further analysis.
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In order to perform PCR verification of the Apc locus, the following PCR primer pair
was used:
Forward primer: GATGGGTCTGTAGTCTGGG
Reverse primer: GGCTCAGCGTTTTCCTAATG
The mixture and reaction conditions for PCR will be given below in Section 2.4.
After gel electrophoresis (also described in Section 2.4), the expected outcome is a single
band at 340 bp if the mouse is wildtype, and a single band at 500 bp if the mouse has the
Apc flox/f lox genotype.
2.2.3 Frozen block tissue preparation
If the goal of sacrificing the mouse is to perform single-molecule FISH experiments,
then we needed to make frozen blocks of the intestinal tissue. To do that, after the
intestinal was removed immediately after mouse sacrifice, the entire intestine was rinsed
with a fixation buffer (4% paraformaldehyde in 1x PBS). Then the intestinal was cut into
smaller fragments, and fixed further in the same fixation buffer with gentle agitation for 2
hours, followed by an overnight fixation in 30% sucrose and 4% paraformaldehyde in lx
PBS with gentle agitation. All the procedures performed so far were carried out either on
ice or in a 4'C chamber. After overnight fixation, the tissue would be cut into even smaller
pieces, and inserted into chilled OCT compound (VWR, Radnor, PA) in plastic containers,
which was quickly cooled over dry ice to solidify. The chilled blocks then were stored at -
80*C. If the mouse intestine was destined for FACS/qPCR quantification, then another set
of protocols were carried out after mouse work, which we will describe in detail below.
2.2.4 Tissue mounting
Two days before the intended imaging experiment, glass coverslips #1 were
cleaned for 15 minutes under sonification with 2% RBS-35 (Thermo Scientific, Rockford, IL)
in Millipore water, rinsed repeatedly with 1 L of Millipore water, cleaned further for 15
minutes under sonification with 70% ethanol in Millipore water under sonification, dried in
air, immersed for 30 minutes in 20% poly-L-lysine (Sigma-Aldrich, St. Louis, MO) in
nuclease-free water, and finally dried overnight. These steps were carried out at room
temperature.
One day before the intended imaging experiment, the frozen block was removed
from -80*C and moved to a cryotome controlled at -20*C. The cryotome sliced the frozen
block in 6-micrometer-think cross sections, which were then mounted onto the glass
coverslips prepared earlier. After mounting, the coverslip was dried at room temperature
for 5 minutes, and then put over dry ice. Afterwards, the coverslips were submerged in
70% ethanol in nuclease-free water and stored at 40C until further processing.
2.3 Staining and visualization
2.3.1 Single-molecule fluorescent in-situ hybridization (FISH)
Single-molecule FISH is an mRNA visualization technique developed by Raj et al.
(2008). This technique calls for a set of 48-96 singly-labeled probes, each about 20 bp in
length, to span the length of the mRNA transcript of interest. When hybridized, the
localized aggregation of many probes to a transcript produces a diffraction-limited dot that
indicates not only the presence, but also the location, of a targeted mRNA molecule in a
cell. Up to three different probe sets could be coupled to fluorophores in different
channels-typically tetramethylrhodamine (TMR), Alexa-594, and Cy5-thereby allowing
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the visualization of up to three different mRNA species in a single tissue sample. We
chose this technique to help us quantify the gene expression patterns in the intestinal crypt
for three reasons. Firstly, single-molecule FISH, unlike traditional immunostaining, has the
ability to locate the position of the transcripts inside cells, and this gives us a detailed
spatial resolution that is unattainable or difficult to attain using other techniques such as
qPCR. Secondly, because of this spatial resolution, we can also study expression pattern
at a single-cell resolution by assigning each FISH dot to a cell, and investigate the
variability in the expression pattern in a population of similar cells. Finally, probe design for
single-molecule FISH is very versatile. While it may not be possible to find the appropriate
antibody for all proteins of interest, as long as the mRNA transcript length is sufficient (e.g.
more than 1000 bp), it is typically straightforward to design an appropriate probe set that
can successfully target the species of interest. In order to perform single-molecule FISH,
we first needed to design appropriate probes against the various mRNA species of interest.
The probe design, coupling, purification, and hybridization protocols have been elaborated
elsewhere (e.g. Biosearch, 2011), so we will not elaborate further here.
The only difference of our technique from the Biosearch protocol is that in addition
to FISH probes, we often also stained the tissue sample with anti-E-cadherin (which will
delineate cell boundaries and make segmentation and imaging processing easier) by
adding 1.5 pL of anti-E-cadherin (Invitrogen, Grand Island, NY) per 150 pL of hybridization
buffer. If DAPI staining is desired (which it often was), the protocol we followed is also
described in Biosearch (2011) as a post-hybridization step. A schematic of the single
molecule FISH procedures is shown below (taken from BioCat, 2012).
The sequences of commonly used probe sets in this thesis are given in Appendix A
at the end of this document.
Stellarmsa" FISH Probes
Figure 2.1. A schematic showing the technique of single-molecule fluorescent in situ
hybridization, as described in Section 2.3.1 in the main text. Schematic taken from BioCat
(2012).
2.3.2 EdU staining
EdU (Invitrogen, Grand Island, NY), when given as a pulse, stains for cells in S
phase, and by counting the fraction of EdU+ cells, it is possible to estimate the proliferation
rate. Furthermore, if we follow the EdU pulse with a time period of delay (known as a
chase), then the stained cells will have migrated up the crypt, and thus we can also use
this as a tool for cell migration. EdU performs similarly compared to BrdU, and we chose it
over BrdU for two reasons. The first reason is that EdU is currently the only method of the
two that is compatible with single-molecule FISH. The second reason is that BrdU requires
denaturing the DNA, while EdU does not. This makes EdU a more straightforward
technique to carry out in our experimental setup.
In order to do EdU staining, as mentioned above, EdU is already injected in the
mouse about 2 hours before sacrifice. Then, in order to visualize the EdU, we need to stain
it after we have completed hybridization using single-molecule FISH but before we add
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glucose oxidase (GLOX) buffer. Thus, in addition to the FISH protocol described in
Biosearch (2011), we would wash the sample, after DAPI staining, with PBS, and then
follow the EdU staining protocol described elsewhere (Invitrogen, 2011), the only
difference being that we found one-fifth of the reagent volume sufficient for our
visualization purposes. After this step, the sample would be washed in glucose oxidase
(GLOX) buffer (as per the final step of single-molecule FISH described in Biosearch, 2011)
before being mounted on a microscope.
2.3.3 Phosphohistone-H3 staining
Occasionally, we also want to verify the cells in the M phase. While mitotic figures
under DAPI is a common way to characterize dividing cells, another staining technique
that we have tried in this thesis is phosphohistone-H3 staining, typically in conjunction with
single-molecule FISH and/or EdU staining. The protocol, in this case, is summarized below.
If single-molecule FISH is desired, perform the hybridization and the washes first,
but stop before the DAPI staining step. Then the sample was washed once in 2x SSC for 5
minutes, and then twice with 1x SSC, for 5 minutes, both at room temperature. Then the
coverslip with the sample was placed in 100 pL of 5% BSA (Amresco, Solon, OH) in lx
PBS, with 5 pL vanadyl-ribonucleoside complex (New England Biolabs, Ipswich, MA)
added. This incubation step took 1 hour at room temperature, typically inside a Petri dish
on top of a sheet of Parafilm. Then after the incubation, the coverslip was lifted carefully
from the Parafilm and transferred to 100 pL of 5% BSA in 1x PBS with 5 pL vanadyl-
ribonucleoside complex, 2.5 pL of RNAsin (Promega, Madison, WI), 5 PL of SUPERasin
(Ambion, Grand Island, NY), 0.5 pL of 20% Tween-20, and 1 pL of phosphohistone-H3
solution (Cell Signaling Technology, Danvers, MA) on top of Parafilm inside a Petri dish.
Another hour-long incubation ensued. Afterwards, the sample was washed in 1 mL of
0.1% Tween-20 (Thermo Scientific, Rockford, IL) in 1x PBS, followed by 3 identical
washes at 10 minutes each, at room temperature on a shaker. After this step, DAPI
staining and the remaining procedures for FISH and/or EdU staining was observed.
2.3.4 Imaging and processing
Imaging was done under an epifluorescence microscope, oil-immersion. Depending
on the fluorophores being used, we utilized different filter cubes in order to capture the
epifluorescence. As a rule, in order to image FISH dots, the exposure time was set to 2-3
seconds. The time was about 500 ms for EdU, 250 ms for TOM, and 25 ms for DAPI. For
a given crypt, typically, a vertical stack of 20 images were taken, with each image having a
thickness of 0.3 microns. This would allow us a 3D reconstruction of the cell and the
location of the FISH dots.
Because the single-molecule FISH probes typically produced diffraction-limited dots,
this could often be detected using an automated algorithm. This algorithm has already
been described elsewhere, such as Itzkovitz and van Oudenaarden (2011). After the dots
have been identified, the cells could then be segmented manually, typically based on a
combination of anti-E-cadherin signals (for cell boundaries) and DAPI stains (for cell nuclei)
The same algorithm described above took care of this and subsequently assigned the dots
to the appropriate cells. However, for signals such as EdU, we evaluated them as a binary
on/off. This was also the case for some transcripts (such as Gob5 for goblet cells and Lyz
for Paneth cells) which were too numerous to accurately count for even a single cell (i.e.
the cells either had no transcripts, or thousands of transcripts). Typically, the analysis is
done on a subset from the vertical image stack (typically 6 images). The raw mRNA counts
were divided by the volume of the cell in order to get the mRNA density (in number of
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transcripts per cubic micron). A sample image processing algorithm is shown below (from
Itzkovitz et al., 2012).
a b
Figure 2.2. A sample showing a typical data analysis algorithm for the case of the intestinal
crypt (with the crypt base located at the bottom, opening longitudinally upwards) with
single-molecule fluorescent in situ hybridization (FISH). The three left panels show FISH
dots corresponding to three mRNA species- Lgr5, Bmil, and Prominin-1, labeled in three
different channels on the same sample. The fourth panel shows the anti-E-cadherin stain
for the cell borders, which was used in this case to manually segment the cell boundaries.
After manual segmentation, the algorithm automatically identifies the FISH dots and
spatially assigns them into the correct cell according to the boundaries, as shown on the
right-most panel. Scale bar is for 5 microns. Image taken from Itzkovitz et al. (2012).
The same algorithm then identified the base of the crypt (the bottommost cell) and
assigned it a cell position of 0. The adjacent cells to either side of cell 0 received a position
number of 1, and so on. The output of this data analysis algorithm is a list of transcript
density or on/off binary signals for the different cells as a function of the cell number for
each crypt we analyzed.
One potential weakness with our processing technique is the manual segmentation
element. Despite the presence of cell border stains, we have been unable to automate this
process satisfactorily, so we have relied on the hand and eye to draw the right cell
boundaries in the algorithm for every cell. This process is not only tedious, but also is
error-prone. For example, the segmentation was typically done over a projection of 6
images in a vertical stack, and it is not always the case that the cell border would remain in
the same place throughout the 6 images. Therefore, we may have mistakenly assigned
some FISH dots to an adjacent cell. We acknowledge this weakness, but argue that on
average, it will not produce a bias, because the error typically only involves the small sliver
of region near the cell boundaries, and it is equally likely to mis-assign FISH dots to the left
adjacent cell than to mis-assign them to the right adjacent cell, so when we examine over
many crypts, there should be no systematic error that arose from this inaccuracy. In the
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case of on/off signals (such as Gob5or EdU), this is typically not a problem, as the signals
were almost always very clear to see relative to the cell borders.
2.4 FACS and qPCR
In Chapter 5, some of our procedures also called for FACS sorting and qPCR, so
here we describe the relevant protocols as they pertain to the mouse intestine. Typically,
this protocol requires the sequential performance of several steps: isolation of intestinal
cells, FACS sorting, DNA extraction, and finally qPCR.
2.4.1 Isolation of intestinal cells
Once we have obtained the mouse intestine after the protocol described in Section
2.2.1, we needed to process it so that we could dissociate the intestinal cells while keeping
them alive for FACS sorting. To do this, we used the following protocol. Unless otherwise
specified, everything was done over ice or in a 40C room.
First, we cut the intestine into smaller pieces, typically 5-cm segments. We then cut
the intestine open, lengthwise, and gently scraped off the villi, since we were only
interested in the crypts. We did so using glass slides. We then washed the intestine
fragments twice with 25 mL 1x PBS without Ca/Mg. The washing was done inside a 50 mL
tube, and we shook the tube gently. This was done with the intention to remove most of
the villi, which were discarded.
Then the intestine tissues were immersed in another 50 mL tube with 5 mM
ethylene glycol tetraacetic acid (EGTA, Sigma-Aldrich, St. Louis, MO) in 1x PBS without
Ca/Mg. This was incubated for 5 minutes with gentle agitation (e.g. on a slowly rotating
device). After 5 minutes, the tube was shaken vigorously, and the solid contents
transferred to another 50 mL tube filled with the same EGTA/PBS mix, for another 3 times.
However, this time, the incubation was 15 minutes (for 3 times) followed by vigorous
shaking. Afterwards, the solid fraction was discarded, and what remained in suspension in
these four EGTA/PBS tubes were isolated crypts.
We then centrifuged these four tubes (5 minutes at 700 rpm) and washed the
pellets with 5 mL S-MEM, in order to remove the EGTA. After another round of
centrifugation (under the same conditions), we resuspended the pellets with 50% v/v 1
mg/mL trypsin and 1% v/v DNAse in 1.5 mL S-MEM (Sigma-Aldrich, St. Louis, MO), for up
to 15 minutes in a 37*C water bath. Periodically (about every 5 minutes), the contents
were examined to note the extent of cell dissociation, and the suspension was pipetted up
and down a few times periodically.
After the cells were sufficiently dissociated, we immediately chilled the suspension
on ice. Typically at this stage, the suspension would become so viscous that we needed to
dilute it in additional S-MEM in order for the subsequent centrifugation to be effective.
Then we moved the samples to a 40C room and centrifuged the vials for 5 minutes
gently at 1300 rpm. Afterwards the samples were moved on ice. After the removal of the
supernatant, we resuspended the cells in 1 mL of 2% w/v BSA in 1x PBS to minimize cell
aggregation or sticking. The suspension was passed through a 40-micron mesh into a
BSA-coated tube. At this point, the cell count was taken.
If desired, about 15 minutes before sorting, we could do a live/dead cell staining
using propidium iodide (PI) by adding 300 pL of 500 nM PI (Invitrogen, Grand Island, NY).
2.4.2 FACS sorting
FACS sorting were performed by qualified technicians at MIT's Koch Institute on
either MoFlow or Aria machines. To prepare for FACS sorting, we typically required a
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negative and a positive control. The negative control would be wildtype cells without any
fluorescence. The positive control would be a population cells with at least some known
non-trivial fluorescent subpopulation (such as a Lgr5:Cre mouse without the Apc
mutagenesis). For all FACS experiments, we were only interested in the TOM and GFP
channels. MoFlow was able to segregate the cells into two distinct subpopulations, and
Aria, four. In the case of Aria, we typically gated for TOM-high GFP-high, TOM-high GFP-
low, TOM-low GFP-high, and TOM-low GFP-low. Because for the purpose of FACS
experiments, we were more concerned about TOM signals, if we used a MoFlow machine
instead, we gated for TOM-high and TOM-low.
The sorted cells were collected in plastic tubes that were seeded with 200 pL of 2%
BSA in 1x PBS, and were stored on ice.
2.4.3 DNA extraction
First, the cells in suspension were spun down for 5 minutes gently at 1300 rpm and
washed once with 1x PBS. Then the cell pellet was resuspended into 500 pL 1x PBS with
0.5% Triton X-1 00 (Sigma-Aldrich, St. Louis, MO) and with 5 pL of 20 mg/mL proteinase K
(New England Biolabs, Ipswich, MA), and incubated for 60 minutes a 650C, with shaking at
800 rpm. After the sample was removed from incubation, it was quickly put into ice, and
the spun at 1 minutes at maximum speed at 40C. On ice, the sample was added 60 pL of
5M sidium acetate (pH = 5.5), vortexed for 5 seconds, added 400 pL filtered cold
isopropanol, vortexed for another 5 minutes, and then incubated for 15 minutes. Then the
sample was spun for 15 minutes at maximum speed at 4C. The supernatant was
removed, and 600 pL of cold 70% ethanol was added. The mixture was vortexed for 5
seconds, and then spun for 5 minutes at maximum speed at 4*C. Finally, the supernatant
was removed, and the wash step with 600 pL cold 70% ethanol was repeated once again.
Then the DNA pellet was air-dried for about 30 minutes at room temperature, and then
solubilized in 200 pL of nuclease-free water. The sample was left to rehydrate for at least 4
hours (up to overnight) at 40C, and then incubated at 550C for 1 hour with shaking at 800
rpm. The DNA concentration was evaluated using a Nanodrop spectrophotometer for DNA
(at 260 nm) and protein (at 290 nm). Typically, a ratio A260/A290 of 1.7-1.9 is satisfactory.
Then the sample was stored long-term at -20*C.
2.4.4 PCR and qPCR reactions and gel electrophoresis
In order to perform PCR, it is desirable to know the DNA concentration, which we
can obtain by measuring on a Nanodrop spectrophotometer. Primer pairs for the loci of
interest were designed, with the details given below. The choice of these primers will be
justified later in Chapter 5.
Gapdh gene
Forward primer: ACCACAGTCCATGCCATCAC
Reverse primer: TCCACCACCCTGTTGCTGTA
Exon 14 of Apc gene
Forward primer: AACCTGTCTGCACACTGCAC
Reverse primer: CAAGCTGGACACATTCCGTA
Exon 15 of Apc gene
Forward primer: GCAAACAGAGCACAGTCCAA
Reverse primer: GAGTTGGCAGGTTCAGCTTC
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To initiate the standard PCR reaction, the following mixture was used: 10 pL of 2x
Phusion High-Fidelity Polymerase Master Mix (New England Biolabs, Ipswich, MA), 1 pL
of 10 pM forward primer, 1 pL of 10 pM reverse primer, 6 pL of template DNA (ideally with
a concentration of 100 ng/pL or higher), and 8 pL nuclease-free water, for a total reaction
volume of 20 pL. The thermoycling conditions are as follows:
Pre-incubation:
Amplification:
Extension:
Hold:
980C for 30 seconds
35 cycles of
(a) 98*C for 10 seconds
(b) 600C for 30 seconds
(c) 720C for 30 seconds
72*C for 10 minutes
at 40C
Once the product has been amplified, it was mixed with 4 pL loading dye (New
England Biolabs, Ipswich, MA) and then loaded into a channel in an agarose gel (made
from 50 g of agarose in 50 mL of 1x TAE buffer) in 1x TAE buffer solution. The
electrophoresis was run with a channel dedicated to 4 pL DNA ladder (New England
Biolabs, Ipwsich, MA) in 16 pL nuclease-free water with 4 pL loading dye. The
electrophoresis reaction was run at 90 V for about 30-60 minutes. Then the gel was taken
out and imaged under UV.
On the other hand, if we want to do a qPCR reaction, then the protocol is slightly
different. We used the following reaction mixture: 5 pL of KAPA SYBR Green Master Mix
(KAPA Biosystems, Woburn, MA), 1 pL of forward primer, 1 pL of reverse primer, 1 pL of
DNA template (ideally with a DNA concentration of 100 ng/pL or higher), and 2 pL of
nuclease-free water, for a total reaction volume of 10 pL. Typically, the same reaction was
done in duplicate or triplicate.
The amplification conditions are as follows:
Pre-incubation:
Amplification:
Melting curve:
Cooling:
Hold:
950C for 5 minutes, at a ramp rate of 4.4 0C/second
45 cycles of
(a) 95*C for 10 seconds, at a ramp rate of 4.4 0C/second
(b) 600C for 10 seconds, at a ramp rate of 2.2*C/second
(c) 720C for 10 seconds, at a ramp rate of 4.4 0C/second
(a) 950C for 5 seconds
(b) 650C for 1 minute
(c) A 2.2 0C/second ramp to 970C, with 5 measurements taken per *C
400C for 30 seconds, at a ramp rate of 4.40C/second
at room temperature
After the amplification reaction is complete, we can perform gel electrophoresis on
the product using the same protocol and reaction mix as described above.
After electrophoresis, if we wish to extract specific DNA bands for further
sequencing, then we used the QlAquick gel extraction kit (QIAGEN, Valencia, CA), using
the protocol as specified for the particular kit. DNA sequencing was done at the
Biopolymer Center at the Koch Institute at MIT, Cambridge, MA in accordance to their
preparation and reaction protocols.
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Chapter 3. Mobility patterns
We are interested first in the mobility characteristics of the different cells in the
normal intestinal crypt. Specifically, are there lineage-dependent differences in proliferation
and migration behaviors in the crypt? If so, how does this challenge the "conveyor belt"
model and inform about the more general phenotypes of the crypt?
In order to do this, we used EdU pulse-chase staining, as explained above in
Chapter 2, in order to gauge both the proliferation and migration rates. Essentially, we
compared the distribution of EdU+ cells when only a pulse was given with the distribution
of EdU+ cells when that pulse was followed by a 24-hour chase. The concept of the EdU
pulse-chase experiment is sketched below. The first column illustrates a simplified
representation of the different cell types that exists in a numbered column of upward-
migration cells, as would be typically found in an intestinal crypt (* for stem cells; # for
rapidly dividing cells; and ^ for terminally divided cells). After EdU pulse, cells which are in
the S-phase will be labelled (shown in blue). Typically, rapidly dividing cells (denoted by #)
have a higher probability of being in the S-phase. EdU pulse alone, therefore, would give
us information about the proliferation rate. However, if the EdU pulse is followed by a
chase (e.g. a delay in sacrificing the mouse), then the original cells which have the EdU
label incorporated will also have divided and migrated upwards, giving rise to progenies
that are also EdU+. Therefore, by tracing the distribution of EdU+ cells in an EdU pulse-
chase experiments (with different chase durations), we can in theory gauge the migration
velocity of the cells.
15A 15^ 11^
14A 14^ 1OA
13"A 13"A 9 5A
12^ 12^ 8^ 4A
11^ 11^ 7A
10" 10"
9^ EdU pulse 9^ 12 h chase 12 h chase
8^ 8" 5^ 2"
7" 7A 4A 2"
6# 1#
5# 5# 1#
4# 4# 2# #
3#* 1# #
2# 2# # #
1* 1***
* stem cell # rapidly proliferating cells " terminally differentiated cells
Figure 3.1 a. A conceptual sketch of the EdU pulse-chase experiment. The first column
illustrates a simplified model of the wildtype crypt, with the different cell types
approximated by the symbols (* for stem cells, # for rapidly proliferating cells, and ^ for
terminally differentiated cells). Th second column illustrates what may happen when EdU
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stain is introduced: cells which are in S-phase (more probably rapidly dividing cells) will be
labelled. If we allow some time period to "chase" the EdU after the pulse, then the original
cells of EdU incorporation will have divided and migrated, resulting in a distribution of
EdU+ cells which can tell us about the migration velocities of the cells.
~I44
Figure 3.1 b. An example of a pulse-chase experiment, using tritiated thymidine (which has
similar experimental function in this case as our EdU), in the intestinal crypt, as taken from
Potten (1998). The series of four panels show the initial pulse (black labeled cells near the
base of the crypt), followed by chases at different time intervals. As we can see, as time
elapses, the labeled cells migrate upwards from the crypt base while retaining the label,
until the cells are shed off at the villus (rightmost panel).
At the same time, we stained the tissue sample with other lineage-dependent
markers such as the transcripts for Gob5. This will allow us to separately gauge the
proliferative and migratory behaviors (based on EdU) stains conditioned on the different
cell types. This is illustrated in the picture below, where Gob5 (single-molecule FISH) is
shown in red, EdU staining in green, and DAPI in blue, for a mouse sacrificed two hours
after EdU injection i.e. no chase).
Figure 3.1. Left plot: A sample of a tissue section showing a crypt (base towards the top-
right, opening diagnolly towards the bottom-left) that has been both hybridized using
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single-molecule fluorescent in situ hybridization (FISH) for the transcripts of a gene for
goblet cell marker Gob5 (in red) and stained with the proliferative marker EdU (in green)
and and nucleus marker DAPI (in blue). Right plot: Another sample, with a crypt with base
towards the bottom-right, opening diagonally towards the top-left.
Then, for each lineage population, we can plot the fraction of EdU+ cells, which we
do below. The left plot below shows the distribution of EdU+ fractions for both the Gob5+
(blue) and the Creb33+ (red) subpopulations after a pulse of EdU was given. Remember
that Gob5+ subpopulation is associated with the secretory lineage (such as goblet cells),
while the Creb33+ is associated with the absorptive lineage.
60
*Crb33+ 50
Pulse 42h
040
'20,
02 I uJ
25 125 225 325 425 25 125 225 325 425
CeI position from crypt base CeUl position from crypt base
Figure 3.2. Right plot: A plot showing the spatial distribution of fraction of EdU+ cells as a
function of cell position from the crypt base, for Gob5+ cells (in blue) and Creb33+ cells (in
red) after a 2-hour EdU pulse. Left plot: A plot showing the estimated cell cycle period, as
estimated by the fraction of EdU+ cells in each bins from the left plot, using the technique
described by Koburg and Maurer, 1962). The histograms are divided into equal bins of 5
cell positions.
Focusing on the left plot (EdU pulse only), we see something interesting: the Gob5+
subpopulation has a different distribution of EdU+ cells compared to the Creb33+
subpopulation. We can quantify this difference in proliferation rates further, by noting that
the S-phase duration for most renewing epithelia is about 7.5 h (Koburg and Maurer, 1962).
Then, from the EdU+ fraction above, we can even approximately infer the cell cycle time
by dividing 7.5 h by the fraction of EdU+ cells. The plot on the right shows the mean cell
cycle times at different cell positions for the two lineages. Let us examine Creb3l3+ cells
(absorptive lineage, in red) first. We note that at low cell positions (below 10), these cells
behave like the rapidly dividing transit amplifying cells, which are known to have a mean
cell cycle time of about 12 hours (Meineke et al., 2001). As we move up the crypt, we see
that the Creb33+ cells mature and stop dividing, as indicated by a drastic increase in the
cell cycle period (because most cells have stopped dividing). In contrast, Gob5+ cells have
a very different profile. We note that at the same cell positions from the crypt base, these
cells cycle at a much slower rate compared to the Creb3/3+ cells. Therefore, it can be said
that the Gob5+ cells not only proliferate much slower than Creb33+ cells, they also mature
at a lower position in the crypt.
One critical control experiment that we needed to do is to test whether the 2-hour
delay between EdU injection and mouse sacrifice constitutes a good EdU "pulse". Some
amount of delay between EdU injection and mouse sacrifice is needed because after
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injection, it takes time for EdU to be delivered to the intestinal crypt. However, if the delay
is too long, then we risk having the EdU continuously incorporated into the cells. In other
words, cells which were in S-phase may have already exited the S-phase into the M-phase
when we sacrificed the mouse but still showed up as EdU+, and cells which were not in S-
phase may have entered into the S-phase during the 2-hour delay, therefore introducing a
systematic bias into our data by exaggerating the EdU+ fraction. In order to evaluate this
effect, we carried out a parallel set of experiment where we sacrificed the mouse one hour
after EdU injection, instead of 2 hours. Fortunately, we did not observe a drastic difference
in the EdU distribution, which suggested that whatever systematic error may have been
introduced would be small. However, to further verify this claim, we did another set of
experiments in which EdU staining was performed alongside a mitotic marker (such as
phospho-histone H3 antibody or even just mitotic figures seen in DAPI). We again did not
observe a significant fraction of EdU+ cells in the M-phase with a 2-hour EdU delay as
prescribed by the pulse experiment. Ultimately, we chose to stay with the 2-hour delay,
because this has been the standard used in other similar EdU pulse-chase experiments for
the "pulse" part (for example, Buske et al., 2011).
However, if we now turn our eyes to analyze the mobility characteristics of the two
lineages, we see a very different picture. The left plot below is reproduced from the EdU+
fraction above from the EdU pulse experiment (without chase) from above. The right plot
below shows the EdU+ fraction as a function of cell position for another set of experiment
where the EdU pulse was followed by a 24-hour chase, again with the two lineages plotted
differently---secretory lineage in blue, and absorptive lineage in red.
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Figure 3.3. Right plot: A plot showing the spatial distribution of fraction of EdU+ cells as a
function of cell position from the crypt base, for Gob5+ cells (in blue) and Creb3/3+ cells (in
red) after a 2-hour EdU pulse. Left plot: The same plot as described previously, but with
the 2-hour EdU pulse followed by a 24-hour chase before mouse sacrifice.
We indeed see a non-trivial migration of the cell populations by comparing the pulse
(left) to the pulse-chase data (right). Notably, EdU+ cells have migrated up the crypt in
both lineages, as can be expected. Now, the question is: Are there differences in the
migration speed of the two lineages?
Extracting the migration speed from the "cloud" of EdU+ cells above is not a trivial
task. As time goes on, EdU continues to be incorporated into the cell, as judged by the
presence of EdU+ cells in the lower crypt (below cell position 10). However, those cells
which had previously incorporated EdU during the S phase and subsequently migrated
now show up as a shifted EdU+ fraction at a higher cell position. In the two plots below, we
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attempt to quantify these different distributions using different statistical measures. The
plots below are the distributions above represented in box-and-whisker plots. The left plot
shows the distributions of the two lineages (Gob5+ and Creb3/3+) for the EdU pulse
experiment. The right plot shows the same distributions for the EdU pulse-chase
experiment. In the box-and-whiskers, the red line represents the 50% percentile (i.e. the
median), while the blue lines the 25% and 75% percentiles. The red crosses are outliers.
The other statistical measures, such as the mode, mean, and standard error of the mean
(sdom), are enumerated above the box-and-whiskers.
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Figure 3.4. The box-and-whisker plots describing the spatial distribution of EdU+ cells of
different lineages (Gob5+ and Creb3/3+) for an EdU pulse experiment (left plot) and an
EdU pulse experiment followed by a 24-hour chase (right plot). It is assumed that the
difference in the distribution between the corresponding lineages on the left compared to
the right plot can serve as a measure of cell migration.
For example, by looking the Gob5+ cells on the left and the right plots, we see that
the mean moved from a cell position of 7.6 to 12.2 in 24 hours. This, of course, does not
reflect the actual migration speed---which is known to be about 1-2 cell position per hour
(Tsubouchi, 1983)---because of the various complications in EdU incorporation as
described above. However, these differences should give us a representative measure of
the bulk migratory effect for the two lineages. Unfortunately, the different statistical
measures failed to detect any significant differences between the mobility characteristics of
the Gob5+ and the Creb3/3+ lineages, so we failed to conclude that there are lineage-
dependent migration differences in the intestinal crypt.
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Chapter 4. Spatial Profiling of Markers
4.1 Data visualization and cryptograms
4.1.1 Lineage profiles are perturbed in APC KO mice.
The figure below illustrates an attempt at representing the expression profiles of
three selected lineage markers---Creb3/3 for differentiated enterocytes (leftmost column of
three color plots), Gob5 for differentiated goblet cells (center column of color plots), and
Lgr5 for stem cells (rightmost column of three color plots)---in the intestinal crypt. The
three rows of color plots refer to the different experimental conditions: the top row of color
plots represents expression levels in wildtype crypts, while the bottom two rows of color
plots demonstrate APC-loss conditions as labeled.
In each color plot, each row represents a separate crypt. The columns are the
different cell positions. The centermost column reflects the base of the crypt, while the two
outer rims of the crypt are the leftmost and rightmost columns, and the crypt opens
symmetrically about the center. The color represents mRNA expression levels, normalized
for each gene to the highest expression level observed in a single cell.
As we can see from the wildtype profile (first row), the Creb3/3 (first column) is lowly
expressed at the bottom of the crypt and increases in expression towards the rim of the
crypt, as the undifferentiated stem cells or partially differentiated transit amplifying cells
mature into one of the different terminal lineages. Likewise, in the second column, we see
that the Gob5 marker is largely absent from the crypt base, and only begins in expression
from cell position 5 and onwards. However, one difference is that there are many more
enterocytes (Creb3l3-expressing cells) compared to goblet cells (Gob5-expressing cells),
which is expected in the normal crypt. In contrast, in the third row of the first column, we
see the expression signature of Lgr5, the stem cell marker. Here, the expression is
centered at the base of the crypt, and fades away around cell position 5. These
observations are consistent with what we expect from a normal crypt.
Things become more interesting as we compare the remarks above for the wildtype
case with the APC-knockout cases, as observed in the two bottom rows of color plots. First
we observe a marked expansion of LGR5-expressing cells beyond cell position 5, even
though it is true that the different crypts have various extent of spatial expansion of Lgr5+
cells. At the same time, as we examine Gob5 and Creb3/3 expression patterns, we find
that the abundance of positive cells have decreased in both cases. In particular, if we
carefully compare the corresponding rows in each color plot for the three genes, we find
that Creb3/3 and Gob5 are only expressed where Lgr5 is low or absent. Namely, the Lgr5
marker seems mutually exclusive to the differentiation markers.
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Figure 4.1. Color plots showing mRNA expression levels, with those within each plot
normalized to the highest value (red) within the plot and zero as the lowest value (blue).
For each color plot, the crypt apex is represented by the middlemost column, while the
leftmost and rightmost columns are the cells closest to the crypt rim. Each separate row for
the color plot shows the profile for a different analyzed crypt. White shows data which are
absent. We studied three lineage markers- Creb3/3 for enterocytes (first column of color
plots), Gob5 for goblet cells (second column of color plots), and Lgr5 for stem cells (third
column of color plots)-under different experimental conditions, with wildtype mice (first
row of color plots), mice with Apc loss after 7 days (second row of color plots), and mice
with APC loss after 14 days (third row of color plots).
4.1.2 Cryptograrns help quantify this lineage perturbation.
While the color plots above are helpful in gaining insights into the expression
patterns of various markers, especially at a single-cell-level resolution, we are also seeking
a more compact way of representing this information. To help us in this, Itzkovitz et al.
(2012) introduced the concept of "cryptograms", where the expression levels at each cell
position are averaged and plotted on a single profile with the x-axis as the cell position
(from the base of the crypt), and the y-axis as the mean expression level. The figures
below demonstrate the cryptograms of Creb3/3 and Lgr5 mRNA levels under different
experimental conditions: wildtype (left) versus APO-KO (middle and right). At a first glace
of the wildtype data, we observe that the cryptogram illustrates what we expect: the Lgr5
expression is concentrated at the base of the crypt and falls off rapidly around cell position
5. On the other hand, Creb3/3 increases its expression starts at cell position 10, and is
highest near the crypt rims. Then, we see in the cryptograms corresponding to APO-KO
that the Lgr5 shows a broader spatial expression compared to the wildtype case, while
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Creb3/3 expression is suppressed on average. However, what is interesting is the
observation that in the APC-KO case, the Lgr5 expression level (in absolute mRNA count)
is not only broader, but actually also higher compared to the wildtype case. In other words,
in the APC-KO case, the stem cells are not only clonally expanding out of their regular
niche, but also on average demonstrate a higher level of Lgr5 compared to the wildtype
case. This observation is something that the color plots above cannot easily capture and
demonstrate. Note that due to the inherent difficulty in accurately counting the number of
Gob5 transcripts because Gob5 is densely expressed in goblet cells, we do not plot the
cryptogram for Gob5, but rather use another method to examine the Gob5 expression later.
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Figure 4.2. Cryptograms of the genes Lgr5 (blue) and Creb3l3 (black) for the wildtype
mouse (left), as well as APO loss for 7 days (middle) and 14 days (right). A cryptogram is a
way of presenting the data where the x-axis denotes the cell position from the crypt base
(with 0 as the crypt base), and the y-axis denotes the average mRNA level for a particular
species at the particular cell position for the many different analyzed crypts. Note that
while Lgr5 (a stem cell marker) shows a declining spatial profile, Creb3/3 (an enterocyte
marker) shows an ascending spatial profile further from the crypt, in the wildtype case.
Note that after APC loss, the Lgr5 profile has a broader expression, which corresponds to
the observation that stem cells can expand out of their original niche, while Creb3/3
expression is suppressed.
4.1.3 Population of Lgr5+ cells are enriched in APC KO.
To help us quantify the system better, we attempt to understand how the stem cell
population may be changed in the APC-KO scenario. In each crypt, we identify a cell to be
Lgr5+ if its expression level exceeds a pre-determined threshold (less than the mean
wildtype Lgr5 level minus the confidence interval). The left plot below shows the probability
of finding an Lgr5+ cells at a particular cell position from the crypt apex. This mirrors the
cryptogram for Lgr5 above, where stem cells are most common at the crypt apex (at
around 50-60%) and declines as we move up the crypt. The similar derangement is
observed in the APC-KO case, where while the fraction of Lgr5+ cells remains consistent
near the crypt apex, the fraction is significantly higher in higher cell positions where Lgr5+
cells are typically not found in the wildtype case. As we can see, in the 7-day APC-KO
case (central plot), the Lgr5+ distribution has not reached a steady state, and thus we
observe a spatial gradient in the fraction of Lgr5+ cells. This suggests that the stem cells
are in the process of clonally expanding out of the crypt. By 14 days after APC loss (right
plot), the profile is much flatter, signifying that by day 14, the clonal expansion within our
region of interest has reached a steady-state.
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Figure 4.3. These plots illustrate the probability of finding Lgr5+ (stem) cells at different cell
positions from the crypt apex (i.e. crypt base), for the wildtype mouse (left), as well as mice
with APC loss for 7 days (middle) and 14 days (right). Note that after APC loss, the
probability of finding Lgr5+ outside of the natural intestinal stem cell niche (typically below
cell position 5) increases greatly.
4.1.4 Goblet cells become rarer in APC KO.
Next, we turn our attention to the goblet cells, another terminally differentiated
lineage for the intestinal crypt. As stated earlier, because the Gob5 transcripts are densely
expressed, it is rather difficult to accurately quantify the Gob5 expression level in each cell.
Furthermore, because the goblet cells occupy a minority of the differentiated lineages
(around 10%), the bulk-average approach of the cryptogram is not as meaningful as it is
for genes such Lgr5 and Creb33. Therefore, instead of averaging the mean transcription
level of Gob5 at each position, we instead identify the fraction of Gob5+ cells at each cell
position using the similar thresholding technique described above for identifying Lgr5+
cells.
As can be seen in the plot below, the wildtype goblet cell profile (blue) shows a
gradual increase as we migrate away from the crypt base, as expected from above for the
behaviors of differentiated lineages. In contrast, we see that in the APC KO scenario, there
is a marked decrease in the fraction of Gob5+ cells, as consistent with the observations
above.
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Figure 4.4. A plot showing the probability of finding Gob5+ (goblet) cells at different cell
positions from the crypt apex (i.e. crypt base) for wildtype (blue solid line) mouse, as
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compared to mice that have lost APC (APC KO) for 7 days (red dashed line) and for 14
days (black dash-dotted line). Note that in the case of APC KO, the fraction of goblet cells
at the later position is suppressed.
To show this reduction in the fraction of Gob5+ cells more conclusively, we did
another quantification, in which for each crypt, we counted the total number of goblet cells
in the crypt and divided this number by the total number of cells counted. This fraction,
while lacking in spatial information, gives us a good measure of the overall density of
goblet cells. In each of the plots below, we illustrate the histogram of the goblet cell density.
As we can see in the wildtype case (left plot), about 13% of the crypt cells are Gob5+. This
number is reduced for APC loss, both 7 days after KO (middle plot, 8% Gob5+) and 14
days after KO (right plot, 3% Gob5+). Given the error bars, we conclude that the three
values lie outside each other's 95% confidence level.
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Figure 4.5. A histogram showing the goblet cell density (i.e. the fraction of cells in an
analyzed crypt that consists of goblet cells) in wildtype mice (left) compared to mice that
have lost APC for 7 days (middle) and for 14 days (right). The mean fraction per crypt is
given. Note the significant reduction of the goblet cell fraction in transformed crypts.
4.1.5 Profiles of proliferation markers also show perturbations in APC KO.
To examine the downstream (and possibly phenotypic) effects of APC KO further,
we selected a pair of markers related to cell proliferation: Ki-67 and Myc (also known as
cMyc). Previous studies at the protein level have remarked an increase in the expression
of both cMyc and Ki-67 after APC loss (Jilong et al., 2007). However, what we found was
somewhat surprising.
The first figure shows the color plots of the expression levels of Ki-67 and cMyc at
the single-cell level in different intestinal crypts. This result is translated to the ensuing
figure below, which plots the respective cryptograms. As can be seen in the wildtype
cryptogram, both Ki-67 (black) and cMyc (red) mRNA expression patterns exhibit a
"peaked" behavior: it is lowly expressed near the crypt base, peaks around cell positions 5-
10, and then falls off towards the rim of the crypt. In the APC-KO cryptogram, this peaked
pattern still persists, though the peaks have shifted towards the rim of the crypt (around
cell position 10). What is more surprising, however, is the absolute level of expression:
while cMyc transcripts see a higher level of expression in the APC KO scenario, the
transcripts for the Ki-67 gene see a lower level of expression. This is quite baffling and
almost contradictory: how is it that the two proliferation markers behave differently upon
APC loss?
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One possible explanation is that cMyc and Ki-67 are regulated via different
pathways. While cMyc is a known downstream gene regulated by the WNT pathway (see,
for example, You et al., 2002), the role of Ki-67 and its regulatory status is much less
known. Therefore, it is not surprising that the two genes are regulated differently. While our
approach using single-molecule FISH is able to draw out the detailed expression profiles of
the different genes, we unfortunately are limited in what we can do to verify the interactions
amongst the different genes and how they may be causally affected by APC loss. After all,
correlation does not imply causation.
However, this does not address another glaring question: Are our observations not
a contradiction with the observations in Jilong et al. (2007) in which both proteins
demonstrate a higher level of expression upon APC loss? To this question, we also do not
offer a definitive answer, but can only remark that transcript levels (which we observe) may
not always correlate with protein levels (which Jilong et al. observed). While in many cases,
single-molecule FISH is highly correlated with protein expression (Raj et al., 2008), there
are also instances, including in the case of intestinal crypt, where, possibly due to post-
transcriptional regulation, there is a observed difference between transcript and protein
levels (see, for example, Muhoz et al., 2012). Later on, we will explore this question further
in a more detailed analysis and discussion.
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Figure 4.6a. Color plots showing mRNA expression levels, with those within each plot
normalized to the highest value (red) within the plot and zero as the lowest value (blue).
For each color plot, the crypt apex is represented by the middlemost column, while the
leftmost and rightmost columns are the cells closest to the crypt rim. Each separate row for
the color plot shows the profile for a different analyzed crypt. White shows data which are
absent. We studied two proliferative markers- Ki-67 (first column of color plots) and cMyc
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(second column of color plots) -under different experimental conditions, with wildtype mice
(first row of color plots), and mice with APC loss after 7 days (second row of color plots).
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Figure 4.6b. Cryptograms showing the spatial expression profiles of the genes Lgr5 (blue),
Ki-67 (black), and cMyc (red) in wildtype mice (left) and in mice that have lost APC for 7
days (right). Note in particular the changes in the cryptograms of the different genes as a
result of APC loss.
4.1.6 Proliferative markers show no significant correlation with Lgr5 on a single-cell level.
Because the seeming direct correlative behavior between Lgr5 and the two
proliferative markers (one goes up and the other goes down in the cryptogram), we are
interested in seeing whether or not this correlation extends to a single-cell level.
Fortunately, the single-molecule FISH technique is able to help us achieve this level of
resolution. In the plots below, we plotted the single-cell correlation of the different pairs of
genes (Lgr5-Ki-67 in blue, left plot; Ki-67-cMyc in green, central plot; Lgr5-cMyc in red,
right plot) for both the wildtype scenario (top row of plots) and the APC-KO scenario
(bottom row of plots). In general, we did not observe any statistically significant positive or
negative correlation between the different pairs of markers. This suggests that while there
is a general correlation at the population level, factors such as noisy expression level may
obscure or eliminate this correlation at the single-cell level.
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Figure 4.7. A series of correlation studies between different gene pairs: Lgr5-Ki-67 (first
column, blue plots), Ki-67-cMy (second column, green plots), and Lgr5-cMyc (third
column, red plots), in wildtype mice (top row) and mice that have lost APC for 7 days
(bottom row). The black lines are (unsuccessful) attempts to linearlly fit the data points in
each plot. We did not find any statistically significant correlation between any of these
different pairs.
4.1.7 The ephrin/eph signaling pathway is also perturbed in APC loss.
We are very interested in characterizing the expression profiles of the genes EphB
and EfnB (a.k.a. EphrinB) in APC loss. In particular, the ephrin signaling pathway
regulates cell sorting and migration in various systems, such as the endothelium (Carlson
et al, 2005), neural crest (De Bellard et al, 2002), as well as the intestinal crypt, where
EPHB2 (at the protein level) is known to be high at the crypt base and low at the crypt rim,
while its counterpart EPHRINB31 is known to be low at the crypt base and high at the crypt
rim. Perturbations in Wnt signaling (e.g. Apc-induced) in colorectal cancer is known to alter
the expression profile of the EPHB2-EPHRINB1 pair (Clevers and Batlle, 2006; Sansom et
al, 2004), thereby possibly perturbing cell adhesion and migration.
The cryptograms below illustrate the patterns for the genes EphB2 (blue) and
EphrinB1 (red), with Lgr5 as a reference (black). As we can see in the wildtype scenario
(left plot), while the spatial variation of EphrinB1 is not very pronounced at a transcriptional
level, we note that indeed, the bottom of the crypt is rich in transcripts for the EphB2 gene,
while the upper part of the crypt is comparatively EphrinB1-rich. In APC loss, this spatial
gradient no longer exists: even as soon as 7 days after APC loss, we note a spatially
uniformly high EphB2 expression throughout the crypt, and a correspondingly uniformly
low EphrinB1. This "flat" profile, compared to the previous cryptograms, is quite surprising
as it shows an unusually "strong" response of Eph/Ephin to APC loss. However, we know
that by day 7, the crypt is only partially populated by LgrS+ stem cells---so how is it that the
alteration can be so complete, if there is also a mix of normal non-stem cells? Could it be
that these non-stem cells also somehow display a perturbed Eph/Ephrin expression
pattern? In the next section, we will examine these unanswered questions in detail.
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Figure 4.8. Cryptograms showing the spatial expression profiles of Lgr5 (black), EphB2
(blue), and EphrinB1 (red) in the intestinal crypts of wildtype mice (left) versus mice that
have lost APC for 7 days (right). Note in particular that APC loss has significantly changed
the expression pattern of EphB2 and EphrinBl, which is described in greater depth in the
main text.
4.1.8 The role of other targets putative stem cell markers.
In this section, we outline the expression patterns of other markers that are of
interest to us. The figure below illustrates the cryptograms of Cyclin-D1 and Olfm4. We
selected Cyclin-D1 because it is often misregulated in WNT abnormalty (for example, see
Sansom et al., 2004). Some studies have proposed that CYCLIN-D1 is a direct target of
WNT signaling, because CYCLIN-D1 is often elevated in transformed crypts that are high
in WNT (for example, Tetsu and McCormick, 1999, and Arber et al., 1996). However,
another camp, noting that CYCLIN-D1 is upregulated only in a delayed manner after APC
loss, believes that CYCLIN-D1 is not a direct target of f-catenin (Sansom et al., 2005).
This second claim though raises an interesting question, because combined with the
observation that CYCLIN-D1 is high only in a subset of transformed cells, it may be the
case that CYCLIN-D1 accounts for a secondary change (subsequent of APC loss) leading
to tumor progression (Sansom et al., 2005). Therefore, CYCLIN-D1 seems to play a very
interesting (and somewhat stochastic) role in the development of colorectal cancer. Can
we uncover this dynamics further by quantifying Cyclin-D1 at the transcript level?
In addition to Cyclin-D1, O/fm4 is also of interest to us because it has been
suggested by some studies (e.g. van der Flier et al., 2009) to be a putative stem cell
marker that has a similar profile as Lgr5. As seen in the figures below, in the wildtype crypt,
Olfm4 has a similar but broader spatial expression pattern as compared to Lgr5. Likewise,
during APC loss, we also see a slightly broader expression of Olfm4, which is expected as
the stem cell niche expands in transformed cells. However, in contrast, we did not see a
significant change in the expression profile of Cyclin-Di, despite claims otherwise at the
protein level. More detailed single-cell-level analysis (from the color plots below) also failed
to reveal possible upregulation at the subpopulation level at the transcript level.
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Figure 4.9a. Color plots showing mRNA expression levels, with those within each plot
normalized to the highest value (red) within the plot and zero as the lowest value (blue).
For each color plot, the crypt apex is represented by the middlemost column, while the
leftmost and rightmost columns are the cells closest to the crypt rim. Each separate row for
the color plot shows the profile for a different analyzed crypt. White shows data which are
absent. We studied two markers- Cyclin-D1 (first column of color plots) and O/fm4
(second column of color plots) -under different experimental conditions, with wildtype mice
(first row of color plots), and mice with APC loss after 7 days (second row of color plots).
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Figure 4.9b. Cryptograms showing the spatial expression profiles of Lgr5 (black), Cyclin-
D1 (blue), and O/fm4 (red) in the intestinal crypts of wildtype mice (left) versus mice that
have lost APC for 7 days (right).
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Beyond Olfm4, we are also interested in various other putative stem cell markers, in
particular those that may denote the "+4" cell population (in contrast to the more broadly
expressing Lgr5, which we used in this thesis to be the stem cell marker). While many
studies have assumed Lgr5 to be a reliable stem cell marker (for example, Barker et al.,
2009), at least for the CBCs, there are also other putative stem cell markers-especially
with respect specifically to the +4 cells-that have been proposed in various studies (as
reviewed in Barker et al., 2012). Previous studies of some of these putative markers with
single-molecule FISH have revealed more ambiguous results (Muhoz et al., 2012) where
the mRNA expression not only do not seem to uniquely identify the stem cell
subpopulations, but also show a broad expression pattern even outside the stem cell niche.
For example, while Sangiorgi and Capecchi (2008) reported, based on lineage tracing
experiments, that Bmil is uniquely expressed in +4 cells, a later study using mRNA FISH
by Itzkovitz et al. (2011) revealed that Bmil shows a broad expression pattern throughout
the entire crypt. This was also confirmed by another study (van der Flier et al., 2009) by
sorting Lgr5+ cells and analyzing Bmil expression level using qPCR. In this section, we
carried out the same analysis on more recent putative +4 cell markers and see whether or
not they are unique to the +4 position at the transcriptional level.
The first marker of interest for us is Hopx, a newly identified putative stem cell
marker especially for the +4 population as shown by Takeda et al. (2011), based on
protein-level lineage tracing. The other marker of interest is Lrigl, which was identified by
Powell et aL (2012) as another possible marker for the +4 population. However, no single-
molecule FISH has been done either on the Hopx or the Lrigl transcripts to date. First we
designed FISH probes against Hopx and were successful at staining the Hopx mRNAs.
Surprisingly, as shown in the left image below, Hopx shows a broad expression pattern
and do not, as we might expect, unique identify the +4 cells. The color plot below (right)
shows 40 analyzed crypts and the broad expression pattern that extends as far as cell
position 20 from the crypt base.
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Figure 4.10a. The left picture shows an image of the different crypts (with crypt base
located at the top, opening longitudinally towards the bottom of the picture) after staining
with single-molecule FISH. The dots are single mRNA molecules for the Hopx gene. Note
the broad expression along the entire length of the crypt. The right picture attempts to
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quantify this observation by plotting the expression level as a color plot (red being the
highest expression level, and blue being the lower) normalized to the highest mRNA
transcript density per cell in all observed crypts. The x-axis shows the cell position from the
crypt base, while the y-axis lists the different crypts analyzed. Note, once again, the broad
Hopx expression along the length of the crypt, as observed earlier in the left picture.
The spatial profiles of these putative stem cell markers such as Hopx are
summarized in the figure below (Muioz et al, 2012). In the leftmost figure, we can see that
Hopx has a peaked behavior at the base of the crypt up to cell position 6, and then tapers
off. However, the profile decidedly negate the claim that Hopx, at the transcriptional level,
may be a unique +4 cell marker. The same conclusion can be drawn to the other putative
markers, Bmil (middle plot) and Lrigl (left plot), whose data we helped analyze in
collaboration with Shalev Itzkovitz (picture taken from Munoz et al, 2012). These
observations echo the earlier observation that some putative +4 markers may actually
have a broad level of expression, at least on a transcriptional level. These observations
also point to the fact that identifying a unique +4 marker may not be as straightforward and
definitive as it may seem.
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Figure 4.10b. This series of plots, taken from Muhoz et al. (2012), show the cryptograms
for the different putative stem cell markers Hopx (left), Bmil (middle), and Lrigl (right) in
the intestinal crypt. The pictures immediately above the plots show a representative single-
molecule FISH image staining for the transcripts of the targeted gene. Note that all these
putative stem cell markers, at the transriptional level, display a broad expression pattern
that is somewhat inconsistent with the stem-cell-specific expression claimed (at the protein
level) from earlier studies.
4.2 Deconvolving extrinsic versus intrinsic effects
4.2.1 Why the cryptogram method is limited
In the section above, we carried out an in-depth spatial profiling of several key
markers, especially in the context of APC loss, and obtained some interesting
observations. However, we also noted that there are some inherent limitations in this
approach of analysis. As an illustration, the figure immediately below reproduces the
cryptograms of Ki-67 (black), Lgr5 (blue) and cMyc (red) in wildtype (top-left plot) and APC
loss (top-right plot). As we noted earlier already, there is a marked perturbation in the
spatial profile of all three genes upon APC loss. However, is this perturbation caused by
intrinsic single-cell-level changes in the transcript expression level, or is it caused by the
extrinsic changes in the altered composition of the different cell lineages in the entire crypt?
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Figure 4.11. This series of plots have been reproduced from earlier in Chapter 4, and
illustrates the need to deconvolve intrinsic and extrinsic factors in the intestinal crypt that
may have affected the cryptograms of the different mRNA species. The plots on the top
row shows the cryptograms of three mRNA species-for the genes Lgr5 (blue), Ki-67
(black), and cMyc (red)-in wildtype mice (left) as well as mice that have lost APC for 7
days (right). The bottom row illustrates the corresponding plots for the probability of finding
Lgr5+ cells at the different cell positions in the same wildtype mice (left) as well as mice
that have lost APC for 7 days (right). The point that we are trying to make is that the
alterations in the cryptograms between health (left) and disease (right) may at least be
partially accounted for by extrinsic factors such as an altered composition of the cell
lineages (as shown in the bottom row), and could also be accounted for by intrinsic factors
such as an inherent change at a single-cell level of the expression patterns once these
cells have lost APC. Parsing out the extrinsic factors and the intrinsic factors, and evaluate
their extent of contribution, is a highly relevant course of investigation.
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To elaborate, from the wildtype cryptogram, we know that Ki-67 (black) on average
has a lower expression level in the stem cell niche (below cell position 5). Now, we also
observe that Ki-67 expression is lowered in the APC-KO case. Is this simply due to the
clonal expansion of Ki-67-low stem cells further up the crypt (as according to the bottom-
right plot), or is this due to the intrinsic reduction of Ki-67 expression of the deranged stem
cells and/or other lineages? As we can see, there are various possible factors---extrinsic
and intrinsic---that can explain the altered cryptogram of Ki-67, and just by examining the
cryptogram alone, we are unable to deconvolve these various factors.
In order to extricate the extrinsic from the intrinsic, we need to condition our
transcript counting based on the lineage type of the cells. That is, we will need to look at
the expression profiles given whether or not a cell is, for example Lgr5+ or Lgr5-. This will
separate out the expression profiles of the stem cells from the non-stem cells.
The plots below show exactly this. We have selected only stem cells in the crypt
(Lgr5+), and then compute the mean expression level for a spatial bin of 5 cell positions
(e.g. cell positions 0-4, cell positions 5-9, and so on). In essence, this is still a cryptogram,
but now conditioned upon Lgr5 expression. We then compare the wildtype expression
pattern (blue bars) with the APC loss expression pattern (red bars).
The left plot shows the Lgr5 expression level for Lgr5+ cells, and here we notice
something interesting: when the cells lose APC signaling (red bars), the mean number of
Lgr5 transcripts actually increase by about 50-100%. This means that those Lgr5+ "stem
cells" which have lost Apc expression are no longer the same as the wildtype Lgr5+ stem
cells. The plot on the right extends a similar analysis to cMyc, and indeed we see the
same observation: the stem cells after APC knock-out on average have a higher cMyc
expression compared to wildtype.
4.2.2 WNT signaling in stem cells
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Figure 4.12. A plot of the mean transcript level for Lgr5 transcripts (left plot) and Myc
transcripts (right plot) in Lgr5+ cells only as a function of cell positions (binned from
positions 0-4, 5-9, 10-14, and 15-19) for the wildtype mice (blue bars) and mice that have
lost APC for 7 days (red bars). Note that after APC loss, there is a statistically significant
increase in both the Lgr5 transcript density and the cMyc transcript density in Lgr5+ cells,
as denoted by the various asterisks above the corresponding bars. The blue bars are
absent at higher crypt positions because for wildtype mice, we typically do not observe
Lgr5+ stem cells at these cell positions. These two plots illustrate the intrinsic effects of
APC loss: the differences in the expression levels are not caused by a different cell
composition along the crypt at the different positions, but rather by the intrinsic alteration in
the expression levels in the same cells (in this case Lgr5+ stem cells) after APC loss.
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This observation is interesting, as it suggests that in addition to the "extrinsic" effect
that stem cells overtaking the crypt may alter the cryptograms of key markers, there is also
an "intrinsic" effect in the stem cells themselves, as APC loss means that they no longer
intrinsically express the same level of markers such as cMyc. This suggests that, indeed,
both extrinsic and intrinsic effects are relevant to examine in the cryptograms of key
markers.
4.2.3 Effects in non-stem cells
While it is interesting to note the "intrinsic" aberrations in expression patterns in
Lgr5+ stem cells, this is hardly surprising, as there is no reason to believe that a stem cell
that has a disturbed Wnt signaling pathway will still have the same genotype and
phenotype as a wildtype stem cell. However, what would be really interesting to investigate
is whether or not such "intrinsic" aberrations also extend to non-stem cells.
If we follow the conventional model of APC loss giving rise to a clonally expanding
stem cell population that ceases to differentiate, then we may assume that the non-stem
cells still retain normal (original) APC function and should behave normally.
However, as illustrated in the figures below, APC loss actually gives rise to
statistically significant gene expression perturbations in Lgr5- cells, even as far as cell
positions 15-19. In the case of cMyc (left plot), the non-stem cells also have an elevated
expression of the mRNAs, while in Ki-67 (right plot), a reduced expression level.
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Figure 4.13. A plot of the mean transcript level for cMyc transcripts (left plot) and Ki-67
transcripts (right plot) in Lgr5- cells only as a function of cell positions (binned from
positions 0-4, 5-9, 10-14, and 15-19) for the wildtype mice (blue bars) and mice that have
lost APC for 7 days (red bars). Note that after APC loss, there is a statistically significant
difference in both the cMyc transcript density (an increase) and the Ki-67transcript density
(a decrease) in Lgr5- cells, as denoted by the various asterisks above the corresponding
bars.
At a first glance, this seems a bit confounding: if the non-stem cells are assumed to
have normal APC function, why is it that their expression of proliferation markers such as
cMyc and Ki-67 is also be altered? There are two potential explanations. Firstly, perhaps
there is some perturbed signaling from the APC-KO stem cells that causes these non-stem
cells to behave differently: in other words, perhaps the crypt now has an altered
microenvironment. Unfortunately, this hypothesis is difficult to test using the tools that we
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have at hand. However, there is also a second potential explanation: these non-stem cells
in fact do not retain functioning APC either (i.e. our assumption is wrong). One way that
this would be possible is that if the clonally expanding Lgr5+ cells that lose their APC
function still retain the ability to differentiate. This second hypothesis, in fact, can be
explored further, which we will do in the subsequent chapter.
4.2.4 Ephrin signaling
In fact, a particularly strong illustration of this "intrinsic" effect is in the EphrinBl
expression level. As shown in the two plots below, upon APC loss, all cells, regardless of
whether they are Lgr5+ (left plot) or Lgr5- (right plot), show a drastic reduction in EphrinBl
expression in all cell positions being observed.
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Figure 4.14. A plot of the mean transcript level for EphrinB1 transcripts (left plot) in Lgr5+
cells (left plot) and Lgr5- cells (right plot) as a function of cell positions (binned from
positions 0-4, 5-9, 10-14, and 15-19) for the wildtype mice (blue bars) and mice that have
lost APC for 7 days (red bars). Note that after APC loss, there is a statistically significant
decrease in the EphrinBl transcript density in both the Lgr5+ as well as the Lgr5- cells, as
denoted by the various asterisks above the corresponding bars. Interestingly, the same
difference was not observed in the EphB2 gene.
Interestingly, EphrinBl's partner gene, EphB2, does not display this "intrinsic"
behavior. Instead, we did not notice a significant difference in the expression levels of
either cell population (Lgr5+ or Lgr5-) upon APC loss. This suggests that the perturbation
we observed earlier in the EphB2 cryptogram comes mostly---if not exclusively---from
"extrinsic" effect of EphB2-high stem cells taking over EphB2-low non-stem cells in the
crypt.
4.2.5 Summary of intrinsic effects in different markers
In the plots above, we only illustrate selected markers with interesting results. We
extended this study to a wider spectrum of markers, and the results are summarized in the
table below.
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Lgr5 o +
Creb313 o o
Gob5 o o
cMyc + +
Ki67
EphB2 o o
EphrinB1 -
Table 4.1. This table shows the intrinsic differences in the transcriptional expression levels
of key genes in stem cells and non-stem cells before and after APC loss (for 7 days). A '+'
symbol denotes that APC loss causes a statistically significant increase in the expression
level in the same cell subpopulation after APC loss. A '-' symbol indicates that APC loss
causes a statistically significant decrease in the expression level in the same cell
subpopulation after APC loss. A 'o' symbol indicates no statistically significant difference
before and after APC loss. A '?' denotes inconclusive or ambiguous results.
In this table, we examine whether or not "intrinsic" effects exist in various markers in
either non-stem cells (Lgr5-) or stem cells (Lgr5+). If a symbol "+" is used, that means that
this particular marker is observed to be expressed more highly in the given subpopulation.
For the symbol "-", this means that the particular marker is expressed more lowly. If the
symbol "o" is used, that means that we did not observe any significant effect. For Ki-67,
the "?" symbol for the Lgr5+ cells show that the effect is unknown.
Thus, as the table shows, the perturbation that results from APC loss is actually
much more nuanced than a single cryptogram can reveal. There are selected markers that
demonstrate strong "intrinsic" effects (such as EphrinB1), and others none (such as
EphB2). Yet some other markers (such as Lgr5) only demonstrate such effect in one
subpopulation (in this case, the stem cells).
In the next chapter, we make an effort to understand this intrinsic effect a bit better
by testing a hypothesis that can potentially explain it: that the non-stem cells may in fact
have already lost their APC function as well.
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Chapter 5. Verifying APC Loss
The interesting observations of "intrinsic" effects in Lgr5- cells in the previous
chapter prompted us to examine the nature of APC loss further. In particular, the particular
question that we have in mind is whether or not the Lgr5- cells are wildtype non-stem cells,
or might some of these cells also harbor the mutant Apc which may account for the
"intrinsic" changes in the Lgr5- population seen in the previous chapter?
While this question seems to be a technical one inspired by the need to probe
further beyond our finite cryptogram analysis in the previous chapter, this question in fact
has broader ramifications. What are the implications if it is true that we also observe APC
loss in Lgr5- cells? As we recall from the genetic construct described earlier, Cre is only
expressed in Lgr5+ cells (i.e. CBCs, and not +4 cells). Apc excision only occurs, in
principle, after Cre is expressed. This means that for APC loss to occur, this cell must be
expressing Lgr5 at one point. If we observe any APC loss in other differentiated lineages
that are Lgr5-, then this implies that these cells must have expressed Lgr5 before. If we
equate Lgr5 expression with stem cell identity, then this points to the hypothesis that even
upon APC loss and Wnt signaling perturbation, some APC-KO stem cells, in addition to
simply clonally expand, may still retain the ability to differentiate into other lineages.
Now, why is it that we arrive at this hypothesis? Beyond being a possible
explanation for our "intrinsic" effect in Lgr5- cells, this hypothesis does not simply come
from our figment of imagination. In fact, it also comes from initial observations in the
tdTomato-GFP mouse. As described previously, this mouse has the following genotype.
Upon injection of tamoxifen, in Lgr5+ cells, Cre is expressed together with GFP. While Cre
excises a vital fragment of the Apc gene, there is also a lox-stop-lox site before tdTomato
that can be targeted. This renders tdTomato expression, which signifies an excision
activity by Cre. Therefore, tdTomato expression should only be possible in cells that at
some point express Lgr5 (and hence Cre).
However, as illustrated in the top-right picture (below), sometimes we observe
differentiation markers, such as Gob5, coexpressed with tdTomato. Furthermore, in the
same picture, we observe that GFP is only expressed in a subset of tdTomato-positive
(TOM+) cells (white arrows). Since GFP is expressed when the Lgr5 promoter is active,
and since Gob5 expression is typically exclusive with Lgr5 expression, this suggests that
there are TOM+ cells which are Lgr5-. However, a more direct evidence is given in the plot
on the top-right, where we observe TOM+ cells (red) which can either be Lgr5+ or Lgr5-
(as gauged by single-molecule FISH; Lgr5 FISH dots shown in the green channel). A
further quantification of these two subpopulations, plotted in the bottom-left, shows that of
all observed TOM+ cells in the crypt, only about 40% turn out to be Lgr5+. What is more
surprising about these two TOM+ subpopulations (Lgr5+ or Lgr5-), as shown in the
bottom-right figure, is that they have very different proliferation rates, as judged by the
fraction of EdU-positive cells. Indeed TOM+Lgr5- cells are almost twice more proliferative
compared to cells which are TOM+Lgr5+. This suggests that while TOM+Lgr5+ cells still
retain their stem-cell-like characteristics such as slow cycling, TOM+Lgr5- cells behave
like the rapidly dividing transit amplifying cells. If we can equate TOM+ with APC loss, then
all these observations only make sense if some APC-KO Lgr5+ cells still retain the ability
to differentiate.
5'
Figure 5.1. The picture on the right shows two crypts (with crypt base at the top-left,
opening longitudinally towards the bottom-right) showing cells that express tdTomato (red)
as well as cells that express Lgr5 transcripts (green). Note that amongst tdTomato-positive
cells, there are both Lgr5+ and Lgr5- cells. The picture on the right shows a crypt (with
crypt base at the top-right, opening longitudinally towards the bottom-left) showing cells
that express tdTomato (pink), GFP (blue overlay), as well as cells that express Gob5
transcripts (green). Note that some tdTomato-positive cells appear also Gob5+. The
imaging was performed on a Rosa-26:TOM;Apc mouse 7 days after tamoxifen injection.
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Figure 5.2. The plot on the left shows that, of all tdTomato-positive cells at different cell
locations, the fraction of those cells which are Lgr5+. Note that this fraction generally
hovers around 0.4. The plot on the right shows that, if we segregate the tdTomato-positive
cells into two subpopulations (Lgr5+ and Lgr5-) and then apply EdU staining, the two
subpopulations have statistically significant difference in the proliferation rates, as
quantified by the fraction of EdU+ cells. Notably, Lgr5- cells proliferative much more rapidly
than Lgr5+ cells. The quantification was performed on a Rosa26TOM;Apc mouse 7 days
after tamoxifen injection.
In order to test this hypothesis, we need to either observe APC loss directly, or need
a reliable proxy for APC loss. In this chapter, we describe the various experimental
approaches we took to test our hypothesis.
5.1 Apc single-molecule FISH
The most straightforward way to verify APC loss is to do single-molecule FISH on
Apc transcripts. The problem is that in our mouse genotype, Apc excision retains the bulk
of the mRNA transcript, and removes only a small fraction (157 bp), which results in a
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frameshift mutation, a premature stop, and thus a truncated protein. It is extremely difficult
to design a probe that spans only 157 bp and that will have a strong enough signal-to-
noise ratio, because for a typical probe length of 20 bp, this can only fit less than 8 FISH
probes, which is far fewer than the typical 48 probes for single-molecule FISH.
However, because our particular genotype after Apc excision results in a nonsense
mutation, we wonder whether or not this can cause nonsense-mediated degradation of the
Apc transcript. If such degradation occurs sufficiently, then we may be able to detect the
absence of the entire Apc transcript, and not just the 157 bp excision fragment. Because
nonsense-mediated degradation starts from the ends of the transcripts, we designed FISH
probes close to either the 5' or 3' ends.
As shown in the two cryptograms below, we did not notice a statistically significant
difference in detected Apc expression levels in the wildtype crypt compared to TOM+
crypts after tamoxifen induction.
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Figure 5.3. Cryptograms reflecting the processed expression level of a single-molecule
FISH probe set designed specifically against the Apc mRNA transcript, for wildtype mice
(left) and mice that have lost APC for 7 days (right). We were attempting to test whether or
not APC loss would result in a detectable nonsense-mediated mRNA degradation. Note
that we did not observe a significant difference in the cryptograms before and after APC
loss. This likely suggests that nonsense-mediated degradation did not play a FISH-
detectable role after APC loss. The quantification was performed on a Rosa26:TOM;Apc
mouse 7 days after tamoxifen injection.
We took a closer look at the data by plotting a histogram of Apc mRNA levels in
three scenarios: wildtype, inducted TOM- cells, and inducted TOM+ cells. As we can see
in the histogram below, the inducted TOM+ cells do not exhibit a significant difference in
histogram distribution compared to the other two control conditions. This therefore rules
out the possibility that we can simply detect APC loss using the argument of nonsense-
mediated degradation.
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Figure 5.4. A histogram reflecting the processed expression level of a single-molecule
FISH probe set designed specifically against the Apc mRNA transcript, for wildtype mice
(red bars) and in the tdTomato-positive (blue bars) and tdTomato-negative (green bars) of
mice that have lost APC for 7 days. We were attempting to test whether or not APC loss
would result in a detectable nonsense-mediated mRNA degradation. We did not observe a
significant difference in the distributions before and after APC loss. This likely suggests
that nonsense-mediated degradation did not play a FISH-detectable role after APC loss.
The quantification was performed on a Rosa26-TOM-Apc mouse 7 days after tamoxifen
injection.
Next, we turned our attention to the short 157-bp excision fragment (exon 14 of the
Apc gene) and wonder whether or not it may be possible to design a few shorter probes
that span the entire section and emit a minimally detectable signal. As illustrated in the
schematic below, we designed three types of FISH probes: "Apcl", "Apc2", and "Apc3".
"Apc 1" and "Apc3" are full-length probes that span the front and end portions of the Apc
transcript that is unaffected by the Cre excision. "Apc2" contains a set of 9 probes
specifically targeted towards the excised exon 14. We labeled the probes using different
fluorophores, and attempted to evaluate the detection ability of the "Apc2" probe set by
quantifying the extent of its colocalization with "Apc1" and "Apc3" probes in wildtype
intestinal crypts.
44 probes 9 probes 43 probes
("Apc 1") ("Apc 2") ("Apc 3")
Apc
transcriptW
Alexa Cy5
Figure 5.5. A schematic showing the probe sets "Apcl", "Apc2", and "Apc3". The set
"Apc1" is designed against exon 1-13 at the Apc locus. The set "Apc2" is designed
specifically against exon 14 at the Apc locus (which would be excised in the case of
tamoxifen-induced Cre activity). The set "Apc3" is designed against the long exon 15 at the
Apc locus. The three probe sets were labeled with different fluorophores (in this case,
Alexa-594, Cy5, and TMR respectively). By performing colocalization analyses of the
probes in the different channels, we hoped to evaluate the reliability of the "Apc2" probe
set, which spans a very short locus and thus contains very few probes (9 probes only).
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As seen in the picture below, we are barely able to detect signals from the "Apc2"
probe set when it is hybridized to a wildtype sample. A sample cross-section analysis of
the intensities (bottom-left plot) demonstrates that the FISH dots are barely above the
noise level, and they have variable intensities, which suggests the high stochasticity in the
number of annealed probes when the probe number is low.
Figure 5.6. The left diagram illustrates a crypt (with the crypt base at the right, opening
longitudinally towards the bottom-left) that has been hybridized with a probe set "Apc2"
which is defined in Figure 5.5. Note that some putative FISH dots are faintly visible. The
top-right diagram shows a closer zoom-in in one region, showing some putative FISH dots.
A cross-section analysis of several of these dots (the cross-section is shown in the yellow
line at the top-right picture) illustrates that the peak intensities are highly variable. This can
be attributed to the fact that the "Apc2" probe set only has 9 probes, so that the stochastic
binding/unbinding of even a few probes from the transcript may have contributed
significantly to this variation in the peak intensities. This experiment was performed in a
wildtype mouse that did not have APC loss.
Nonetheless, we decided to test whether or not "Apc2" is a reliable detection
method. Our approach is to co-hybridize the same sample with all of "Apcl ", "Apc2", and
"Apc3" in different channels, and measure the extent of colocalization of the identified dots.
Because "Apcl" and "Apc3" have a high number of probes, we are quite confident that we
can detect reliable FISH dots for Apc transcripts, so these two channels serve as controls
against which the detection ability of "Apc2" will be compared.
The two images below show the x-y locations of the identified FISH dots, for "Apc2"-
Alexa (red solid dots) and "Apc3"-Cy5 (blue open circles) in the same tissue samples. As
we can see, while there is some extent of colocalization between the identified "Apc2" and
"Apc3" dots, these are not sufficiently reliable, as seen by the low colocalization fraction
value, as calculated using the method described in Semrau et al. (2011). Therefore, we
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concluded that due to technical challenges, single-molecule FISH on the Apc gene is
unlikely to yield reliable results that can support or reject our hypothesis.
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Figure 5.7. A colocalization analysis testing
the "Apc3" probe set in two sample images.
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The plots show the identified FISH dots in the
"Apc2" channel (solid red dots) and in the "Apc3" channel (open blue circles) for the same
images when "Apc2" and "Apc3" probe sets are hybridized against the same sample in
different fluorescent channels in a wildtype mouse (that did not have APC loss). If the
"Apc2" probe set is reliable, then we would expect a high degree of colocalization
compared to the reference "Apc3" probe set. Unfortunately, this was not to be, and when
we quantified colocalization, the fraction colocalized is typically below 0.5. The
colocalization fraction was calculated using the method described in Semrau et al. (2011).
5.2 FACS and qPCR
Instead of single-molecule FISH, we turned our attention to an alternative method. If
we dissociate the intestinal epithelial, we can FACS-sort the TOM+ cells and through
qPCR verify whether or not these cells have pronounced Apc excision event. While we will
be unable to directly detect APC loss in situ, if we can establish this relationship, then we
can introduce TOM+ (which is easily detectable in situ) as a reliable proxy for APC loss.
This technique is challenging in that it requires the reliable establishment of several
moving parts: (1) dissociating intestinal cells, (2) FACS sorting, (3) extracting genomic
DNA, and (4) performing quantitative PCR. Therefore, to establish the validity of the final
result, we will need to convincingly show that each single moving part has been mastered.
5.2.1 Dissociating intestinal cells
This technique has already been described in the Materials and Methods section.
However, in order for the downstream FACS sorting to work, we ideally need at least 10
million cells per mL in suspension. Our early attempts were marred by excessive cell lysis,
which resulted in very low cell count, as well as a coagulation of the suspension from the
lysate, which made the cells almost impossible to be centrifuged into a separable pellet.
By the careful addition of DNAse through various stages of coagulation-prone steps
(especially after trypsin has been added) and by serial dilution of the samples to reduce
their viscosity, we were able to isolate about 10-20 million cells from an entire mouse
intestine. After the traumatic dissociation procedure, we typically have a viability rate of
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about 60%. When suspended into 1 mL of PBS/BSA, this gave us a cell count that meets
the lower minimum for FACS analysis.
However, another inherent difficulty is that intestinal epithelial cells are extremely
sticky, and tend to form clumps. Even after BSA has been added, and the cells passed
through the filter, these individual cells can clump together within a matter of 20 minutes.
Therefore, during a normal FACS-sorting session which lasted about 40-60 minutes, it was
often necessary to remove the sample, centrifuge, and then re-filter the suspension in
order to not clog up the FACS machine.
5.2.2 FACS sorting
In order to check that the FACS technique works in our samples, the first
experiments that we performed were controls, in which we sorted both the wildtype and
the induced Lgr5:GFP-IRES-Cre mouse. Unlike the hitherto uncharacterized TOM+ mouse
genotype that we are working with, this GFP genotype has been sorted in the past in the
intestinal crypts before (e.g. Wiebrands, 2012), and would provide a reliable "gold
standard" to which we can compare our technique.
As shown below in the two FACS plots, the sorted Lgr5:GFP-IRES-Cre mouse (right
plot) has a distinct minor subpopulation of cells whose GFP intensity is about 10 times
brighter than the control (left plot). The GFP+ cells occupy about 4% of the isolated
intestinal epithelial cells, which is consistent with the experiments carried out by other
people.
WT mouse Lgr5:GFP-Cre mouse
0
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Figure 5.8. The results from a FACS experiment on wildtype (left) and Lgr5:GFP-IRES-Cre
mouse (right), with the x-axis showing the logarithmic intensity of GFP, and y-axis showing
the logarithmic intensity of TOM. The left plot demonstrates the existence of a small
subpopulation of GFP-high cells that can be sorted.
Next, we started sorting TOM+ cells in the Rosa-26:LSL-TOM mouse. As shown in
the plots below, we were also able to segregate a small fraction (in red) of TOM+ cells
which are significantly off the main axis. We were able to sort the cells into up to 4
subpopulations: GFP-TOM-, GFP-TOM+, GFP+TOM-, and GFP+TOM+.
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Figure 5.9. The results from a FACS experiment on wildtype (left) and Lgr5:GFP-IRES-
CRE; Rosa-26:LSL-TOM; Apc (right) mouse, with the x-axis showing the logarithmic
intensity of TOM, and y-axis showing the logarithmic intensity of GFP. The left plot
demonstrates the existence of a small subpopulation of GFP-high and TOM-high cells that
can be sorted (in P4, right plot), as well as some cells which are simply high in GFP but
low in TOM (in P6, right plot).
To further verify the reliability of FACS sorting, we took the FACS-sorted
subpopulations and then imaged each subpopulation under an epifluorescence
microscope. The plot below (top plot) shows the TOM and GFP signals under
epifluorescence imaging, with the GFP-TOM- subpopulation (as sorted by FACS) as red
open circles, and with the GFP+TOM+ subpopulation as blue x's. As we can see, the two
subpopulations are well-separated on the plot. The two lower images also show the cell
populations under the TOM channel under the same exposure and excitation settings---
and we indeed observe a much brighter fluorescence from the TOM+ subpopulation. This
confirms the reliability for FACS in sorting out TOM+ cells.
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Figure 5.10. Top plot: Verification of sorted cells under an epifluorescent microscope, with
intensities in TOM (x-axis) and GFP (y-axis) plotted in logarithmic scale for the sorted
TOM-low GFP-low cells (red open circles) and TOM-high GFP-high cells (blue x's). Bottom
plots: Sample images in the TOM channel for the TOM-low GFP-low cells (left) and TOM-
high GFP-high cells (right), with the same exposure and imaging setting for ease of
comparison.
5.2.3 Extracting genomic DNA
While the steps so far seem quite reliable, the FACS-sorted cells were challenging
to extract DNA, in particular because the cell count was often very low. For example, with
a typical input into FACS of 10 million cells, we might expect about 500,000 to 3 million
cells in the negative (GFP-TOM-) pool, while anywhere between 5,000 to 100,000 cells in
the positive (TOM+) pool.
We tried various DNA extraction techniques---such as phenol-chloroform extraction
and the use of ready-made extraction kits (such as the QlAGEN DNeasy kit). While some
methods were more reliable than others, at the end, we found that for downstream qPCR
to perform effectively, we ideally need at least 50,000 to 100,000 cells. For example, the
gel image below shows PCR of a control gene (Gapdh) on samples of different serially
diluted cell counts, and the readily observable band at about 450 bp disappears as the cell
count is gradually lowered.
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Figure 5.11. The amplification of genomic DNA starting with samples of different cell
counts, using primers for a reference gene, Gapdh. The leftmost lane denotes the
reference ladder. The remaining lanes, from left to right, denote the amplification results
starting originally with 1,500,000 cells, 750,000 cells, 375,000 cells, 37,500 cells, and
3,750 cells, respectively. As the number of starting cells goes down, we can see that the
Gapdh band (at about 450 bp) becomes dimmer and dimmer, suggesting the lower limit for
detectable signal as a function of cell count.
It took us various attempts in order to improve all the upstream techniques so that
we had enough cells in order to extract genomic DNA and perform qPCR.
5.2.4 qPCR
Through qPCR on the different sorted subpopulations (e.g. TOM- versus TOM+),
we hope to establish TOM+ as a reliable proxy for APC loss. In order to achieve this, we
designed two pairs of primers around the Apc region of interest. As shown in the
schematic below, it is exon 14 that is flanked by two loxP sites, while the other Apc exons
are intact after tamoxifen-induced Cre excision event. The first pair specifically spans exon
14, while the second pair spans the neighboring exon 15, which serves as a "standard" to
which any reduction in the abundance of exon 14 can be compared.
157 bp 236 bp
loxP loxP
Apc
locus IIntron
Figure 5.12. Schematic illustrating the design of the primer pairs targeting exon 14 and
exon 15 of the Apc locus for qPCR experiments. The detailed sequences of these primers
are given in Chapter 2 (Materials and Methods).
Because these two pairs of probes were newly designed, we first needed to validate
the probes and make sure that they have "linear" behavior in our region of interest. To test
this, we first isolated some DNA from a wildtype mouse, and serially diluted the DNA
sample 8 times. Each sample was added an equal concentration of either primer pair
(Exon 14 or exon 15). During real-time qPCR, the CT value---which is defined as the PCR
cycle number at which the amplification curve meets the threshold level (for the
concentration of amplified product)---was recorded. The CT values were then plotted
against the DNA dilution, and if the primers have a "linear" amplification efficiency, then
every time we dilute the original sample, then the corresponding CT value for that sample
should be delayed by one PCR cycle. This plot, when done logarithmically, is called a
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qPCR titration curve. And here, the primers for exon 15 of Apc serves as the internal
reference for our qPCR experiment. We chose exon 15 over the traditional GAPDH
because exon 15 is located right next to the genomic region of interest, and thus serves as
a better internal reference.
The image below on the left shows gel electrophoresis of the amplification products
from exon 14 (e14) and exon 15 (e15) at different dilutions. We first note that, the amplified
product corresponding to exon 14 has a length of 157 bp and that corresponding to exon
15 has a length of 236 bp. The bands for el 4 and el 5 are consistent with the fragment
lengths. We then note that as we serially dilute the samples, the band also becomes less
and less bright, as expected.
The plot below on the right demonstrates a more quantitative approach using a
qPCR titration curve. As we can see, both the primer pairs for exon 14 and exon 15
demonstrate a linear behavior: as the original DNA concentration is diluted, the CT value
also increases. However, unlike the "gold standard" control of GAPDH primers, we note
that the slopes fitted to the exon 14 and exon 15 titration curves are not perfectly -1. This
suggests that the two primers have slightly worse efficiency compared to GAPDH---in
other words, during each PCR cycle, the concentration of the amplified product increases
by 1.94 times instead of by 2 times. However, as long as the titration curve is linear---
which it is---such a difference in amplification efficiency can be accounted for and will not
cause any experimental problems. These data suggest that the primers we designed for
exon 14 and exon 15 of Apc are validated primers that we can use for qPCR.
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Figure 5.13. Validation of the primer pairs targeting exons 14 and 15 of the Apc locus. The
left picture shows the amplification results from the two primers on wildtype mouse DNA
sample, with different starting DNA concentrations (noted above, 1:1, 1:2, and so on). Note
the well-defined bands at 157 bp (for exon 14, denoted el 4 above) and 236 bp (for exon
15, denoted el 5 above). As the starting DNA is more diluted, we see that as expected, the
bands become more blurry. The right picture shows the qPCR titration curve, which
consists of CT values plotted as a function of different DNA starting concentrations (plotted
on the x-axis logarithmically) for the different primer pairs: exon 15 of the Apc locus (blue
diamonds), exon 14 of the Apc locus (red x's), and the reference primer pair at the Gapdh
locus (green triangles). The lines are the linear fits to the titration curves, and as we can
see from the generally satisfactory fit, both primers for exons 14 and 15 of the Apc locus
have been successfully validated.
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With the PCR primers validated, it is now possible to calculate the relative
abundance of exon 14 and exon 15 fragments in the different FACS-sorted subpopulations.
If the hypothesis is true that TOM+ cells can act as a proxy for APC loss, then we should
expect that there will be a significantly reduced abundance of exon 14 in TOM+ cells
(relative to exon 15 in the same cells, as well as relative to a control cell with known
functioning genomic Apc). Given the definition of the CT value, it can be shown that the
relative abundance of DNA in exon 14 in TOM+ cells---which we will denote as
[DNA](TOM+,E14)---compared to the abundance of DNA in exon 15 in TOM+ cells---which
we will denote as [DNA](TOM+,E15)---will be given as follows (Marino et al., 2003):
where 814 is the amplification efficiency of the primers for exon 14, 815 that for exon 15 (as
established in the qPCR titration curves above), and CT(TOM+,E14) denotes the CT value
of the sample of TOM+ cells amplified with the exon 14 primer, and so forth. If it is true that
exon 14 is excised in TOM+ cells, then we expect this ratio to be much smaller than 1. If,
however, we carry the control experiment in TOM- cells, then we expect that this ratio
should be comparable to 1.
Having carried out the real experiment in triplicates, we concluded with the following
figures:
[DNA](TOM+, E14) / [DNA](TOM+, E15) = 0.40, and
[DNA](TOM-,E14) / [DNA](TOM-,E15) = 0.89.
While we do observe a reduction in the abundance of exon 14, the difference corresponds
to a difference in ACT value of only 1. This is rather disappointing, because it implies that,
for whatever reason, after sorted the cells for TOM+, only about 60% of these cells have
had APC loss.
What might account for this unsatisfactory result? One potential explanation is that
FACS-sorting is known to be imperfect: while we did some basic verification using
epifluorescence microscopy, it is unlikely that all the cells sorted into the TOM+ bin are
TOM+: some TOM- may also have sneaked into the TOM+ population, thereby introducing
the unexcised exon. Furthermore, during the isolation and dissociation of the crypt, on
average 40% of the cells have lysed, emptying their contents into the suspension. While
we did try to purify the live-cell fraction by spinning down the cells into a pellet, it is
imaginable that some impurities still remain, including DNA fragments. Such impurities,
either caused by imperfect FACS sorting or premature cell lysis, may have contaminated
the TOM+ sample, thereby causing the very sensitive qPCR to pick up some weaker exon
14 signal. Yet another potential explanation is that Cre excision is not perfect. In this case,
we subjected our mice to a tamoxifen pulse. The brief expression of Cre, we assume, is
sufficient to excise two flox sites: both Apc's floxed exon 14 and the lox-stop-lox in front of
tdTomato. However, the efficacy of this double excision event is still open to debate, and
probably depends on the specific mouse model: while some sources (e.g. Schepers et al.,
2012 and Itzkovitz, 2012) claim that this system is very sensitive and fast-acting, other
authorities (e.g. Engelward, 2012 and Tammela, 2012) have claimed that an efficient
double excision event is not guaranteed. At the minimum, even 7 days after we inject
tamoxifen, it is observed that only about 43% of the crypts show any fluorescence. This
already suggests the possible patchiness of either Cre expression or Cre excision. One
can imagine that if we have access to mice of more complex phenotype (e.g. brainbow
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mouse, with different flox sites), we can devise a rigorous gauge of the efficiency of Cre
activity. However, this technical question is unfortunately beyond the scope of this thesis.
5.3 External studies and potential implications
While we were carrying out the various methods to test our hypothesis, it also came
to our attention that another research group carried out similar work as us and their
results-published in summer 2012 (Schepers et al., 2012)-may shed some light onto
validating or negating our hypothesis. In particular, they made use of a more advanced
mouse strain with a multicolor Cre-reporter R26R-Confetti with the knock-in allele GFP-
IRES-Cre under one Lgr5 promoter. This not only allowed for lineage tracing, but also for
re-tracing at a later time by color conversion, as shown in the diagram below (Schepers et
al., 2012). And because retracing is a rare event (in about 6% of the recombined cells), the
researchers assumed that the retraced cells within a crypt must have originated from a
single Lgr5+ cell.
Transient Cre recombination Color conversion
Rosa26-Confetti locus Tracing' Re-trcing
Figure 5.14. An illustration of the Rosa26-Confetti locus, as used by Schepers et al. (2012).
The left picture shows the original construct of the locus. Upon transient Cre recombination
(second column), one of the four colors can be expressed. Upon color conversion (third
column), retracing can be done using a different color.
Notably, upon APC loss, the researchers noted that the resultant adenomatous cells
only consists of 5-10% of Lgr5+ cells. Within these adenomas, there are also Paneth cells,
suggesting that these Paneth cells may have arisen from the transformed Lgr5+ cells. This
is in agreement with our initial observations above. By retracing the lineages after the first
tamoxifen injection (and APC loss), the researchers were able to subsequently show that
some of the Paneth cells and Lgr5- transit-amplifying-like cells indeed arose from Lgr5+
cells that originally expressed one of the confetti color and subsequently underwent a color
conversion.
In our view, the authors never satisfactorily addressed the question of whether or
not the initial expression of a confetti color is a reliable proxy for APC loss (just as in our
case, whether or not TOM+ is a reliable proxy for APC loss), except by mentioning in
passing that the recombination event occured at the Apc locus more efficiently than at the
Rosa-26 locus, due to the observation that some adenomas failed to express any one of
the confetti colors. This, however, does not preclude possible instances where
recombination occured at the Rosa-26 locus without touching the Apc locus. Even experts
such as Engelward (2012) and Tammela (2012) acknowledged this potential weakness,
but unfortunately, we were unable to reliably demonstrate the goodness of the proxy by
qPCR either way. Therefore, this is a mystery that we have to leave to other researchers in
this field to continue to contend.
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Chapter 6. Conclusions and discussions
6.1 Summary
In this thesis, we have two major aims in investigation in the intestinal crypt: (1) the
dynamics of cell migration and its lineage dependence, and (2) the spatial profile of the
different genetic markers in the intestinal crypt in health and disease (APC-induced
carcinogenesis). In Chapter 3, we explored the simultaneous use of EdU pulse-chase
labeling combined with single molecule fluorescent in situ hybridization (FISH) in order to
probe any lineage-dependent migration behaviors such as differences in velocities.
Unfortunately, we did not find a significant difference that would warrant continnued
investigation in this direction. In Chapter 4, we started evaluating the spatial profiles of the
different markers in both the wildtype crypts and in crypts of mice that have lost APC.
While we were able to identify various interesting perturbations in markers for
differentiation (such as Creb3/3 and Gob5), proliferation (such as Ki67 and Myc), and
migration (such as EphrinBl and EphB2), at first, because of the way we analyzed the
data, we were unable to parse out whether or not these differences were primarily due to
the altered composition of the different cell types in the crypt (i.e. extrinsic factors) or due
to the intrinsic changes in the gene expression profiles within the individual cells as a
consequence of their losing APC action. We probed this distinction further, and were able
to demonstrate sometimes that there are both extrinsic and intrinsic factors at play for the
different markers, as summarized in Table 1. In fact, what is somewhat perplexing to us is
that even non-stem cells (Lgr5- cells) sometimes demonstrated perturbed intrinsic
expression profiles. One explanation for this is that those non-stem cells are in fact
progenies from the originally transformed Lgr5+ cells that, despite the constantly high
WNT signaling, still managed to differentiate and given rise to non-stem cells. In order to
explore this perplexing observation further, in Chapter 5, we sought first to seek to
establish a good proxy for APC loss in order to study whether or not cells that have lost
APC may indeed still co-express differentiation markers or display other non-stem-cell
behaviors. Unfortunately, various approaches to approach this proxy did not yield positive
results, and we closed our study with remaining uncertainties regarding the subsequent
dynamics and fates of the transformed stem cells. This question was also lightly touched
upon by recent studies such as Schepers et al. (2012) using a confetti mouse strain, but
again, the central question of confetti expression as a reliable proxy for APC loss is still not
completely resolved.
However, suppose that we can assume that confetti expression, and in our case
TOM expression, is a good proxy for Apc loss. What then? What are the potential
biological implications given this assumption? If it is true that we can establish that TOM+
cells are sufficiently enriched in cells that have lost APC (e.g. > 95% of the population),
then it will give us the confidence in equating a TOM+ cell with a cell that has lost APC
function. This means that our preliminary observations in Figures 5.1 and 5.2 become
highly interesting, as these figures suggest that transformed stem cells (TOM+ cells) may
still retain the ability to differentiate into non-stem cells, such as cells with transit-amplifying
characteristics (i.e. a higher proliferaiton rate) as well as cells that actually co-express
differentiation markers (i.e. Gob5). This would then suggest that despite the constantly
high WNTsignaling, the transformed stem cells may still be able to downregulate Lgr5-
and differentiate to form what may be normal or at least quasi-normal tissue. This
observation by itself, phenomenologically, would be hardly surprising, as we know that in
early intestinal adenomas, the crypts still maintain some semblance of normal morphology,
and we also know that APC loss first gives rise to benign adenomas, and it is only
subsequent mutations that may cause a full-fledged malignant tumor. However, from the
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dynamics perspective, it would be a highly interesting question to study the subsequent
dynamics and fates of transformed stem cells, which are hitherto less than elucidated. In
particular, traditionally, people may have a somewhat deterministic view in terms of the
clonal expansion of stem cells out of their niche after WNTupregulation, but the reality
might paint a more nuanced picture whereby the transformed stem cells may stochastically
choose either to differentiate semi-normally into one of the few lineages, or to remain a
stem cell abnormally out of their niche. If this stochasticity is at play, then what factors
underlie this stochasticity? If we are able to quantify this stochasticity in great detail, then
this understanding will not only have powerful ramifications in the study of early-stage
development of the intestinal cancer, but also of a myriad of other types of cancers that
putatively stem from a transformed stem cell.
6.2 Discussions
In this section, we have a more in-depth discussion regarding our experimental and
analytical work in general, outlining some potential weaknesses and insufficiencies, and
proposing various alternative experiments that can be used to amend or further the work.
6.2.1 Choice of transcript counting
One significant question that arises from our approach is the choice to study the
gene expression at the transcription level (i.e. using single molecule FISH as opposed to
immunostaining or potentially reporter proteins). While we have justified this selection in
Chapter 2 in terms of technical feasibility and a generally satisfactory correlation between
mRNA and protein levels in many biological systems, we actually never formally
established this relationship in the intestinal crypt. This issue is especially pressing in the
case where we actually observe a disagreement of the specificity of putative "+4" cell
markers such as Hopx and Lrig1 between our studies (at the transcriptional level)
compared to prior studies (at the protein level). If, for example, we found that the
previously claimed putative "+4" cell markers were in fact broadly expressed and not
expressed in a "+4"-specific manner, then we could have explored this issue further by
trying to immunostain for the corresponding protein products such as HOPX. However, we
did not carry out such experiments in our studies, primarily because it is not clear that
antibodies against many putative stem cell markers are reliable or even reliable, and to be
fair, such direction was not the emphasis of our study either.
6.2.2 Lineage tracing as a tool to probe the relationship between TOM+ and APC loss
One remaining mystery is whether or not TOM+ cells can act as a sufficient proxy
for cells that have lost APC function. In this topic, we also have not exhausted all our
options for verification. Beyond our experiments in single molecule FISH and in qPCR, we
could have approached the same question from another angle of lineage tracing. To
elaborate, if we inject tamoxifen at a very low dosage, so that Cre induction is a rare event,
then after several days of delay, we can have the ability to look at the different crypts
holistically. We expect to be seeing both transformed crypts (with abnormal morphologies
and clonal expansion of Lgr5+ cells out of the original stem cell niche) as well as normal
crypts that do not display any signs of abnormalty. At the same time, we can also quantify
whether or not a crypt has TOM+ cells. Because Cre induction is a rare event at a low
tamoxifen dose, whenever we see TOM+ cells in a crypt, we can assume that they all
originate from a single cell. From this, we can get some estimate about the efficiency of
co-excision events (both at the Apc locus and at the Rosa-26 locus). To illustrate, if out of
all the crypts that have TOM+ cells, all of these crypts also display abnormal behaviors as
described above, then we can infer that given that a cell is TOM+, then it is also very likely
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that it gives rise to cells with abnormal behaviors (such as a clonal expansion of stem
cells). While this is still not direct proof of APC loss, it does link TOM+ to phenotypical
aberrations, and we deem this to be a sufficient link to establish APC loss.
However, this set of lineage tracing experiments were not performed during our
studies, mainly for technical reasons. We were advised, for example, by Itzkovitz (2012)-
who carried out such low-dose tamoxifen experiments for his investigation-against
carrying out experiments in this direction because of the extreme difficulty in succeeding,
and even if we manage to succeed, the arduous process of identifying rare excision events.
If we had more time or resources at our disposal, we may have entertained this alternative
approach to the question of establishing a TOM-based proxy for APC loss, but both time
and resources were working against us in the final stages of our experimental investigation.
6.2.3 Lineage tracing as a tool to probe migration distributions
In the same vein, the power of lineage tracing can be extended further, to answer
other questions of interest related to cell mobility. For example, as we showed in Chapter 3,
during our EdU pulse-chase experiments, we were thwarted in our ability to clearly identify
the migration velocities of the different intestinal lineages because EdU staining gives a
broad distribution of EdU+ cells. In this case, we could also have used lineage tracing to
our advantage. Specifically, even if we use a wildtype mouse whose only transgenic
elements are Rosa-26: LSL-tdTomato, and Lgr5: EGFP-IRES-Cre, then tamoxifen injection
will serve as the zero-time starting point of the EdU pulse-chase experiment, at which time
some Lgr5+ stem cells will start expressing TOM. After a few days, we expect some of
these stem cells to produce TOM+ progenies that will migrate upward along the crypt. For
each crypt, the highest front of TOM+ cells can be used as an approximation for the cell
migration velocity.
We can even do better: suppose we now lower the tamoxifen dose in the same
system, to the point that each crypt only reasonably has one TOM+ stem cell to start with,
then we can in effect trace the migration pattern of the progenies from a single stem cell.
This not only will give us a more refined estimation of the migration speed, but will also
enable us to further quantify the idea of "clonal dispersion" as proposed by Bjerknes and
Cheng (1999) in their experimental observations. While there is a potential risk and
weakness that since the crypt is a three-dimensional structure and thus the trace of TOM+
cells can migrate out of the cross-section that we are examining, this problem can be
mitigated by a more careful sectioning of consecutive planes in an intestine, and using the
image stacks from the different tissue sections so that we can reconstruct an
understanding of the entire crypt (with the TOM+ traces) in three dimensions. However, for
the same reasons as above, this set of lineage tracing experiments were not done in the
scope of this thesis.
6.2.4 Cell migration in disease
While in Chapter 3, we attempted to quantify (unsuccessfully) the migration
characteristics of the wildtype crypt, if we were able to obtain a higher-resolution migration
profile using the lineage tracing described in Section 6.2.3, then another highly interesting
question to investigate would be the extent to which the observed migration behaviors are
altered in diseases such as Apc-induced colon cancer. Indeed, not much is known about
this topic. The only attempt in our awareness that deals with this issue comes from
Sansom et al. (2004), in which the researchers used a set of BrdU pulse-chase
experiments to demonstrate that in APC loss, the migration of the transformed stem cells
are abolished, as shown in the figure below.
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Figure 6.1. A study from Sansom et al. (2004) showing the results of BrdU pulse-chase
experiments for wildtype crypts (left plot) and Apc-transformed crypts, 3 days after
tamoxifen induction (right plot). The black bars show the distribution of BrdU+ cells as a
function of cell position from the crypt base after an BrdU pulse, while the white bars show
the same distribution after an BrdU pulse followed by a 24-hour chase. By comparing the
black and white distributions, we can approximate the cell migration. As seen above, while
the wildtype crypt has a proliferative zone that is confined to cell positions less than 20,
and has significant cell migration over 24 hours as seen by the shift between the two
distributions, in the case of transformed crypts, not only is the proliferative zone expanded
beyond the original niche, but he migration behavior seems greatly diminished, as judged
by the lack of shift between the black and white distributions.
This is an interesting and somewhat surprising observation that may make sense in
retrospect: even in the normal crypt, stem cells are not known to migrate, so in the
transformed crypt, there is no reason to suspect that they will lose their fixed anchor.
However, this study also raises more questions: If it is indeed true that transformed stem
cells do not migrate, then how is it that the stem cells can expand out of the typical stem
cell niche? As we hinted in Chapters 4 and 5, the transformed crypt may indeed have a
more complex dynamics related to stem cells and differentiated cells. How does this
dynamics play out in view of the migration characteristics? For example, do the other
transformed differentiated cells-suppose they exist- behave the same or differently in
terms of cell migration compared to wildtype differentiated cells? If so, can such
differences explain the altered migration dynamics consistent with Sansom et al. (2004)?
These are highly fascinating but hiterto unanswered questions.
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Appendices
A. FISH probe sequences for selected markers
Lgr5 (set of 96 probes)
AAGGACAGGAGCATGTGGAC
TCACAGTGACAGTGTGATGG
TGAAGACGCTGAGGTTGGAG
ATACTGAGGTCCAGGTAGGA
GGGTAGCTGACTGATGTTGT
TAGGAAGCAGAGGCGATGTA
TTCCAGCAAGACGTAACTCT
TTGGGAATGTGTGTCAAAGC
AAGCACTTTGAGGCTGTGAA
TCTCAGCTGGTTGTTCTGCA
AAATTCTGTAGCGCTTCCTC
ATCTAGGCGCAGGGATTGAA
GCACGTAGCTGATGTGGTTG
ATTGTCATCTAGCCACAGGT
AACTTCTGAAAGCCTGGACA
TTGTTCAGGGCCAAGGTCAT
GTAGTCTGCTATGTGGTGTA
AGGCTGGAGAGGTTTCCAAA
ATTATGGAGATGCAGAACCA
TTCCCAGGGAGTGGATTCTA
TGGAGTCCATCAAAGCATTT
TAAATCTAAAGTCTCCAGGC
GTGGGGAATTCATCAAGGTT
GTTGGAGAGTGTCTTGATTG
CTGTGGAATCCTAGTTCCTT
CGGTATTGACCTGATGTTGT
ATAAGAGAAGGGTTGCCTAC
GGGGTTGTCATAGAAGTGTA
CAGATACTCCAACAAATTGG
CTTAGTTCAGGCAAATGCTG
AGGCACCATTCAAAGTCAGT
CCTGTCAAGTGAGGAAATTC
TTAAAGTCAGACTCTCCAGG
AGAGATGAGATCTTTGCTCC
TAGGTAACTGATCACAGACG
GACAAATCTAGCACTTGGAG
GTAAGTCTTCGAGTAGGTTG
TTTTGGCAGCCTGACAAACT
GCCTCAGGTCAATTTTCTGA
GCTGCCCTTAATTTCATAGA
GGAGGTTAAACAACTGCTGA
TTCCATGCTAAGTTCAGAGA
CATTGGGGTGAATGATAGCA
AGAGACGGCAACGTAGAAAA
GATTGGATGATAGGTCCAAC_
TCTTGAGCTCTGGGAAGTTT
GGTAAGCAGATGGCATTTCT
TATAGACATTCTCACACCCC
CGTCGTCTTTATTCCATTGG
TTATGAAGGTCGTCCACACT
CTTGAAATAACCCAGCGTCT
TAGGAAATCTTCAAGGTCCC
TCAGGTCTTCCTCAAAGTCA
TACCAAATAGGTGCTCACAG
ATTGCAGGAAAGCGCCAGTA
AACACGGTCAAAGCCACCAA
AGAGATGTACAGAGGAGTTC
CCCCAATTAGCAGCTTTATG
AGAATGTCCACTACCGCGAT
AAAAGTGAATGCATCCACGG
ACGCACCGTGCTGAGCAAAA
AACGATTTGGCAGCCGATTC
GGAAGCAAAAATGGACAGGA
TGAGCAGGAAGATCGACGAT
ACAGAAAAACCTCGTTCCAG
CTTCAAACTTCGAAGAGCAC
AGGCTAAAAAGGGGAGCTTT
ACATAGCAAAACGATCGCTC
AAGGGGATTGTGGCAATGGT
CATTGTACTTACTGCCTCCT
AACACGAGAGCCACCATGTA
GAGGAAACAGAGAGAGTTGA
CTTTGTGTAGGCAATGGTCA
CTTTCTCCAAACTGCAGTAG
ATCCCAAAGATTCTCCAGCT
CAATGTGCTTCACCATCGAA
TAAAGGATGCAGTTGGCGAA
AAGGATAAGAAAGCCACGGG
AGGTGAGGTTTAGCAAAGAG
TTAATGACGTCAGGACTGAT
GGACGATCACGAGAAGTATA
TGGGTTGAGACAGGAAGGAA
GGGGATTGAAGACAATGTAG
CTGCCCATATCCTCCTTAAA
TCCAGAAACGGGTATGCTTT
AGACTCGCGTGTTTTGATCT
ATCGTCCGAGTTAATGGACA
ACTCACAGGACCGTTTCTCA
AAGGATACTAAGGCTTGGGT
AAGGCAAGTCATAGGCTATG
77
AACCATGTAACCCAGTCACA TCATGGGGTAAGCTGGTGAT
GCTCGGTTCCCTGTTAATTT GAAGAGAGATGACAGCTTTC
AGATGGTATCAGGCTCTGTA GAGACATGGGACAAATGCAA
Gob5 (set of 48 probes)
ACTCAGAACTCCTTCCAGAA ATGGGAGTGGTTTGCTTGAA
TTGTTCAGTTGGATGAGGGA ATTTGCAGCAGTGAGAAGGT
TGAATGAGGGCTTCATCTTC CCCGGACTTATCAAGAACTA
GAGTCACCATGTCCTTTATG AGACGATCATCGTTCAGCAT
TTCAAACAGGTATGGAGAGG ACATAGGCAGCACTGTCAAA
CGGGAATCAAAATGGCAACA CAGCACCACTGTTTAACTGT
TATTCAGGCTTTGCCTTCCA TGCTTGATCAGCAGATCTCT
AGGTTTCAAGTTTTGGCCTC ATATAGATGTCCCTCCTGCA
GATACAAGGACATCAGCGTT ACTGTAAATGCTGTCCGAAG
TATATGTTCGGTGTAGGGCT CAGATCCATCAGTTGGATAC
AAGTCAGGAGTCAGGTGAAT AAGCAGCTGCTAATGGTGTT
AGTCAGCTTCTTTCCTGCTA ACAGCTGCTCAAGCTCTTTA
ATGGACAAAGGTCCTGTCTT ATCCGAAGAGTATGTCTGCA
TTAAACACTCCCCATCGGAA CAAGACCATTGTTCTGAACC
GAACTTCTCGTCGTTGTTGT TTCTGGAGATTAACTCCCCT
GGGGTTTTCCTTTGGATAAG TGAGCCATTCATCCATTGGT
TTTTACCGGTAATGGCTGCT ATTGTAGGAGGATGCGTTGT
TTAGTGATACAACTGCCTCC AACCATTTTGTTCCACTCCG
CGTTACTCTGTCGATTACAC CCTTAGTGGTTGTGTCTAGT
GGTGTGGATCTGGTACAAAT TTCCAAAAGCCAACCTTAGC
ATGATGGAAGCCTTCTCGTT TAATAGGAGGCAGTGTAGCA
GGGGCTTCTTGATTGTGATT TTCTTATTCACTACCGGGGT
GCATCGTTGGTTTTGGTCAT TTGCATACACTGTTACAGGG
TCAGATTCCTGGATGACTTC ATTCAATCAAGGCTGTGACG
Creb3/3 (set of 38 probes)
ATCTTTCCAGCCGCTATGTC GTTCTCCAGACCATCAATGT
ATCAAACAGGAGGTCAAGGA TGGGCAGTACACGCTGACAT
AGCTCCACGTTTCTCAGGAT ATGCAAAACCTTCCTCTGCA
CCCAGGATGCAATTTAGGAA CTGCTCCAGAAGAGACAAAT
ATAATGGAGAGCTGGGGTCA ACAAGTGCCTGCAGGTGTTT
AAGGTAGATCCTCAGAGATG TGGCTTGCTGGTTGACTGGA
TTCAGTGCCACTACGAGGAG AGAAGGACCGCTATGCAGGT
TGACACCTGGCTACCGTGTT GATGATCAGGGCGAAGGACA
ACTCCTGGACTTGTGTCCTT AGTTGAAAGGGCTGATGGAG
TCCAGGTCAATGGCCACTGA CCAGGGCTGTCAACTTTGTT
TACAGGGTATCTGTGCTCCA TTCTGGAAAACACTCGCACT
TCCTTCACAGTGAGGTTGAA TTTGTGGGGGGTACCAACGT
AAGGAATGCTGTTGCAAGTC AAATTTCCCCAGTCTGCACT
ATCCTCTGTCAGCACCAGCT CAGGTTGTCCAACATTGGAA
TCTTTAGCCAGCAGCTTCTT TGGAGTTGTCTAGCTCTTCT
ATACTTGGTGAGAGGCAGCT ACTGAGCAGTGGTTCTGAAG
CGGATTTTTTTCAAAACTCG ATCTCCCCTGGTATCTCCAG
CTGTTTGTTCCGGATCTTTC TAAGCCACCTTGGTACCCAG
TCTTCCTGCTTTCTTGAGCT AATGCATCTTGCACCAGACG
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Ki-67 (set of 96 probes)
ATACTCCTTCCAAACAGGCA
GCTGGATACGAATGTCACAT
CCTCTTGCTCTTTGACTTCA
GAGTTGGATTGGTAGAACTG
CTCATCTATAGTAACCCCGT
TTATGTCTCCATGTCTCAGC
TAAAGGAGCGGTCAATGATG
CCATCCTCATGATTTCCATC
TGGAAATTCTGTTGGCTTGC
GTTCCTTTCCAAGGGACTTT
AGAAGCTATCTCTTGAGGCT
TATCTTGACCTTCCCCATCA
CCCTTGGCATACACAAAAGA
TGTTCTTTGAGCCATCTGAG
TACATGCCCTGATGAGTCTT
TATGTTTCTGCCAGTGTGCT
TAAAGAGATCCCCAGAAGTG
AAGACTTCGGTTCCCTGTAA
ATTGCTAAGGCTCTGTGTAG
AGGGAGATTCCTTTTCGTTG
GGGTTCTGATTTCCTACAAG
TGACACCAATAGCTGTGTCT
TCCACTAGACTTTGCTCTTG
TTCCTACTTTGGGTGAAGAG
TTAGCTGTCTCTGTGGAAGT
TTAAGTTGCTGTGAATGCCG
CAGTAACACGAGAGTCTTCA
CAGATTCACAGAATGTCGTC
ACTGTTTTATGGACTGCCTG
TGGTTTCTAGTCGCCAGTTT
AATGTTCTGGTGTATCAGCG
CCTTTGCAGGAATACTTCTC
TTTGTGTCTCTGCAGATGGA
AAGGCGCTGAGTTAAAGAGA
AGTTTCTCAGGCTTGCTGAA
AACGGAACTAAGACCAGGTA
GGAATCACCAAAGTTGCTGA
GCATTCCCTCACTCTTGTTA
GGATACACGTCTTCTCTTCA
GGTGTATTAGGAGGCAAGTT
TGGCGTTTCTCCTCTTTTCA
TGATTGTCTTGAGGACAGCT
TTGATCATTTGTCCTCGGTG
ATTTGCTTCCACTGGAAGTC
GGGAATGTCTGTCTCACATA
TGTAGAATGCCATGCTGACT
TCGCCTTTTGGAGCAAATCA
TCAAGTTGGCTTCAGAAGCT
TCAGCCCATGATTTTGCAAC
GTGTTTGTTTCACGCCAAGT
GACATGTTTCGCAACTTTCG
TCTTGCTCGTCTGCTTTTGA
TTGTGGGTTTCTTTGGAGTG
GCATGGCCTGTAGTAAATTG
TACAATGGTACAGGGAGAGT
TTTCAATCTGCGCTCTACCT
TTCAGCATTTTGTAGGGTCG
CCACTTTTCGGTTTAGCATC
CCTGACAGATCTTCACTGAA
TGTATCACTCATCTGCTGCT
CTGAATTGGAAAGTACGGAG
CTCAGGTATGTCTCCTGAAT
CCAAAATCTCTGTGGTGATG
CGAGTACTGGATAGCACTTT
TATCAGACTGCTGCTTTGCT
CTTAAGGTAGGACTTGCAGA
TTTCATGTTTGATGCTCCGC
GGACATTCTTAGGAGTTTGC
GTCTTCTTCTCAAGGTCAGT
TAACTTGCTCACACTCGATG
GTCTGAGCTCTCTAGATCTT
GCAAGGACTGCTTCTGTTTT
ATGTCTTGCTGTGGTGTTCT
TTTGTTCTCGAAATGTCCCC
ATTGTCCTGCACCTGTTGAT
TGCATCTTTGAGGAGCGTTT
GCTGATGTCTTTTCTGAACC
TCTTTTGTCGGCTTCTGCTT
GACCATCTGACTTCCTAGTA
TCAGCATAGTCTGCTGTTTG
CCTTGTCCTTGACTAAGTAG
GCATGGATTCCTCTAGGTTT
TAGAGGTTGTGCCTTTTTGC
AAAGTGTTCCTTGAGACCAG
GGTTTATCTTTGGGGTTTGG
GTGACTTGTGGTGATTTGCA
GTGGCTTTGTGTTTGTTGTG
TTCTTCCCAGATGTGCTAGT
GAGCTTTCTTCCTTCATGTC
CCCTGGCATATGTATACGTT
GCTTTGATATCCTCACACTC
CTGTTGAGGTCAGCATTTCA
CTAAAGTCCTCTTGCTTCCA
GGGCTGAGCCTTTTTTTTAG
TGGAAACAAGTCAGGTCTTC
GTGGAGATTTGCTGGGAATT
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EphB2 (set of 48 probes)
AAGATGGCACCATTCTGGAT
ACTTCTTCAGCATTGGCGAT
GTAGAGTTTGATGGGCACAT
TTGCACATGCAGCGACCTAT
TGAAGGTTCCTGATGGACAA
TTGATGGGACAGTGGGTGCA
TTGCGGCATACACAGTTGGT
TTGTGCAAGGCATGTCTAAG
TTGACGCTGGAGATCACAGC
TAAACAAGATCCTCGCGACC
ACAGCTCTTGCAGATGATGT
AGCAGGTCACTGATGTAGAT
ATCTCGAAGGTGTACTGCGT
AACTGAGGTGAGAAGGGACT
TTGGTGGTGATGTTCACAGA
TAGTCCAGGATCACACCGTT
CTTCTCATAGTACTGCAGCT
TTTATGGCCGTGGCGTTGTA
TGCACAGTGACTGTGTTGGT
ACCTGGAAGACATAGATGGC
AGTACATCTTGCCACTGTAG
TCGGCTTCTGTCATGGTTTG
TTTTCCTTGATGCTGGTCTG
ACAGCGATGAGGAAGACTAA
Ephrin-B1 (set of 48 probes)
AAGCCACTTGCTGAGCCAAC
ACAGCGTCAGCACGACCATA
AGGTTCTTGGCCAACGGCGT
TTAAGAGAGCTCCAGGACAC
CTTCCCACTTAGGAACTTAG
ATCTTCGGGTAGATCACCAA
AGATGATGTCCAGCTTGTCT
TTGTAGTACTCGTAGGGCCG
CTCTGGCCGCACCAGGTACA
AAGCACAGTGCTGCAAGCAG
AAGTGACCAGTACATTGGGA
ATTTCCTGGTGTGGCTTGTT
TTGGAACTTGATGGTGAAGC
CCATGTAGTTGGGGCTGAAC
CGTGGTACTTTTTGAATTCC
GGACGTTGATGTAATGTAGT
TTCTCCAGTCCCTCCAAGCT
TAGTGCGGGTGCGACACACA
CCCAACCTTCATAACGATCT
GTGTCACAGCATTTGGATCT
CGGCTGGTAGTCAACTGCTC
TGTTGTCTGACTCCTTGCTT
AGCCTGTGTGGCTGTCTTGA
TCAGAGTCACCCTGGGATCC
TGGTTCACAGTCTCATGCTT
ACCTGGGCCACTCTTCTCTT
TTGAAGAAGCTGTCAGAGTC
TGCGAACAATGCTACCTTGG
AGCAGGAAGATGACACAGCC
GACTGTCAAGAAGATGATGA
GCTTGCGGAGCTTGAGTAGT
TGCTGTGTATGCTTGCGATG
TAGGGTACTGAGCGAGAGGG
TGTACCACTACCCCCTTTGG
ATGATGATGTCGCTGGGCTC
TGTTCTCTGTAGTCCGTAAG
TTCTCATAGTGGGGGCAGTA
ATGCCCGTAGTCCCCACTCA
TCTCCTGGACGATGTAGACA
ACCTTGTAGTAGATGTTCGC
Olfm4 (set of 48 probes)
80
ACATACGATGGCAATGACGA
TTGTCCGTGTACTCTGAGTC
TCCGCTGGTGTAGTGTTGTA
TATAGATCTTCATGCCTGGG
TCTTCATAGGTGAAAGGGTC
ACTCCCGCACTGCCTCATTA
GAGATGTCAATTTCCTTGGC
TCACCTGCTCAATCTTGACA
ACTGCAGACCTCACCAAATT
TTGCCTGGCAGCTTCAAATG
GATGGCTACAAAGATCTCTC
TTCTCCGTGTATCCTGACTT
ATGGATGCCTCACTCAGGAA
TTCCAGATGGATGACATTGG
AGGTGTGCTCTTGGTGACAA
CCATGAATTCAGTGATGATC
AAGGAGTCCAGAGATCCGTT
TGTGAACTGCCCATCGTTTT
AGCATGCCCACCAGTTGGAT
TACTTCATGCCGGCTGCAAT
ACGGTGCACGTAGTTCATGT
AGGATGTTTCGAGCAGCAAG
TTACACACCAGGTTGCTGTT
TGAGAGCCCAAAATCAGACA
GAAAGAGAAGGCTGTAACTC
AGAGCCAAGGCAGAACTGAA
AATGTGCAGAGGTCAGAGTT
TGTTGGAGGTGTGGTCAATT
AAAGTGGCTGAGACACAGTC
TCCACAGACCCAGTGAAATT
AAACAGAACACTGGCAGGTC
TGTGAGCTGTGTACTCTAAG
CTCTCTCTCGAATTTCTGAG
GACATACTCCTTCACCTTAG
GCCTCTTCTCATACACACTT
TAAGAGATGCTGTCCTTCTC
CAACTCAAAGTCCAGTTCTG
ATCTCCTTCACTTCCAGCTT
CTTCAGCTGTAAGACCAGTT
CCACTTCGAGCATGTCAATA
CCAAGAGGGTCATATTCCTT
TCTAGAGACTCCAGCTTCTC
GCGAATGCTAAGGACATTGT
TTGGTCTTCAGAGCCAAGAT
TTGGAGGCCTCACATTCTTT
ATACTTCCAGCTGCTCCTAA
CCAAAAGTTCAGGATCCAGA
GCTGGTGGAAAAGAGAAAAG
Bmil (set of 48 probes)
GGTATGTCCATTTTACTCCT
GACGTCAATCTGGAAAGTAT
TTAAAGGTTCCTCTTCATAC
TCCATTAGCGTGTAGTAATC
CCAGGTATAAATGTAGGCAA
AAGGTAGTGGGCCATTTCTT
GTTGGCCGAACTCTGTATTT
ACTCATCTTCATTCTTTTGC
ATTCGTCAGTCCATCCCTCT
AGTCACTTTCCAGCTCTCCA
CTGTTGGCCTTGTCACTCCC
TGGAGGGAACACCTCCGGCT
GGACTGGGCAAACAGGAAGA
AGGAGACTGCACTGGAGTGC
AAATGTGAGGGAACTGTGGG
CTGGTTCCATTCATGGTACT
GTGGTTAGCACTGGGGCTGT
GTCTACTGGCAAAGGAAGAT
CCATTTAGTGATGATTTTCG
ACCAGATGAAGTTGCTGATG
GTAACTAAATCAGGGGGTTG
GCATCTATAAAGCTGTAATG
GGACGACAGTCACATGTATT
GTCACTACAAAAGGAAGCAA
81
ATTCTGGTTGTTCGATGCAT
GGGATTTAGCTCAGTGATCT
CACACAGGACACACATTAAG
GTGGCATCAATGAAGTACCC
ATGTAGACATTCTATTATGG
CAATACATGTTTTACAGAAG
TTGCTGGTCTCCAAGTAACG
GACATCACAAATAGGACAAT
GTGGTCTGGTTTTGTGAACC
TTATCTGACCTTATGTTCAG
GTATACAATATCTTGAAGAG
TGAAAAGCCCTGGGACTAAT
CTTCTTCTCTTCATCTCATT
CGGGTGAGCTGCATAAAAAT
AGCCATTGGCAGCATCAGCT
ACTTCTCCTCGGTCTTCATT
AATCCTCTTCTCCTCATCTG
GCTTATTATCTCATCATCAG
GATCAAAGAACTCAATAGAC
ACTTTCCGATCCAATCTGCT
TTCCTTAGGCTTCTCTTTAT
AGTACCTTTTATCATTCACC
AGTCATTGCTGCTGGGCATC
GAAACTTTCTCAAGTGCATC
GGCCAATGAAACATTTTGCG
TGAGCTGAATCACAGAAGGA
CCCCAGGCACCATATTTATA
ATGCTGAGGAGAGTAATCTC
TCTGTATTCAAAGGTGCCAC
GTAATACTCTAGAGCCCTTG
CTCGGAAGTGGGAATAGATT
TGAATGCTACTGTACCACCT
CCCCATTGTACCAATTCACA
GCCGATTCACATCAACTACA
ATTATTGTAGGCAGCCAGAG
GGTCAATGTCTTGCCAATTC
TAAATTGCCCACAGTGCTTG
TCACTATGTTACCAGTGCTG
CAAGAGTGGTGTCATTGAGT
GTAACCCAAGTGCTTATCAC
AACAGATGGCTTGTACTGCT
CACATACCATGAAGGCATTC
GTGCGAGTAGCATAAAGAAC
CCTCTCTGTGTTTGTGTCAT
TCATTGTGATGCCTAGGTTG
GCTCTGAATTCTTTCCTGCA
GGTCAAAGGGATGGTAATTG
GCGTCTGTAAGAAGACAAGA
,
Hopx (set of 32 probes)
ATACTGAGGAAGCGCCTCAA
AGAGGAGGAAGAAGACGCCT
GTGCGCGTCTGACTAAGGAT
TTGTACTCCAGGATCTCCAC
GTGCTTGTTGACCTTGTTGA
ATTTCTGCGTCTGCTCCTCC
TCTGCCAGGCGCTGCTTAAA
ATTCCGAAGGCAAGCCTTCT
CCCTAGTCCGTAACAGATCT
AGTTCCAAGAGCAAGCTCAA
CGAGGGAAGGAAGAAGAGAT
CATCAAAACAGCCTGGGTAA
GACATTCAACACTGCACTGA
GTGTTAAATAGCAGGACAGC
CTGCATTTAGCTCCCTGTTA
CAAGCCATCACTTTACACAG
B. Mouse protocol
Here below we append a copy of our mouse protocol as approved by MIT's
Comittee on Animal Care. The sections highlighted in yellow include the most recent
revisions to the protocol as of February 2012.
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AAATCCAAAGGCAAGCCACA
GGTTCCCACATCATCTTTCA
TACTGGAAGGTGATGGCCAA
GGGGATGGTCCATATGAATT
AATAGAAGCCAGGCAGCTCT
CCTGCCTGTTCTGTTATCTT
AAGTGAACTCAGGAGGTGTT
TTTAGTGAAGCAGAAGGAGG
TTCTCATTCAACCACCAGTG
GAATGACTCAAATACACCCA
GGGAAGGAACTGTTCATTCA
TTCCAAGGTAACACAGCTGT
CCATAGCTGCTATACTAGGT
TACTTGC1TT1CTGCCCCTT
GGTAAATTCTAGACTCTGTA
GCAGTTCATTTTATTCAGCA
,
Version: 4/11 CAC New/Three-Year Protocol Application for the Use of Animals at MIT/WIBR/Broad Institute
This form is required for all new studies and every third year for ongoing studies.
The "CAC Annual Renewal Application for the Use of Animals at MIT/WIBR/Broad
Institute" must be submitted on an annual basis in intervening years to secure
continued approval; the CAC will send a renewal reminder approximately one
month in advance of the due date. Animal orders will be held on protocols that are
overdue for renewal.
THE CONTENTS OF THIS DOCUMENT WILL REPLACE ALL PREVIOUSLY APPROVED
PROCEDURES UNDER PRIOR VERSIONS OF THIS PROTOCOL.
INSTRUCTIO 1. Complete this form using Word. If cutting and pasting from other documents, paste as
NS FOR "unformatted text". If text exceeds allotted space, use Table Tools to insert additional
PREPARATIO rows.
N AND 2. This form is reviewed by both scientists and non-scientists; please use language that will
SUBMISSION be understood by a non-scientific reader, and identify the meaning of any acronyms at
their first use.
3. Refer to the DCM Laboratory Animal User's Handbook for information on general
procedures, drug doses, acceptable methods of euthanasia, etc. (available at the CAC
website: https://web.mit.edu/comp-med/restrict/cac/LAUH link.html)
4. Answer all questions. Reprints or copies of other printed materials will not be accepted
in lieu of explanation in each section.
5. When completed, submit an e-copy (Word format preferred) to cacpo@mit.edu.
Signature pages may be submitted separately in hard-copy to the CAC office (Room 16-
408; Fax: 617.258.8257).
6. If all animal work will be taking place at a collaborator's academic institution,
submit the "CAC Protocol Application for Off-Campus Collaborations Involving Use of
Animals," plus additional documentation as described on that form.
Section 1
General
Information
Current protocol
number (if three-
year renewal):
Not applicable
fitle of protocol [CAC will edit titles that exceed 100 characters]:
Variability of cell behaviors in early intestinal tumors involving
Apc deficiency and/or Kras overexpression
Principal Investigator (PI): Alexander van Departmental Affiliation/DLC: Physics and
Dudenaarden iology
PI E-mail address: PI office phone: PI office address (Bldg-Room):
avano@mit.edu 6172534446 8-371B
Lab Research Contact: Kevin Kung Lab Administrative Contact: Monica Wolf
Lab Research Contact E-mail address: Lab Administrative Contact E-mail address:
kkung@mit.edu mwolf@mit.edu
Lab Research Contact phone: 45042 Lab Administrative
6172534829
Contact phone:
_________________________ ± _____________________ _____________________ _____________________ ___________________
Funding agency Grant number Internal
Cost
Object
Date
grant
submitte
d
Date
grant
begins
Date
grant
ends
MIT Start-up N/A 1559200 N/A N/A N/A
Funds for
Alexander van
Oudenaarden
All funding for this research must be listed above. Press tab while in last cell to add a row;
repeat as needed.
Does the information in this form agree with the animal use section of the grant
application(s)?
E] Yes X N/A (Internal funds only) El N/A (No animal use section in grant) E] No (Explain):
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Section 2
Funding
Information
Select one of the options below to indicate the source of peer review (peer review must be
refreshed at each three-year renewal):
- Governmental or external, non-profit funding agency (name agency if not listed in table above):
FI A peer review letter is attached (see https://web.mit.edu/comp-med/restrict/cac/assist3.htm for
guidance)
X Publication record using similar methods (provide brief list of relevant citations <3 years old):
On the mouse phenotype:
Barker, N, et al. 2009. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457: 608-
11.
On the use of BrdU/EdU pulse-chase:
Schepers, A.G., et al. 2011. Lgr5 intestinal stem cells have high telomerase activity and randomly
segregate their chromosomes. EMBO 30: 1104-9.
Seno, H., et al. 2009. Efficient colonic mucosal wound repair requires Trem2 signaling. PNAS
106(1): 256-61.
E Not applicable because this is a teaching or DCM services protocol
Section 3a Enumerate (1, 2, 3...) the specific aims of your research. Concisely explain scientific merit
Specific Aims (i.e., why the experiments are important) and justify your choice of animal model.
Colorectal cancer is amongst the top five most common cancers (NCI, 2011). In particular, there is a class of
colorectal cancers with a clear hereditary cause. For example, patients with familiar adenomatous polyposis (FAP)
develop numerous benign polyps in the large intestine, and acquired secondary mutations that often lead to cancer
before age 40 (Bisgaard et al., 1994). Linkage analysis showed that most common mutations for FAP are located in
the APC gene (Kartheuser et al., 1995), a tumor suppressor gene and negative regulator in the Wnt signaling
pathway that controls cell proliferation and stem cell maintenance (Goss and Groden, 2000). Likewise, 85% of the
sporadic cases of colorectal cancer also involve APC mutations (Medema and Vermeulen, 2011). Based on knock-
out studies, there is evidence that the loss of Apc in the intestinal stem cells lead to the upregulation of key genes in
the Wnt pathway (Sansom et al., 2007), as well as the macroscopic formation of adenomas (Barker et al., 2009).
However, the precise mechanism by which this phenomenon occurs is less than clear: for example, how do Apc-
deficient stem cells clonally expand? What are the roles of other "normal" cells and the underlying mesenchyme in
this transformative process? How do different cells proliferate and migrate in normal and diseased circumstances?
In order to answer questions like these, it is essential to study the system in vivo, as so far attempts at
reproducing the spatial arrangements of the intestinal cells in vitro have not been met with success. We propose
mice as the animal model for the following reasons: (1) the murine genome is well-characterized and can be easily
manipulated; (2) murine and human intestinal structure are similar both physiologically and molecularly; and (3)
key genes implicated in human intestinal cancer also have homologues in mice. More specifically, Apc deficiency
is known to affect the duodenum segment of the mouse intestine, so our model system will be mostly on the crypts
and villi of the murine duodenum.
1. Study the dynamics and spatial distribution of relevant mRNAs in induced Apc knockout mice.
Currently, the state-of-the-art studies on spatial distribution of genes in normal and diseased intestine have relied
immunostaining and/or fluorescent proteins. While this approach has shed considerable light to the progression of
intestinal cancer (for example, Barker et al, 2009), technical difficulties such as the limited repertoire of antibodies
currently available. We can achieve an ever better single-cell-level quantitation in this model system using the
single-molecule mRNA in situ hybridization method in order to understand the role of Apc deficiency on both the
mean level as well as the variability of the expression patterns of relevant genes, such as downstream WNT
signaling targets (e.g. cMyc, Ki-67) and cell differentiation markers (e.g. Gob5, Creb313).
2. Characterize the dynamics and spatial distribution of cell proliferation and migration in induced Apc
knockout mice.
Many of the mRNAs (such as Ephrin, Ki-67, and Creb313) studied in Specific Aim 1 are closely related to cell-level
properties such as differentiation, proliferation, and migration. It would therefore be highly informative for us to
establish the link between changes in genotype to phenotypic modifications. To this end, we propose to probe cell
proliferation and migration using a pulse-chase method (as described in Sansom et al., 2004) involving EdU and/or
BrdU.
3. Develop a method allowing FACS separation (sorting) of cells in mouse tissue, based on single-molecule
mRNA FISH.
Currently, to physically separate and analyze specific cell populations in mouse tissue, researchers use a panel of
fluorescent proteins expressed exogenously by the animal, or stain the cells with fluorescently labeled antibodies.
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These methods have a number of serious limitations, such as comparatively low number of available mouse strains,
expressing fluorescent proteins, or low number of available antibodies. Creating a new antibody or especially a
mouse strain require a lot of time, labor and money. In contrast, the single molecule mRNA FISH is relatively
inexpensive, simple method, detecting endogenous mRNAS (which allows to use genetically unmodified mice).
Simplicity of probe generation makes the choice of target mRNAs (and therefore target cell populations) virtually
unlimited, and coupling probes with various fluorophores allows simultaneous use of three colors for sorting. The
proposed method will dramatically enhance our capabilities in genome-wide analysis of mouse cell populations
while significantly reduce its cost and the amount of required labor.
4. Characterize the RNA content of FACS-sorted cells in the Apc knockout model.
While Specific Aims 1 and 2 propose to study the consequences of Apc deficiency using selected markers of cell
differentiation, proliferation, and migration, our ultimate goal is to sort these different cell subpopulations in the Apc
knockout model using the FACS method described in Specific Aim 3, and perform a genome-wide analysis of each
cell subpopulation. This will allow us to interrogate a much wider range of potential genes implicated in the Apc-
mediated cancer-forming process.
5. Evaluate the role of Kras overexperssion in the Apc knockout model.
While Apc is a relevant gene in our cancer model, it typically only results in benign polyps, which only becomes
malignant upon acquiring secondary mutations such as Kras overexpression. Thus, our interest in the Cre-inducible
Kras-overexpressing mice is twofold. Firstly, what is the specific role of Kras in cell behaviors in the crypt, in the
absence of Apc deficiency. We plan to compare the results here with the results obtained using similar procedures in
Specific Aims 1-4. We are also interested in crossing Cre-inducible Kras-overexpressing and Cre-inducible Apc-
deficient mice to study the effects of Kras on the Apc-deficient genotype in an attempt to understand the early
timepoints of malignancy development in intestinal cancer.
Works cited:
Barker, N., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457: 608-12.
Bisgaard, M.L., Fenger, K., Buelow, S., et al. 1994. Familial adenomatous polyposis (FAP): Frequency, penetrance,
and mutation rate. Human Mutation 3(2): 121-5.
Goss, K.H., and Groden, J. 2000. Biology of the adenomatous polyposis coli tumor suppressor. J. Clin. Oncol. 18:
1967-79.
Kartheuser, A., West, S., Walon, C., et al. 1995. The genetic background of familial adenomatous polyposis.
Linkage analysis, the APC gene identification and mutation screening. Acta Gastroenterol. BeIg. 58(5-6): 433-51.
Medema, J.P., and Vermeulen, L. 2011. Microenvironmental regulation of stem cells in intestinal homeostasis and
cancer. Nature 474: 318-26.
National Cancer Institute (NCI). Common cancer types. Accessed 13 Sept. 2011.
<http://www.cancer.gov/cancertopics/types/commoncancers>.
Sansom, O.J., ei al. Myc deletion rescues Apc deficiency in the small intestine. Nature 446: 676-9.
Section 3b Briefly summarize your progress for each Specific Aim (identified by number above) since
Progress the last renewal. Include successful and failed outcomes.
Statement > Not applicable (new application)(3-Year
Renewals only)Provide a summary of any morbidity encountered during or following experimental
procedures, how it was managed, and what your plans are for refinement of the model to
avoid morbidity.
> Not applicable (new application)
Section 4 The contents of this document will replace all previously approved procedures
General under prior versions of this protocol. Do not omit any procedures you intend to
Procedures continue.
(Refer to DCM Summarize sequentially all animal procedures.
Lab Animal - Make clear the sequence of procedures each animal might undergo, from arrival toUsers' euthanasia-specify time intervals between procedures, endpoints of experimental use,
Handbook for and the final disposition of animals.
common - Describe all techniques used; specific supplement forms (see list below) should be
procedures) referenced in lieu of duplicating all details here.
Breeding (wildtype)
Female C57BL/6 mice, older than eight weeks, will be bred with male C57BL/6 mice to
produce embryos. One male and two female mice will be housed in the same cage four
nights a week until a plug is seen. Plugs will be checked for twice a day, by handling the
female mouse by its tail and gently opening up her vaginal cavity with appropriately sized,
sterilized forceps. Once a plug has been identified, the female mice will be separated into
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another cage. Female mice will be removed from the male's cages during the other three
evenings of the week in order to encourage mating. Male mice will not be moved from their
original cages, and will never be mixed with non sibling male mice.
Breeding (transgenic)
If we wish to cross between different transgenic strains, or between a transgenic strain and
a wildtype strain, then the exact procedure as wildtype breeding (as described above) will
be followed, except that mice of the appropriate genotype will be housed together.
Euthanasia
The mice will be euthanized via C02 asphyxiation. Standard protocols will be followed.
Anesthesia (isofluorane)
A glass jar will be prepared in a ventilated hood (i.e. the air is not recirculated back into the
room). A piece of isofluorane-soaked gauze will be placed at the bottom of the jar. Another
piece of dry gauze will be placed on top of it so that the mouse will not come into direct
contact with isofluorane. The mouse will be put into the jar, with the lid closed. Vital signs of
the mouse will be carefully monitored, and care will be taken not to overdose the mouse.
Genotyping
Due to random segregation during breeding, we may not always achieve the desired
genotype. To verify the genotype, we will snip a portion of the adult mouse's tail and search
for the desired genotype (e.g. EGFP-IRES-Cre) via a polymerase chain reaction (PCR) assay.
To perform PCR we will extract 20 ng of DNA from the tail and add to it 4 microliters of 25
mM of MgCl2 (Roche, Biochemicals), 1 microliter of the appropriate 10mM of
deoxynucleotide triphosphate mix (dNTP) (Amersham Pharmacia Biotech, Inc.), four-tenths
of a microliter of 20 mM sense and antisense primers for the mG gene, half a microliter of 5
units per microliter AmpliTaqGold DNA polymerase, 2.5 microliters of 1OX PCR buffer and
15.2 microliters of DNAse and RNAse free water. We will extract PCR profiles by performing
various cycles at appropriate temperatures for designated periods of time and resolve our
PCR product on an agarose gel. We will then only use the tissue from the animals with the
desired genotype.
Tamoxifen administration
Purpose: Achieve temporal and spatial control of oncogene induction and tumor suppressor
loss in combination with tissue-specific CreER alleles.
Tamoxifen (0.1 mg to 9 mg/40g of body weight) dissolved in corn oil will be injected into
the peritoneum of mice (including pregnant mice to deliver Tamoxifen to the pups) carrying
CreER alleles. Animals will receive up to 5 consecutive doses of intraperitoneal. To prevent
corn-oil induced peritonitis, in some cases, tamoxifen will be dissolved in 0.5%
Carboxymethyl cellulose, 0.4% Tween 80, 0.9% NaCl solution and delivered by oral gavage.
These procedure are not expected to cause pain. For oral gavage delivery, animals are
anesthetized using 2-3% isoflurane if they exhibit distress to the gavage procedure.
Animals are monitored for distress immediately after administration, and daily for at least 7
days to ensure there is no irritation from the application. Mice will be monitored at least
twice weekly thereafter.
Animals will be euthanized by C02 asphyxiation if there are any signs of distress. In
addition, mice will be euthanized by C02 asphyxiation 0-30 days after tamoxifen
administration. During this time period, BrdU or EdU may be administered.
The frequency of dosing will be up to 3 times/week.
BrdU administration
Purpose: Assess cellular proliferation in vivo.
Working solution of 3mg/mi in PBS, injected i.p. at 10ul/gram body weight. Upon necropsy
and histological analysis, cells in S phase will be labeled by BrdU.
Morbidity nor pain are expected.
Animals are monitored throughout the procedure
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Mice will be euthanized by C02 asphyxiation 0-5 days after BrdU administration or as soon
as there are any signs of distress.
EdU administration
Purpose: Assess cellular proliferation in vivo.
Working solution of 10mg/mi in PBS, injected i.p. at 15ul/gram body weight. Upon necropsy
and histological analysis, cells in S phase will be labeled by BrdU.
Morbidity nor pain are expected.
Animals are monitored throughout the procedure
Mice will be euthanized by C02 asphyxation 0-5 days after EdU administration if there are
any signs of distress.
Supplement forms must be filled out for the following procedures. Check the boxes
of all procedures that apply (double-click box and select "Checked") and provide completed
forms. Download current versions of supplement forms at: https://web.mit.edu/comp-
med/restrict/cac/forms.htm; older versions will be rejected.
n A. Surgical Procedures
Li B. Polyclonal and Monoclonal Antibody Production
C. Administration of Non-Hazardous or Non-Pharmaceutical Grade Compounds
D. Use of Human or Rodent Cells or Tissue in Animals
E. Device Implantation
X F. Transgenic/Knock-out Animals
n G. Behavioral Training and Restraint Techniques
L H. Teaching Proposal
X I. Use of Hazardous Materials in Animals
Li J. Modification to Standard Food or Water Provision
X K. Tumor Induction
Animal identification techniques (select all that apply):
X Cage cards ElEar punch X Ear tags ElCollar and tags []Tattoo FjMicrochip E]Toe-
clipping* DOther (explain):
Age of animal at time of identification procedure: (tail-clipping) less than 15 days
without anesthesia, over 15 days with anesthesia (isofluorane) for tail clipping
Anesthesia used for identification procedure: Isoflurane
If animals are genotyped, describe procedures (if details not already provided in
text above):
See general procedures above.
*Note: Toe-clipping of rodents requires scientific justification that other methods of
identification are not adequate. Toe clipping can only be done between 10-14 days of age;
anesthesia is not required. Toe-tattooing is a humane alternative that provides permanent
ID without amputation and avoids ear-tag loss and associated dermatitis; DCM vet staff can
provide instruction.
Provide specific agents, doses, and route of administration for euthanasia of each species:
> All mice will be sacrificed via C02 asphyxiation
If requesting either cervical dislocation or decapitation without anesthesia as a
method of euthanasia, provide scientific justification:
> Not applicable
For all procedures, indicate which have not been performed in this laboratory before and
how personnel will be trained in new techniques?
> All procedures described are new. Kevin Kung and Kay Wiebrands will receive specific
training from a certified lab member experienced with such procedures carried out in my lab
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and verified by DCM personnel. Anna van Oudenaarden has had 8 years of experience
working with mice in the Massachusetts General Hospital (IRB SRAC certified), but will seek
to be recertified by DCM personnel.
Is there a potential for the development of morbidity? (Note: Procedures such as
surgery, tumor induction, transgenic experiments, injections of adjuvant, prolonged
restraint, water restriction, ascites production, etc., all have inherent risk of medical
problems).
E- No
X Yes (describe the expected morbidity, procedures responsible, frequency and duration
of observations, criteria for intervention, and objective criteria for humane endpoints that
will result in euthanasia)
> Mice with induced Apc deficiency may develop multiple benign intestinal polyps, which
may lead to rectal bleeding, weight loss, and rectal prolapse after about 3 weeks post-
induction. There are no other expected morbidity than the inherent risks of the approved
procedures that aim to generate, study, and treat mice that develop cancer (and
metastases), in order to further both our understanding of the human disease and develop
improved treatment for human cancers.
Investigators will monitor animals at least twice weekly. When mice develop significant
tumor burden, mice will be monitored daily.
Animals will be euthanized if they exhibit any of the following:
1. inability of the animal to ambulate, eat, drink, urinate and defecate without
discomfort
2. net weight loss in excess of 20% of starting body weight
3. untreatable organ failure
4. A Body Condition score <2
5. tumors exceeding 10% of body weight (not greater than 1cm in diameter except
when approved)
6. tumors that are so large that necrosis or ulceration of the skin surface is imminent
7. developed labored breathing (dyspnea) related to metastatic tumors, fluid
accumulations, circulatory problems, anemia or metabolic acidosis
Will all animal care and use be conducted on-campus?
X Yes (proceed to next question) M No (indicate off-campus locations and animal-related
activities below)
Location* Animal-related activity (e.g., husbandry, antibody production,
*Attach a copy of the most recent IACUC approval notification from the off-campus
institution (not necessary for contract facilities--e.g., Covance).
Will you remove living animals from DCM facilities or bring them into the lab from
off-campus?
El No (proceed to Section 5) X Yes (please enter destination(s) and activities into the
table below)
Building and Type of procedure (e.g., behavioral studies, perfusion,
Room Number euthanasia, necropsy with tissue collection, terminal surgery,
survival surgery, etc.)
68-365 euthanasia, necropsy with tissue collection
[Press tab while in last cell to add a row; repeat as needed]
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*Describe how animals will be transported to or from areas outside of DCM animal
facilities, and whether they will be returned afterwards to DCM housing; specify
DCM rooms in which animals are housed (if known):
> Animals will be brought down to the lab in their cages. Animals will not return to DCM.
Section 5 Investigators are required to annually document their consideration of alternative
Search for animal models and methods. The Animal Welfare Information Center of the National
Alternatives Agricultural Library offers assistance and database search services for alternative models
and methods (http://www.nal.usda.gov/awic). Keywords should be selected based on their
potential to identify published work that is similar to that proposed and the availability or
lack of alternative models and methods.
Name of database(s) searched: Pubmed Literature search, Google Scholar
Date of search (month/day/year): Sep. 29, ears covered by search: 2010-present
2011
Keywords used (include species, genetic modifications (transgenic and knockout mice),
procedures likely to cause pain/distress, and methods that will minimize pain and distress
(drug choices for anesthesia and analgesia, refinements to invasive procedures, use of
humane endpoints for euthanasia such as body condition scoring)):
> Mouse and/or colon cancer/ carcinoma and/or APC / cMyc / Lgr5 / Ki67 / Ephrin / Eph /
p53/ Kras/ Rosa26 / and/or metastasis/ imaging/ luciferase/ and/or BRDU/ EdU /
tamoxifen/ doxycycline (and their health effects) / and mouse/cancer and/or genetic tracing
and/or pulse-chase experiment with Edu/BrdU and Wnt, single molecule FISH, FACS, C57BL/6
mice, mouse breeding, C02 asphyxiation, genotyping mice / tail-clipping, health effects of mouse ear tags
and ear punch, IP injection, mouse anesthesia procedures, mouse euthanesia procedures.
CONCLUSIONS FROM SEARCH FOR ALTERNATIVES
Explain how the choice of animal model (species, strain and/or genetic
modifications) is the best model available to address the scientific hypothesis.
Explain why phylogenetically lower species, in vitro, or non-animal systems would not be
suitable. Explain how use of the proposed animal model will add to work previously
reported, particularly if aspects of the study will duplicate previous work by your lab or
others.
> The species was chosen because of the similarities between mouse and human cancer.
Any lower species or non-animal system would not be a comparable genetic or physiological
match to humans for our purposes. As often as possible, we use tissue culture cell-based in
vitro systems. However, in general, in vitro systems cannot fully substitute the proposed in
vivo animal model because the appropriate intestinal physiology has not yet been
successfully reproduced.
We have chosen a Cre-inducible Apc knock-out mouse in order to study the downstream
effects of Apc deficiency. This strain was chosen to better simulate the spontaneous loss of
Apc (e.g. in adulthood) as the initiation step of cancer, in the relevant cells (i.e. stem cells)
only. Since Cre expression may not be perfectly homogeneous, the addition of Lgr5::GFP-
IRES-Cre allows for visualization by GFP of Cre expression, and identifies cells where Lgr5 is
actively expressed (e.g. the stem cells). Furthermore, not all Cre action is complete, so the
addition of Rosa26-RFP allows for confirmation of Cre action, and thus the likelihood of loss
of Apc. We have chosen the Cre-inducible Kras mouse for the same reason that it closely
simulates the real-life spontaneous overexpression of Ras.
Explain how the choice of methods (e.g., surgical approach, choice of anesthetic
or analgesic, choice of adjuvant, choice of reward paradigm in behavioral
assessments, etc.) will minimize potential for pain, discomfort, distress, and
morbidity. Describe how your methods and drug selection compare to similar
methods in this field of research. If pain-relieving drugs cannot be used for
scientific reasons, explain the rationale. Examples of procedures with the potential to
cause pain and distress include, but are not limited to: surgery, water and/or food
restriction, prolonged physical restraint, adjuvants, tumor induction, infectious diseases,
irradiation, use of paralytics under anesthesia, decapitation or cervical dislocation without
anesthesia, neonatal anesthesia using hypothermia, and toxic substance administration.
CAC-approved euthanasia methods (see Lab Animal Users' Handbook) and routine handling
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and injections (other than adjuvants) are not considered to cause pain or distress.
> Procedure
1. Tail clipping
Method of relieving pain and distress
Isoflurane
These procedures described above reflect standard procedures used in recent research, and aim to
minimize the potential for pain, discomfort, distress, and morbidity.
The following criteria are used for establishing humane endpoints resulting in euthanasia:
1) inability of the animal to ambulate, eat, drink, urinate and defecate without discomfort
2) net weight loss in excess of 20% of starting body weight
3) untreatable organ failure with imminent death
4) tumors exceeding 10% of body weight (not greater than 1 cm)
5) tumors that are so large that necrosis or ulceration of the skin surface is imminent
6) developed labored breathing (dyspnea) related to metastatic tumors, fluid
accumulations, circulatory problemsL anemia or metabolic acidosis
Section 6 Animal species, strains, or stocks to be used in the coming year. Estimate required
number of each species for the first year of the project:
- Specify strain/stock as applicable (Tg/KO mice may be combined on a single row in the
table; supply Supplement F and enter "See Supp F" in the Source column)
, Estimate how many animals are expected to be used within each Pain and Distress
Category
o Category B: Breeding for colony maintenance, held for future use, or retired from
active use
o Category C: Procedures with no or only momentary pain and distress and no need
for anesthetics, analgesics, or tranquilizers (e.g., brief manual restraint;
most blood sampling; gastric gavage; euthanasia for tissue harvest;
routine injections; behavioral observations)
o Category D: Procedures likely to cause pain or stress relieved by use of anesthetics,
analgesics, and/or tranquilizers or by humane euthanasia based on well-
defined endpoints (e.g., terminal or survival surgery; retro-orbital blood
collection; food/water restriction; induced infections, tumors,
inflammation; toxic substances; frequent, prolonged (>1 week) injection
schedule)
o Category E: Unrelieved pain or stress (e.g., withholding analgesia for pain studies;
aversive stimuli (shocks, high decibel noise); stressful restraint; seizures;
death as an endpoint). Note: Provide scientific justification in
Section 5, Choice of Methods.
- If ordering pregnant animals that will give birth, include litters in Quantity to be
Generated column.
Species, Quantity to be Source of Quantity to be Expected
Strain, Ordered/Requested* incoming Generated or Already Total
and/or Stock animals* On-Campus under this
* Protocol
B C D E B C D E
Mouse 50 120 0 0 Jackson 770 899 0 1180
Labs 70 230 700
and
Jack lab
[Press tab while in last cell to add a row; repeat as needed].
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Rationale
for Species
and
Numbers
*An Animal/Purchase Care Request form must be submitted to the DCM Animal Purchasing
Agent for all animals used at contract facilities, ordered from vendors, obtained from other
PIs, or transferred between protocols.
**List name of vendor or PI and institution if another lab. Please note that embryo transfer
rederivation will be required for animals received from non-standard vendors.
Describe study group sizes and number of experiments in the next year that justify
the animal numbers requested under Categories B, C, D and E. If breeding animals in-
house, be sure to account for numbers needed to maintain the colony. Include evidence of
retrospective or prospective statistical methods that support your estimates.
> There are several experiments described in the five Specific Aims, as described below.
As a rule, we will be ordering all of our wildtype mice from the Jackson Labs. We will only
breed genetically modified mice in our lab.
Maintenance (genetically modified): We need 2 cages per strain. With 5 strains (Apc
+/-, Lgr5-GFP-Cre, Rosa26-LacZ, Rosa26-TOM, and Kras) and 4 mice/cage, we require at
least 40 mice. However, due to possible breeding difficulties, we require about 60 mice (B in
"quantity to be ordered/requested"). Furthermore, we need to breed these mouse strains in
order to maintain the strain. We expect that each strain, over the year, will produce 14
mice for maintenance purposes. Given 5 strains, this will sum to 70 mice (B in "Quantity to
be generated").
Crossing (genetically modified): To generate mice of desired genotypes for experiments,
we need to cross the different strains of maintenance mice, as follows:
Apc +/- X Lgr5-Cre-GFP
Lgr5-Cre-GFP X ROSA26-TOM
Lgr5-Cre-GFP X ROSA26-LacZ
Apc+/- X Kras
Lgr5-Cre-GFP X Kras
Considering 3 cages per strain, with 5 strains (listed above) and 4 mice/cage, this yields 60
mice. Accounting for breeding difficulties, we need about 70 mice (B -in "quamtity to-be
generatted). These mice will be genotyped and thus may involved procedures causing
momentary pain (C in "quantity to be generated).
EdU pulse-chase (WT): We plan to vary both the time of Apc excision as well as the
length of the EdU chase. For wildtype, we need 10 EdU chase time points, done in duplicate,
which requires 20 mice per experiment. Over the year, we expect to complete 5
experiments, which requires 100 mice (WT) (C in "quantity to be ordered/requested"). EdU
IP injection is expected to cause momentary pain, and these mice will be euthanized for
tissue harvest.
FACS-sorting experiments (WT): For FACS experiments on dissociated mouse intestines,
we will need 20 wildtype mice throughout the year (with different markers for cell
differentiation to be investigated). This adds up to 120 wildtype ice, whieh will be ordcrcd
(C in "quantity to be er-deed/requested&). These mice will be euthanized for tissue harvest
(C in "quantity to be ordered/requested").
EdU pulse-chase experiments (genetically modified): We plan to vary both the time of
Apc excision as well as the length of the EdU chase. For Apc-deficient mice, assuming 5
time points for Apc excision and 10 time points for the EdU chase, we will end up with 50
experimental conditions. Done in duplicate, this requires 100 mice/experiment. Over the
year, we expect to carry out 5 experiments, which requires 500 mice. In addition, we also
to carry out a comparative Kras (Apc+/+) experiment (100 mice), as well as a Kras-Apc-/-
experiment (100 mice), which will require another 100 mice in total. This sums up to 700
mice (C on "quantity te be generated"). These mice may develop tumor load, and thus are
categorized under D in "quantity to be generated". Finally, as a parallel control experiment
involving lineage tracing of the stem cells using LacZ (e.g. for non-FISH imaging methods
such as immunostaining), we will require both LacZ mice as well as LacZ;Apc-/- mice, 30
per strain per year (C in "quantity to be generated").
FACS-sorting experiments (genetically modified): There are two mice strains in this
experiment: Lgr5-Cre-GFP, and Lgr5-Cre-GFP X ROSA26-TOM. We need at least 50 mice of
each strain throughout the year, yielding 100 mice total (C in "quantity to be generated").
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EdU injection and euthanasia for tissue harvest are involved.
Animal use since last annual renewal: Using a retrospective evaluation of expected and
unexpected outcomes, how many animals of each species have been used since the last
protocol review under Categories B, C, D and E?
NOTE: An animal is considered "used" when first obtained, whether or not it has been
actively manipulated. Species with multiyear use (e.g. nonhuman primates, ferrets,
rabbits) are counted as "used" each year.
Species, Strain, and/or Category/Experimental Use
Stock Category Category C Category D Category E*
BI
Not applicable
[Press tab while in last cell to add a row; repeat as needed]
*Please explain why animals in table above were classified as Category E, if
applicable:
Section 7 List hazardous agents ("hazmats") to be used in animals. All use of hazardous
Hazardous materials must be described in detail on a Supplement I, "Use of Hazardous Materials in
Materials Animals". Be sure to indicate in the Personnel Table (Section 8) which personnel will be
In Animals handling each of these hazards.
Radioactive
Chemical* Tamoxifen, 5-ethynyl-2'-deoxyuridine (EdU), bromodeoxyuridine (BrdU)
Nanoparticl
e*
Biological*
*
* Chemicals are considered hazardous if the MSDS or other sources indicate there is a
human health hazard during dosing, husbandry, or necropsy of animals. Novel compounds
without established hazard information are considered on a case-by-case basis. Many FDA-
approved drugs for humans and all nanoparticles are considered potentially hazardous.
**Biological hazardous agents include potentially infectious agents, primary human cells or
established human cell lines, and recombinant RNA or DNA, including gene transfer
vectors.
Note that use of hazardous acients may not begin until all of the following have occurred (in
listed order):
1) The CAC has approved this protocol application;
2) A specific "Protection/Control Required" form for each particular hazard involved has
been generated by DCM and EHS (the CAC coordinates this process, and it may take
from one to five weeks);
3) Study personnel have been contacted by the DCM Hazards Coordinator (Dr. Mary
Patterson) or her designee to discuss the study and receive orientation to use of these
specific hazards in animals.
Section 8 List all personnel to participate in the study.
Personnel o Personnel working with animals must be CAC-certified in advance. Information on
Qualification obtaining CAC certification may be found at https://web.mit.edu/comp-
s med/restrict/cac/training new.htm.
o It is the PI's responsibility to affirm that all participants understand DCM and CAC
policies (see DCM Lab Animal User's Handbook and policy section on CAC website) and are
adequately trained in protocol-specific procedures. If training is needed for specific animal
procedures, contact DCM veterinary staff for assistance.
o All new protocol participants performing surgery (or others desiring additional training)
must contact either Dr. Alison Hayward (ahayward@mit.edu/x2-3629) or Dr. Robert Marini
92
(rmarini@mit.edu/x4-3340) for review of MIT guidelines for surgery.
Always list Principal Investigator. Describe protocol responsibilities as "supervision" if PI has
no animal contact.
Name: Year of Surviva "Hazmats" to be Protocol Summarize relevant prior
CAC- I or used in animals responsibilities experience and training
certificati Termin (Identify the ("All" or beyond CAC-certification
on al hazmats") keywords if (Do not leave blanki)
Surger limited
Y participation)
("Y" if
YES)
"Ann Example" 2008 Y BRDU Surgery & Surgery wet lab with DCM
Necropsy vet 12/2008; 1.5 yrs
experience in rodent
surgery at MIT. Annual
rodent refresher 3/2010.
PI (required): 2010 No None Supervision CAC certified
van
Oudenaarden,
Alexander
Kung, Kevin 2011-in No EdU, BrdU, All CAC certification in
progress tamoxifen progress
van 2011-in No EdU, BrdU, All 8 yrs experience with
Oudenaarden, progress tamoxifen rodents at MGH, IRB
Anna SRAC training certified;
CAC certification in
progress
Wiebrands, Kay 2011-in No EdU, BrdU, All CAC certification in
progress tamoxifen progress
[Press tab while in last cell to add a row; repeat as neededl
Section 9 All personnel on this protocol with ANY animal contact must have an Animal
Occupational Handler's Baseline Occupational Health Questionnaire (OHQ) evaluated by an
Health EHS physician or nurse.
Questionnaires are available at the CAC website: https://web.mit.edu/comp-
med/restrict/cac/forms. htm
and may be submitted electronically; manually (send directly to MIT Medical Employee
and Occupational Health Office (EOHS, E23-180)); or in person (schedule an
appointment with the EOHS (Jackie Sherry, X3-8552, E23-180)).
Has everyone listed on this protocol submitted an OHQ?
X Yes [I No (Explain):
Are there any occupational health issues that have developed for any protocol
participant since a questionnaire was first submitted?
X No
E Yes. These health issues have been evaluated by MIT Medical. F-1 Yes F-1 No
(Explain):
For users of materials/substances potentially hazardous to human health, have
personnel been educated about health risks?
X Yes E- N/A El No (Explain):
Note that information about safety and health measures (e.g., immunizations,
protection against explosion and fire) is available through DCM, EHS, and the MIT
Medical Department.
93
Have all protocol personnel been instructed on DCM requirements for use of personnel
protection equipment in animal facilities (PPE: shoe covers, head covers, and lab
coats; gloves when handling animals; masks and mucous membrane protection for
contact with nonhuman primates)?
X Yes [~ No (Explain):
In lab animal use areas, PPE (lab coats and gloves when handling animals, plus masks
and mucous membrane protection for contact with nonhuman primates) should also be
worn.
For personnel working with nonhuman primates, list each name with the date
of the most recent tuberculosis screen by MIT Medical (must be current
within one year). Protocol approval and renewal are contingent upon strict
compliance by all participants; "pending" is not satisfactory.
Name: Date of most recent TB screen
Not applicable
Investigators working with nonhuman primates (including tissue harvest) are advised
to obtain exposure control training from EHS at X2-3477.
Section 10 October 7,
PI Signature 2011
Principal Investigator Date
By signing above, the PI confirms s/he has reviewed and authorized
this application.
- When completed, submit an e-copy (Word format preferred) to
cacpo@mit.edu. Signature pages may be submitted separately in hard-copy to the
CAC office (Room 16-408; Fax: 617.258.8257); provide adequate detail so it is
obvious with which protocol the paperwork should be associated.
- New Protocols and Annual Renewals must be received by the first Friday of the
month to be reviewed at the following month's CAC meeting.
- Three-Year Renewals must be received at least two months before they are
scheduled to expire. This is to ensure adequate review and revision time to
prevent lapse between expiration of the old protocol and approval of the new one;
no animal use may occur under an expired protocol. The CAC will notify you
approximately one month in advance of the expected submission deadline.
The CAC meets on the first or second Thursday of every month except August and
December. The meeting schedule is posted at the CAC website
(https://web.mit.edu/comp-med/restrict/cac/schedule.htm).
Note that a substantial change in protocol, an increase in the number of animals used,
a change in the animal species used, or addition of personnel necessitates an
addendum to this form. The principal investigator must sign the addendum before it
will be reviewed by the committee.
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Strains and Sources
Supplement F: Transgenic I Knock-out Animals
This form may be submitted in support of a protocol application or separately, as an addendum.
If this is an addendum, please also provide a cover letter that includes the following information:
1) PI Name/Department; 2) Protocol Number/Title; 3) Contact Person/Contact Details; 4) A
statement verifying that the animals described below will be used according to methods already
described in the main protocol, or a description of the new methods to be used; and 5) PI
Signature (required).
Include appropriate additional supplement forms, if applicable:
A Supplement A must also be submitted if your lab is producing these animals (Supplement A is
not required if the DCM / KI Transgenic Core will produce the animals).
A Supplement C must also be submitted if a non-hazardous agent will be given or a Supplement
I nIm ie hA1q[4~ if n ha arrni n t j ji l ha rikmn t O irh nn ~rce nllinl mvnrncinn
If requesting variants of common transgenic strains identified in the table below, the variants do not
need to be individually specified (unless they have inherent morbidity, in which case they need to
be individually listed in the second table); please quantify by overall type and indicate source(s)
below:
Common Tg strain* Total Quantity Source** In-house
to be Received Production
Quantity
Strains Expressing Cre
Recombinase only
Strains Expressing FLP
Recombinase only
Strains Expressing
beta-galactosidase(lacZ) only
Strains Expressing
Luciferase (luc) only
Strains expressing only
fluorescent proteins
(GFP, mCherry, DsRed,
etc.)
For all other transgenic strains, please enter standardized nomenclature, source, and quantity of
ach strain into the table below; press tab in last cell to add a new row for each strain:
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Other Tg/KO strains* Total Quantity Source** In-house
to be Received Production
Quantity
APC-flox-exonl4/+ (Apc 36 Jacks lab 42
+/-) on C57BL/6 (maintenance)
Lgr5; EGFP-IRES- 36 Jacks lab 150 (FACS expt)
CreERT2 (Cre) on 42
C57BL/6 (maintenance)
Rosa26-LSL-LacZ 36 Jacks lab 42
2lox/2lox (LacZ) on (maintenance)
C57BL/6
Rosa26-LSL-tdTomato 36 Jackson Labs 42
(TOM) on C57BL/6 (maintenance)
LSL Kras G12D (Kras) on 36 Jacks lab 42
C57BL/6 (maintenance)
APC- exon14 flox/flox; 0 Crossing two 42
Lgr5-EGFP-CreERT2 strains (maintenance)
(Cre; Apc fl/fl) on + 1500 (EdU
C57BL/6 expt)
Lgr5;EGFP-IRES- 0 Crossing two 42
CreERT2; Rosa26-LSL- strains (maintenance)
tdTomato (Cre; TOM) on
C57BL/6
Lgr5;EGFP-IRES- 0 Crossing two 42
CreERT2; Rosa26-LSL- strains (maintenance)
LacZ 2lox/2Iox + 90 (EdU expt)
(Cre;LacZ) on C57BL/6
Apc-flox-exonl4/+; LSL 0 Crossing two 42
Kras G12D (Apc - strains (maintenance)
/+;Kras) on C57BL/6
Lgr5;EGFP-IRES- 0 Crossing two 42
CreERT2; LSL Kras G12D; strains (maintenance)
Rosa26-LSL-tdTomato + 300 (Edu
(Cre;Kras;TOM) on expt)
C57BL/6
Lgr5;EGFP-IRES- 0 Crossing two 300 (EdU expt)
CreERT2; Apc-exon14 strains
flox/flox; LSL Kras
G12D; Rosa26-LSL-
tdTomato (Cre;Apc -/-
;Kras;TOM) on C57BL/6
Lgr5;EGFP-IRES- 0 Crossing two 150 (FACS expt)
CreERT2; Rosa26-LSL- strains
tdTomato (Cre;TOM) on
C57BL/6
Lgr5;EGFP-IRES- 0 Crossing two 90 (EdU expt)
CreERT2; Rosa26-LSL- strains
LacZ 2lox/2lox; APC-
exon14 flox/flox (Cre;
Apc-/-; LacZ)
*Visit http://www.informatics.jax.org/mqihome/nomen/strains.shtmI for guidance on nomenclature
** E.g., DCM / KI Transgenic Core; Vendor (identify); Investigator (identify)
By genotype, justify the quantity of animals needed both for breeding and experiments until the next
protocol renewal period:
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> All estimates listed below are based on one year of study. For a 3-year protocol
validity period, please multiply all numbers below by 3. There are several experiments
described in the five Specific Aims, as described in the main protocol document.
As a rule, we will be ordering all of our wildtype mice from the Jackson Labs. We will
only breed genetically modified mice in our lab.
Maintenance (genetically modified): We need 2 cages per strain. With 5 strains
(Apc +/-, Lgr5-GFP-Cre, Rosa26-LacZ, Rosa26-TOM, and Kras) and 4 mice/cage, we
require at least 40 mice. However, due to possible breeding difficulties, we require
about 60 mice (12 mice/strain). Over 3 years, this amounts to 36 mice/strain.
Crossing (genetically modified): To generate mice of desired genotypes for
experiments, we need to cross the different strains of maintenance mice, as follows:
Apc +/- X Lgr5-Cre-GFP
Lgr5-Cre-GFP X ROSA26-TOM
Lgr5-Cre-GFP X ROSA26-LacZ
Apc+/- X Kras
Lgr5-Cre-GFP X Kras
Considering 3 cages per strain, with 5 strains (listed above) and 4 mice/cage, this
yields 60 mice. Accounting for breeding difficulties, we need about 70 mice (14
mice/strain). Over 3 years, this amounts to 42 mice/strain.
EdU pulse-chase experiments (genetically modified): We plan to vary both the
time of Apc excision as well as the length of the EdU chase. For Apc-deficient mice,
assuming 5 time points for Apc excision and 10 time points for the EdU chase, we will
end up with 50 experimental conditions. Done in duplicate, this requires 100
mice/experiment. Over the year, we expect to carry out 5 experiments, which requires
500 mice. Over 3 years, this amounts to approximately 1500 mice. In addition, we
also to carry out a comparative Kras (Apc+/+) experiment (100 mice, or 300 mice
over 3 years), as well as a Kras-Apc-/- experiment (100 mice, or 300 mice over 3
years). Finally, as a parallel control experiment involving lineage tracing of the stem
cells using LacZ (e.g. for non-FISH imaging methods such as immunostaining), we will
require both LacZ mice as well as LacZ;Apc-/- mice, 30 per strain per year. Over 3
years, this amounts to 90 mice per strain.
FACS-sorting experiments (genetically modified): There are two mice strains in
this experiment: Lgr5-Cre-GFP, and Lgr5-Cre-GFP X ROSA26-TOM. We need at least
50 mice of each strain throughout the year. This amounts to 150 mice for each
genotype for the 3 years.
Describe genetic alterations you either plan to induce or that have already been characterized in the
animal model(s) above and how the genetic predisposition will help fulfill your objectives:
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>The overall is to create accurate mouse models of human cancers. We will construct
and analyze a series of mouse strains that carry mutations in various tumor
suppressor genes or oncogenes. These animals will be valuable in studying the
function of tumor suppressor genes in normal cells and in tumorigenesis. These mice
have already been generated in the Jacks Lab, and thus there is no need for us to
perform genetic modification, except for crossing existing strains to create new strains
of a novel genotype. Methods used in the Jacks lab (as approved previously by DCM)
involving recombinant DNA included: transformation of E. coli with recombinant
plasmids; transfection of murine cells via calcium phosphate precipitation of DNA,
electroporation, or use of commercial kits (e.g. fugene, mirus); retroviral and lentiviral
infection of mouse cells with recombinant viruses of ecotropic and amphotropic host
range; adenoviral infection of mouse cells with self-inactivating recombinant viruses;
adenoviral and lentiviral infection of living mice by injection or intranasal delivery.
Mouse strains were created using the technique of gene targeting in mouse embryonic
stem (ES) cells. Targeting vectors (composed of sequences from the targeted gene,
selectable genes, and plasmid sequences) were constructed and introduced into ES
cells by electroporation. Mutant ES cells were used to make chimeric animals, which
were used to make mice carrying a germline mutation in the targeted gene. Tumor
suppressor genes and oncogenes that have been targeted in this way include Apc and
Kras G12D. In addition, we will intercross animals heterozygous for a given mutation
to create animals or embryos that are homozygous for the mutation. We are interested
in the course of tumor development in these animals, probing specifically at the spatial
distribution of cell differentiation, proliferation, and migration in the crypt/villus
structure when Apc and/or Kras is perturbed.
The Jacks lab used the Cre/loxP technology to create conditional alleles of genes in
mice. The Cre recombinase is a phage protein that has no activity in mammalian cells
unless these cells contain loxP sites. When loxP sites are present, the Cre
recombinase specifically deletes the sequences flanked by the loxP sites. The only
function of the Cre enzyme is to cut these sites and ligate the pieces together.
Introduction of virus carrying the LacZ, EGFP, or tdTomato gene allowed for visual
scoring of infection efficiency. Adenovirus is replication-incompetent, but could infect
human cells; it does not infect non-dividing cells and does not integrate into the
genome. Also, humans should not have Cre-recombinase recognition sequences.
Through the course of our experiment, we will also use these fluorescent proteins to
identify cells with Cre activity, and to FACS-sort cells.
The Jacks lab expressed the Cre recombinase in mouse cells (in vivo and ex vivo)
using a lentiviral vector because many of the cells to be targeted do not actively
divide. The system used was based on the pHR' lentivirus-based gene delivery system
originally developed by the laboratory of Dr. Inder Verma. It was a three-vector-
system based on the HIV-1 retroviral backbone; one plasmid contains the gene
encoding Cre recombinase, one plasmid contained viral structural proteins and the pol
gene, and the third plasmid contained the gene encoding the viral envelope (the
amphotropic VSV-G protein). Virus was generated upon cotransfection of these three
plasmids into 293T cells. Use of a three-plasmid system minimized the possibility that
replication competent viruses could be created. All infected cells were be analyzed for
horizontal transfer. The Jacks lab also developed a system based on Lentilox 3.7, a
vector which contained the psi packaging signal, a U6 promoter for the expression of
the shRNA, a multiple cloning site for introduction of short hairpin RNAs of interest,
and a green fluorescent protein gene (GFP) controlled by a CMV promoter. Their
system is a Cre-inducible, conditional system, in which small oligonucleotides
containing 18-23 bp corresponding to the gene for knockdown are cloned into "pSico"
(pPrime) and will be expressed only in the presence of Cre recombinase. Virus was
produced by cotransfection of three independent plasmids into 293T cells: pSico, the
CMV8.2R plasmid containing the structural proteins and the pol gene, and a third
plasmid, VSV-G that encoded the envelope. 293T transfectant supernatant was
collected and used to infect cells of interest directly, or concentrated for use in embryo
infections. Only in the presence of Cre would the short oligonucleotide be made.
Describe the expected phenotypic expression of the alteration(s) and whether morbidity is expected
from either the genetic modification or additional experimental manipulations:
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Instructions
Section 1
General Information
Section 2
Type of Hazard
> Homozygous Apc inactivation is expected to lead to the formation of benign polyps in the intestine
within 3 weeks of conditional induction. Overexpression of Kras G12D is expected to lead to more
expanded and proliferative crypts, but without the formation of polyps. The simultaneous
inactivation will lead to a rapid development of malignant tumors in the intestine. The expression of
LacZ, EGFP, or tdTomato should have no significant macroscopic manifestations, but the specific
expressing cells should fluoresce.
If pain and suffering is apparent, we will euthanize the animal(s) as soon as possible (per criteria
described in animal protocol). Euthanasia is done according to the DCM Laboratory Animal Users'
Handbook.
All experimental manipulations of genetically altered animals must be described in an
approved protocol. If unexpected phenotypes that impact animal welfare develop, or if
procedures need to be changed, send a separate memo to the CAC describing the
developments, the adverse effects on animal welfare, and how it will be managed.
Supplement I: Use of Hazardous Materials in Animals (EdU)
This form may be submitted in support of a protocol application or separately, as an addendum.
Fill out one form for each hazardous agent (radioactive, chemical, biological) unless agents are
closely related (e.g., similar radioisotopes may be combined) or two agents will be administered
together (e.g., a radiolabeled chemical agent). Investigators must obtain an RPP authorization
for radioactive hazards or a Biological Project Registration number for biological hazards
from EHS before the CAC can approve this research. For general information regarding
hazardous agents, call the MIT EHS at X2-3477 or WIBR EHS at X8-5212.
If this is an addendum, please also provide a cover letter that includes the following: PI
Name/Department; Protocol Number/Title; Contact Person/Contact Email; Objectives and
Rationale; and PI Signature (required). Once completed, return this form to the CAC (16-
408, cacpo@mit.edu, fax 617-258-8257).
Principal Investigator: Alexander van Phone: 6172534446 Email: avano@mit.edu
Oudenaarden
Department: Biology and Physics Address: 31 Ames Street, 68-371, Department
of Biology, Cambridge, Massachusetts 02139
Title of CAC Protocol: Variability of cell behaviors in early intestinal CAC Protocol Number:
tumors involving Apc deficiency and/or Kras overexpression N/A
Contact Person: Kevin Kung hone: 45042 Email: kkung@mit.edu
BIOLOGICAL HAZARD Biological project registration number:
Name:
Amount kept in laboratory:
RADIOACTIVE HAZARD RPP authorization number for P1:
Isotope(s):
Total amount of activity (pCi) per experiment Preparation/chemical form:
and per animal:
CHEMICAL HAZARD* Storage location and physical state:
Name: 5-ethynyl-2'-deoxyuridine (EdU) 8-365, refrigerator at 2-6C, solid, 5 mg
Method of preparation and amount: Make 10 ource: Invitrogen Click-iT EdU Imaging Kits
mM stock solution in DMSO (2 mL of DMSO)
Attach MSDS for all chemical hazards and relevant scientific literature to clarify
occupational health risk.
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Administration of
Multiple Hazards
Section 3
Personnel Training
Section 4
Administering Hazard
Do not refer to
sections of the CAC
protocol. The EHS
reviewer receives this
form only and it must
contain all details of
dosing, time points,
etc.
Section 5
Manipulations and
Procedures
If an individual animal will receive other hazards in addition to those listed above, AT ANY TIME,
list other agents here (in Section 5 of this form, describe the time interval(s) between dosing with
the different hazards): Some mice may receive both EdU and BrdU injection, usually within
4 hours apart from each other. Furthermore, about 0-30 days before EdU or BrdU
injection, the animal may be injected with tamoxifen. Health of all animals is assessed
prior to administration of any additional compounds.Animals will be moved by DCM staff
o appropriate containment area for second hazard. Any procedure involving multiple
hazards is listed on protocol.
Training history is available on the EHS website http://web.mit.edu/environment/training/ or
from WIBR EHS. Appropriate courses may include Radiation Safety; Chemical Hazards
(General Chemical Hygiene and Managing Hazardous Waste); and Biosafety/Bloodborne
Pathogens. All personnel must be CAC-certified and an approved participant on the CAC
protocol cited above.
List all personnel handling List pertinent EHS (MIT and/or WIBR) training and date
hazard received
Kevin Kung Managing Hazardous Waste (501c); Lab Specific
Chem Hygiene Training (110c); CAC training in
progress
Anna van Oudenaarden Managing Hazardous Waste (501c); Lab Specific
Chem Hygiene Training (110c); CAC training in
progress
Kay Wiebrands Managing Hazardous Waste (501c); Lab Specific
Chem Hygiene Training (110c); CAC training in
progress
(Press "Tab" while in bottom-right cell if more rows are needed)
Give specific details of:
a. Species/strain AND numbers of animals. Indicate if immunosuppressed.
Mus Musculus Genotype
Wildtype (C57BL/6) - 120 mice/year for EdU experiments
Lgr5;EGFP-IRES-CreERT2 (Cre) on C57BL/6 - 50 mice/year for FACS experiments
APC-exonl4 flox/flox; Lgr5-EGFP-CreERT2 (Cre;Apc -/-) on C57BL/6 - 500 mice/year for
EdU experiments
Lgr5;EGFP-IRES-CreERT2; LSL Kras G 12D; Rosa26-LSL-tdTomato (Cre;Kras;TOM) on
C57BL/6 - 100 mice/year for EdU experiments
Lgr5;EGFP-IRES-GreERT2;Apc-exonl14 flox/flox; LSL Kras G 1 2D; Rosa26-LSL-tdTomato
(Cre;Apc -/-; Kras;TOM) on C57BL/6 - 100 mice/year for EdU pexiermnets
Lgf5;EGFP-IRES-CreERT2;Rosa26-LSL-tdTomato (Cre;TOM) on C57BL/6 - 50 mice/year for
FAC experiments
a. Dose per animal (amount per unit body weight AND total volume per dose): 10
mg/kg, 15 pUg b.w.
b. Route of administration: l.P.
c. Frequency of dosing: Once
d. Survival time after dosing (how long before animal is euthanized): 0-5 days
Describe all manipulation(s) to prepare the material for dosing. Note that administration by any
route other than orally requires a sterile prep (default should include filtration through a 0.22
micron filter).
> Given 5 mg of powder, dissolve in 2 mL PBS (making 10 mM stock solution). All
prenaration conditions will be under sterile conditions includina filtration throuah a 0.22Do not refer to m
sections of the CAC mirnfitr
cl Th Provide details on administration of the hazardous materials to the animal(s). Indicate any other
reviewer Tceives this animal manipulations that are planned after the hazard(s) have been administered (e.g., surgery,
form only and it must transport out of animal facility, behavioral testing, etc.), including procedures at necropsy unique
contain all details of to the hazardous material. If additional hazards will be used in the same animal, describe timeintervals between dosing with the different agents:
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dosing, time points,
etc.
Section 6
Agent/Metabolite
Excretion/iSecretion
or Propagation
Section 7
Compliance
Statement
> EdU will be administered to the animal I.P. Release the mouse back to its cage, monitor
its health daily, and sacrifice at different time points (between 0-5 days) after injection.
Intestines will be removed post-mortem and used in experiments.
If any of the above procedures will be performed outside of DCM animal facilities, list those
locations and how animal(s) are transported:
> None
Provide amounts (chemical/biological hazards) or activity (radioactive hazards) expected
to be excreted/secreted. Appropriate scientific literature must be consulted to complete this
section; any answer of "unknown" must be substantiated.
Urine: None Feces: None Expired air: None
Secretions (be specific): None Duration of excretions/secretions: None
Method of detecting agent/metabolite: N/A gist metabolites to be excreted/secreted: 5-
ethynyl uridine (EU) and 2-deoxyribose
Are any metabolites hazardous? If yes, which Are any metabolites volatile? If yes, which
ones? ones?
N/A N/A
List reference/source(s) of information on metabolites and excretion/secretion:
Chehrehasa, F, et al. J Neuro Meth. 177: 122-30 (2008)
Kriss JP, Revesz L; Cancer Res 22: 254-65 (1962)
National Toxicology Program. <http://ntp.niehs.nih.gov/index.cfm?objectid=E881298F-BDB5-
82F8-FC1 D4DF2995D656D>. 2011.
For biological hazards, will the agent replicate in the animal? How is this monitored? (Provide
references.):
I affirm the accuracy of all the information on this "Use of Hazardous Materials in Animals"
form.
I agree that hazard use in animals cannot start until the following has occurred, in listed
order:
(1) The CAC has approved the corresponding protocol application/addendum that
describes the use of hazardous materials in animals.
(2) A specific "DCM Protection/Control Required for Hazard Use in Animals" form for each
particular hazard has been generated by DCM and EHS.
(3) Study personnel have been contacted by the DCM Hazards Coordinator (Dr. Mary
Patterson, mmpatt@mit.edu, X4-5403) or designee for consultation, space allocation, and
orientation in the animal facility on the use of each particular hazard in animals. This
training needs to occur shortly before the study is initiated; retraining may be required if
the study is delayed.
Principal Investigator (print name) Signature Date October 7, 2011
Alexander van Oudenaarden
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Supplement I: Use of Hazardous Materials in Animals (tamixofen)
Instructions
Section 1
General Information
Section 2
Type of Hazard
Administration of
Multiple Hazards
Section 3
Personnel Training
This form may be submitted in support of a protocol application or separately, as an addendum.
Fill out one form for each hazardous agent (radioactive, chemical, biological) unless agents are
closely related (e.g., similar radioisotopes may be combined) or two agents will be administered
together (e.g., a radiolabeled chemical agent). Investigators must obtain an RPP authorization
for radioactive hazards or a Biological Project Registration number for biological hazards
from EHS before the CAC can approve this research. For general information regarding
hazardous agents, call the MIT EHS at X2-3477 or WIBR EHS at X8-5212.
If this is an addendum, please also provide a cover letter that includes the following: PI
Name/Department; Protocol Number/Title; Contact Person/Contact Email; Objectives and
Rationale; and PI Signature (required). Once completed, return this form to the CAC (16-
408, cacpo@mit.edu, fax 617-258-8257).
Principal Investigator: Alexander van Phone: 6172534446 Email: avano@mit.edu
Oudenaarden
Department: Biology and Physics Address: 31 Ames Street, 68-371, Department
of Biology, Cambridge Massachusetts 02139
Title of CAC Protocol: Variability of cell behaviors in early intestinal CAC Protocol Number:
tumors involving Apc deficiency and/or Kras overexpression N/A
Contact Person: Kevin Kung Phone: 45042 Email: kkung@mit.edu
BIOLOGICAL HAZARD Biological project registration number:
Name:
Amount kept in laboratory:
RADIOACTIVE HAZARD RPP authorization number for Pl:
Isotope(s):
Total amount of activity (pCi) per experiment Preparation/chemical form:
and per animal:
CHEMICAL HAZARD* torage location and physical state:
Name: Tamoxifen 8-365, in refrigerator, 2-8 C, solid state
Method of preparation and amount: ource: Sigma T5648-5G
Resuspend at 0.3 mg/L in 100% EtOH and
stored at -20C
*Attach MSDS for all chemical hazards and relevant scientific literature to clarify
occupational health risk.
If an individual animal will receive other hazards in addition to those listed above, AT ANY TIME,
list other agents here (in Section 5 of this form, describe the time interval(s) between dosing with
the different hazards): Some mice may receive EdU and/or BrdU injection after tamoxifen
injection, usually within 0-30 days apart from each other. Health of all animals is
assessed prior to administration of any additional compounds. Animals will be moved by
DCM staff to appropriate containment area for second hazard. Any procedure involving
multiple hazards is listed on protocol.
Training history is available on the EHS website http://web.mit.edu/environment/training/ or
from WIBR EHS. Appropriate courses may include Radiation Safety; Chemical Hazards
(General Chemical Hygiene and Managing Hazardous Waste); and Biosafety/Bloodborne
Pathogens. All personnel must be CAC-certified and an approved participant on the CAC
protocol cited above.
List all personnel handling List pertinent EHS (MIT and/or WIBR) training and date
hazard received
Kevin Kung Managing Hazardous Waste (501c); Lab Specific Chem
Hygiene Training (11 c); CAC training in progress
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Section 4
Administering Hazard
Do not refer to
sections of the CAC
protocol. The EHS
reviewer receives this
form only and it must
contain all details of
dosing, time points,
etc.
Section 5
Manipulations and
Procedures
Do not refer to
sections of the CAC
protocol. The EHS
reviewer receives this
form only and it must
contain all details of
dosing, time points,
etc.
Section 6
Agent/Metabolite
Excretion/Secretion
Anna van Oudenaarden Managing Hazardous Waste (501c); Lab Specific Chem
Hygiene Training (110c); 8 yrs experience with
rodents at MGH, IBR SRAC training certified; CAC
training in progress
Kay Wiebrands Managing Hazardous Waste (501c); Lab Specific Chem
Hygiene Training (11 c); CAC training in progress
(Press "Tab" while in bottom-right cell if more rows are needed)
Give specific details of:
a. Species/strain AND numbers of animals. Indicate if immunosuppressed.
Mus Musculus Genotype
Lgr5;EGFP-IRES-CreERT2 (Cre) on C57BL/6 - 50 mice/year for FACS experiments
APC-exonl4 flox/flox; Lgr5-EGFP-CreERT2 (Cre;Apc -/-) on C57BL/6 - 500 mice/year for
EdU experiments
Lgr5;EGFP-IRES-CreERT2; LSL Kras G12D; Rosa26-LSL-tdTomato (Cre;Kras;TOM) on
C57BL/6 - 100 mice/year for EdU experiments
Lgr5;EGFP-IRES-CreERT2;Apc-exonl4 flox/flox; LSL Kras G12D; Rosa26-LSL-tdTomato
(Cre;Apc -/-; Kras;TOM) on C57BL/6 - 100 mice/year for EdU pexiermnets
Lgf5;EGFP-IRES-CreERT2;Rosa26-LSL-tdTomato (Cre;TOM) on C57BL/6 - 50 mice/year for
FAC experiments
b. Dose per animal (amount per unit body weight AND total volume per dose): 0.1-9
mg/40g of b.w.
c. Route of administration: .P.
d. Frequency of dosing: Up to 3x/week
e. Survival time after dosing (how long before animal is euthanized): 0-30 days
Describe all manipulation(s) to prepare the material for dosing. Note that administration by any
route other than orally requires a sterile prep (default should include filtration through a 0.22
micron filter).
> Resuspend powder at 0.3 mg/L in 100% EtOH and stored at -20C. All preparation
conditions will be under sterile conditions, including filtration through a 0.22 micron filter.
Provide details on administration of the hazardous materials to the animal(s). Indicate any other
animal manipulations that are planned after the hazard(s) have been administered (e.g., surgery,
transport out of animal facility, behavioral testing, etc.), including procedures at necropsy unique
to the hazardous material. If additional hazards will be used in the same animal, describe time
intervals between dosing with the different agents:
> Tamoxifen (0.1 mg to 9 mg/40g of body weight) dissolved in corn oil will be
injected into the peritoneum of mice (including pregnant mice to deliver Tamoxifen to
the pups) carrying CreER alleles. Animals will receive up to 5 consecutive doses of
intraperitoneal tamoxifen. To prevent corn-oil induced peritonitis, in some cases,
tamoxifen will be dissolved in 0.5% Carboxymethyl cellulose, 0.4% Tween 80, 0.9%
NaCl solution and delivered by oral gavage. These procedure are not expected to
cause pain. For oral gavage delivery, animals are anesthetized using 2-3%
isoflurane if they exhibit distress to the gavage procedure. Animals, after being
released back into the cage, are monitored for distress immediately after
administration, and daily for at least 7 days to ensure there is no irritation from the
application. Mice will be monitored at least twice weekly thereafter. Mice will be
euthanized at different time points (between 0-30 days) after injection. Intestines will be removed
post-mortem and used in experiments.
If any of the above procedures will be performed outside of DCM animal facilities, list those
locations and how animal(s) are transported:
> None
Provide amounts (chemicaVbiological hazards) or activity (radioactive hazards) expected
to be excreted/secreted. Appropriate scientific literature must be consulted to complete this
section; any answer of "unknown" must be substantiated.
Urine: None Feces: Primary Expired air: None
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or Propagation
Section 7
Compliance
Statement
Secretions (be specific): Secondary, breast Duration of excretions/secretions: 5-7 days
milk 
____________________
Method of detecting agent/metabolite: N/A List metabolites to be excreted/secreted: 4-
hydroxytamoxifen, N-desmethyl-4-
_ydroxytamoxifen (endoxifen)
Are any metabolites hazardous? If yes, which Are any metabolites volatile? If yes, which
ones? anes?
No N/A
List reference/source(s) of information on metabolites and excretion/secretion:
Kisanga, ER, Mellgren, G, and Lien, EA. Anticancer Res. 25(6C): 4487-92, 2005.
Americal Cancer Society.
<http://www.cancer. org/Treatment/TreatmentsandSideEff ects/G uidetoCancerDrugs/Tamoxifen>,
2011.
For biological hazards, will the agent replicate in the animal? How is this monitored? (Provide
references.):
I affirm the accuracy of all the information on this "Use of Hazardous Materials in Animals"
form.
I agree that hazard use in animals cannot start until the following has occurred, in listed
order:
(1) The CAC has approved the corresponding protocol application/addendum that
describes the use of hazardous materials in animals.
(2) A specific "DCM Protection/Control Required for Hazard Use in Animals" form for each
particular hazard has been generated by DCM and EHS.
(3) Study personnel have been contacted by the DCM Hazards Coordinator (Dr. Mary
Patterson, mmpattamit.edu, X4-5403) or designee for consultation, space allocation, and
orientation in the animal facility on the use of each particular hazard in animals. This
training needs to occur shortly before the study is initiated; retraining may be required if
the study is delayed.
Principal Investigator (print name) Signature Date
Alexander van Oudenaarden October 7, 2011
Supplement K: Tumor Induction
This form may be submitted in support of a protocol application or separately, as an addendum.
If this is an addendum, please also provide a cover letter that includes the following: PI
Name/Department; Protocol Number/Title; Contact Person/Contact Details; and Pl Signature
(required).
A Supplement A must also be submitted if tumor cells are surgically implanted.
A Supplement D must also be submitted if human or animal cells are being used to induce
Explain your objectives: Establish a murine intestinal cancer model that is representative of
human intestinal cancer involving Apc deficiency and/or Kras overexpression. Please see
the Specific Aims section for further details.
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Objectives
Animal Species Animal species (indicate strain and/or genetic modification when appropriate) and quantities per
to be used year:
Mus musculus
Genotype
Lgr5;EGFP-IRES-CreERT2 (Cre) on C57BL/6 - 50 mice for FACS experiments
APC-exon14 flox/flox; Lgr5-EGFP-CreERT2 (Cre;Apc -/-) on C57BL/6 - 500 mice for EdU
experiments
Lgr5;EGFP-IRES-CreERT2; LSL Kras G12D; Rosa26-LSL-tdTomato (Cre;Kras;TOM) on C57BL/6
- 100 mice for EdU experiments
Lgr5;EGFP-IRES-CreERT2;Apc-exonl14 flox/flox; LSL Kras G 1 2D; Rosa26-LSL-tdTomato
(Cre;Apc -/-; Kras;TOM) on C57BL/6 - 100 mice for EdU pexiermnets
Lgf5;EGFP-IRES-CreERT2;Rosa26-LSL-tdTomato (Cre;TOM) on C57BL/6 - 50 mice for FAC
experiments
Tumor Induction Method of tumor induction:
> Conditional knockout of Apc, and/or conditional overexpression of Kras. This is achieved
by the tamoxifen injection procedure as described in Section 4 in the suitable mouse
strains (one that contains Apc-exon14 flox/flox and/or LSL Kras G12D). Mice after
tamoxifen injection will be monitored periodically, and will be euthanized 0-30 days after
injection as different timepoints for tumor development.
Describe number and location of site(s) of tumor induction:
> Intestine
Describe anticipated rate of tumor growth and estimated final size of tumor(s) required by the
study. If more than one tumor, provide estimated desired cumulative mass:
> With Apc deficiency, benign polyps expand at an approximate rate of 2 cells/day (based
on previous data), for a maximum duration of 30 days. There is rapid development of
primary tumors when Apc deficiency is combined with Kras overexpression. Tumor size is
not to exceed 1 cm in diameter. Prior studies have estimated a frequency of tumor of 3.6
lesions/mouse after 3 weeks of induction (Hung et aL, PNAS, 2010). The estimated
cumulative mass is about 3 g/mouse, at an approximate rate of 1 g/week.
Describe monitoring for untoward effects of the induction agent(s) and expected tumor-associated
morbidity. Indicate how many times per week animals will be monitored, and list criteria for
euthanasia. Indicate whether metastasis is expected, and provide likely clinical signs:
> Animals will be monitored at least once weekly following tumor initiation.
Tumors are expected to reach a palpable, measurable size before causing
distress. Animals will be euthanized if any of the following occur: inability
of the animal to ambulate, eat, drink, urinate and defecate without
discomfort, net weight loss in excess of 20% of starting body weight, poor
body condition, or recommendation by veterinary staff.
Superseding standard Guidelines for "Experimental Endpoints" (criteria for euthanasia) may be found at the CAC
euthanasia criteria website:https://web.mit.edulcomp-med/restrict/cac/sptopl0.htm If you expect to supersede standard
euthanasia criteria for tumors in rodents, provide scientific justification for each type of tumor
model:
> Not applicable
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Indicate the substitute criteria for euthanasia scientifically required by your study in the table
below:
Standard criteria for euthanasia Requested substitute criteria*
Body Condition Score < 2
Tumor ulceration
Aggregate tumor burden > 1 cm
in diameter
Tumor impedes eating, urination,
defecation, or ambulation
*Bi-weekly checks (3-4 day intervals) will be required for animals once they have exceeded the
standard criteria for euthanasia. If approved by the CAC, a CAC-issued notice will be posted in
the animal housing room.
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